

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
11 November 2004 (11.11.2004)

PCT

(10) International Publication Number  
**WO 2004/096980 A2**

(51) International Patent Classification<sup>7</sup>: C12N  
(21) International Application Number: PCT/IL2004/000078  
(22) International Filing Date: 27 January 2004 (27.01.2004)  
(25) Filing Language: English  
(26) Publication Language: English  
(30) Priority Data:  
10/426,002 30 April 2003 (30.04.2003) US

(71) Applicant (for all designated States except US): **COMPU-GEN LTD.** [IL/IL]; 72 Pinchas Rosen Street, 69 512 Tel Aviv (IL).  
(72) Inventors; and  
(75) Inventors/Applicants (for US only): **AYALON-SOF-FER, Michal** [IL/IL]; 14 HaNoter Street, 47 210 Ramat HaSharon (IL). **POLLOCK, Sarah** [IL/IL]; 16 Hoshea Street, Apt. 2, 63 506 Tel Aviv (IL). **DIBER, Alex** [IL/IL]; 4 HaNeurim Street, Apt. 3, 46 308 Herzlia (IL). **LEVINE, Zurit** [IL/IL]; 4 Reihan Street, 46 419 Herzlia (IL). **NEMZER, Sergey** [IL/IL]; 5 HaRenanim Street, 52 595 Ramat Gan (IL). **DAHARY, Dvir** [IL/IL]; 23 Pinkas Street, 62 662 Tel Aviv (IL). **SOREK, Rotem** [IL/IL]; 15 Aharonovich Street, 76 564 Rehovot (IL). **LEVANON, Erez** [IL/IL]; 73 Menachem Begin Street, 49 732 Petach Tikva (IL). **ROTMAN, Galit** [IL/IL]; 5 Yair Shtem Street, 46 412 Herzlia (IL). **SAVITSKY, Kineret** [IL/IL]; 44 Metudela Street, 69 548 Tel Aviv (IL). **CHERMESH, Chen** [IL/IL]; 58b Kordova Street, 50 297 Mishmar HaShiva (IL). **MINTZ, Liat** [US/US]; 2 Kulesa Court, East Brunswick, NJ 08816 (US). **FREILICH, Shiri** [IL/IL]; 119 Aba Hushi Street, 34 987 Haifa (IL).

**BECK, Nili** [IL/IL]; 4/10 Mota Gur Street, 44 405 Kfar Saba (IL). **ZHU, Wei-Yong** [US/US]; 308 Quail Ridge Drive, Plainsboro, NJ 08536 (US). **WASSERMAN, Alon** [US/US]; 564 First Avenue, Apt. 13a, Ne, NY 10016 (US). **AZAR, Idit** [IL/IL]; 29 Shalom Aleichem Street, 63 344 Tel Aviv (IL). **BERNSTEIN, Jeanne** [IL/IL]; 23 Harimon Street, 40 300 Kfar Yona (IL).

(74) Agent: **G. E. EHRLICH (1995) LTD.**; 11 Menachem Begin Street, 52 521 Ramat-Gan (IL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL POLYNUCLEOTIDES ENCODING SOLUBLE POLYPEPTIDES AND METHODS USING SAME

(57) Abstract: An isolated polynucleotide is provided. The isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

BEST AVAILABLE COPY



WO 2004/096980 A2

# NOVEL POLYNUCLEOTIDES ENCODING SOLUBLE POLYPEPTIDES AND METHODS USING SAME

## FIELD AND BACKGROUND OF THE INVENTION

5           The present invention relates to novel soluble polypeptides and polynucleotides encoding same and more particularly, to therapeutic and diagnostic methods and kits utilizing same.

          Extracellular proteins including receptors and their corresponding ligands play active roles in the formation, differentiation and maintenance of multicellular  
10       organisms. Any fate of an individual cell including proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from distant cells and/or the immediate environment. This information is often transmitted by secreted polypeptides such as, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones, which are, in  
15       turn, received and interpreted by diverse cell receptors or membrane-bound proteins. These secreted polypeptides or signaling molecules are normally transferred through the cellular secretory pathway to reach their site of action at the extracellular environment.

          Secreted proteins have various industrial applications, including as  
20       pharmaceuticals, diagnostics, biosensors and bioreactors. Most protein drugs available to date, including thrombolytic polypeptide sequences, interferons, interleukins, erythropoietins, colony stimulating factors, and various other cytokines, are secretory proteins. Their receptors, which are membrane proteins, also have potential as therapeutic or diagnostic polynucleotide or polypeptide sequences. For example,  
25       receptor immunoadhesins, can be employed as therapeutic polynucleotide or polypeptide sequences to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.

          For these reasons, efforts are being made by both industry and academia to  
30       identify new, native, membrane-bound or secreted proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for such proteins. Examples of such screening methods and techniques are described in, for example, Klein et al., Proc. Natl. Acad. Sci. 93:7108-7113 (1996); U.S. Pat. No. 5,536,637

The present inventors have previously designed algorithms, which allow for the mass prediction of yet unknown gene products and for annotating these [see US patent No: 6,625,545; U.S. Pat. Appl. No. 10/426,002; a U.S. patent application entitled METHODS AND SYSTEMS FOR ANNOTATING BIOMOLECULAR SEQUENCES (Attorney Docket No. 26940), filed concurrently herewith, assigned to the same assignee hereof and contains subject matter related, in certain respects, to the subject matter of the instant application, the teachings of all of which are incorporated herein by reference; and Example 1 of the Examples section which follows].

While applying the above-mentioned algorithms the present inventors uncovered novel naturally occurring variants of extracellular gene products, which as described above, play pivotal roles in disease onset and progression. As such these variants can be used in the diagnosis and therapy of a wide range of diseases.

#### SUMMARY OF THE INVENTION

According to one aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to further features in preferred embodiments of the invention described below, the nucleic acid sequence is as set forth in SEQ ID NO: 3 or 4.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 1 or 2.

According to another aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 3 or 4.

According to yet another aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 1 or 2.

According to still another aspect of the present invention there is provided a nucleic acid construct comprising any of the isolated polynucleotide of the present invention.

According to still further features in the described preferred embodiments the nucleic acid construct further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

According to still further features in the described preferred embodiments the nucleic acid construct further comprising a positive and a negative selection markers for selecting for homologous recombination events.

According to an additional aspect of the present invention there is provided a  
5 host cell comprising the nucleic acid construct.

According to yet an additional aspect of the present invention there is provided  
An isolated polypeptide comprising an amino acid sequence at least 70 % identical to  
SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland  
(<http://www.ch.embnet.org/index.html>) using default parameters or an active portion  
10 thereof.

According to still an additional aspect of the present invention there is  
provided An antibody or an antibody fragment being capable of specifically binding a  
polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1,  
as determined using the LALIGN software of EMBnet switzerland  
15 (<http://www.ch.embnet.org/index.html>) using default parameters.

According to a further aspect of the present invention there is provided an  
oligonucleotide specifically hybridizable with a nucleic acid sequence encoding a  
polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 1, as  
determined using the LALIGN software of EMBnet switzerland  
20 (<http://www.ch.embnet.org/index.html>) using default parameters.

According to yet a further aspect of the present invention there is provided A  
pharmaceutical composition comprising a therapeutically effective amount of a  
polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1,  
as determined using the LALIGN software of EMBnet switzerland  
25 (<http://www.ch.embnet.org/index.html>) using default parameters and a  
pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided A  
method of treating Met-related disease in a subject, the method comprising  
upregulating in the subject expression of a polypeptide having an amino acid  
30 sequence at least 70 % identical to SEQ ID NO: 1 as determined using the LALIGN  
software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default  
parameters, thereby treating the Met-related disease in a subject.



According to still a further aspect of the present invention there is provided An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland  
5 (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 7 or 8.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 5 or 6.

10 According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 7 or 8.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 5 or 6.

According to still a further aspect of the present invention there is provided an  
15 isolated polypeptide comprising an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an  
20 antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided an  
25 oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided a  
30 pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland

5

(<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating an IL-6-related disease in a subject, the method comprising  
5 upregulating in the subject expression of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters, thereby treating the IL-6-related disease in the subject.

According to still a further aspect of the present invention there is provided an  
10 isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still further features in the described preferred embodiments the  
15 nucleic acid sequence is as set forth in SEQ ID NO: 11 or 12.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 9 or 10.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 11 or 12.

20 According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 9 or 10.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland  
25 (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the  
30 LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide

having an amino acid at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a IL-7 polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 15 or 16.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 13 or 14.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 15 or 16.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 13 or 14.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 19 or 20.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 17 or 18.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 19 or 20.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 17 or 18.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 60 % identical to  
5 SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an  
10 amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide  
15 having an amino acid at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a  
20 polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a  
25 method of treating TNFR9-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

30 According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as

determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 27 or 28.

5 According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 25 or 26.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 27 or 28.

10 According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 25 or 26.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion  
15 thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>)  
20 using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>)  
25 using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland  
30 (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating IL-4R-related disease in a subject, the method comprising

upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

5 According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

10 According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 23 or 24.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 21 or 22.

15 According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 23 or 24.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 21 or 22.

20 According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

25 According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

30 According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland  
5 (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating IL-4R-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid  
10 sequence at least 50 % identical to SEQ ID NO: 21 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide  
15 having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 31 or 32.

20 According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 29 or 30.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 31 or 32.

25 According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 29 or 30.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion  
30 thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using



the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide  
5 having an amino acid at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a  
10 polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a  
15 method of treating TGR2-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided an  
20 isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still further features in the described preferred embodiments the  
25 nucleic acid sequence is as set forth in SEQ ID NO: 35 or 36.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 33 or 34.

According to still a further aspect of the present invention there is provided an  
30 isolated polynucleotide as set forth in SEQ ID NO: 35 or 36.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 33 or 34.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating ITAV-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 39.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 37 or 38.

5 According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 39.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 37 or 38.

10 According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

15 According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

20 According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

25 According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

30 According to still a further aspect of the present invention there is provided a method of treating IL10-R-B-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37 as determined using the LALIGN

software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide  
5 having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 43 or 40.

10 According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 41 or 42.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 43 or 40.

15 According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 41 or 42.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion  
20 thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>)  
25 using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>)  
30 using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41,

as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating INR1-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to still further features in the described preferred embodiments the upregulating expression of the polypeptide is effected by: (i) administering the polypeptide to the subject; and/or (ii) administering an expressible polynucleotide encoding the polypeptide.

The present invention successfully addresses the shortcomings of the presently known configurations by providing novel soluble polypeptides and polynucleotides encoding thereof, which can be used in the diagnosis and treatment of a wide range of diseases.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

## BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the

description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.

In the drawings:

FIGs. 1a-b present the nucleic acid sequence (Figure 1a) and amino acid  
5 sequence (Figure 1b) of the Met variant of the present invention (SEQ ID NO: 3 and 1, respectively).

FIG. 2 is a schematic illustration depicting a graphical viewer scheme  
presenting the new variant of Met (transcript\_9) as compared to the wild type mRNA.  
The ESTs supporting the new variant are indicated. Transcript indicated as "0"  
10 represents known mRNA. The color code is as follows: red= genomic DNA; pink=  
refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same  
directinality as their annotation; black= ESTs aligned in the opposite directinality to  
their annotation; grey= ESTs without direction annotation; dark blue= predicted  
transcripts; turquoise = predicted polypeptide.

15 FIG. 3 is an amino acid sequence alignment between wild-type c-Met protein  
and the protein variant of the present invention, as determined using the Smith and  
Waterman model query db, with the following parameters: -mode=qqglobal -onestrand  
-gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 4 is a schematic illustration showing the protein domain structure of wild-  
20 type c-Met protein and the variant of the present invention (SEQ ID NO: 1). Unique  
region is indicated by U (SEQ ID NO: 2).

FIGs. 5a-b present the nucleic acid sequence (Figure 5a) and amino acid  
sequence (Figure 5b) of the IL-6 variant of the present invention (SEQ ID NO: 7 and  
5, respectively). Start and stop codons are highlighted. Unique sequence region is  
25 highlighted.

FIG. 6 is a schematic illustration depicting a graphical viewer scheme  
presenting the new variant of IL-6 (transcript\_6) as compared to the wild type mRNA.  
The ESTs supporting the new variant are indicated. Transcript indicated as "0"  
represents known mRNA. The color code is as follows: red= genomic DNA; pink=  
30 refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same  
directinality as their annotation; black= ESTs aligned in the opposite directinality to  
their annotation; grey= ESTs without direction annotation; dark blue= predicted  
transcripts; turquoise = predicted polypeptide.

FIG. 7 is an amino acid sequence alignment between wild-type IL-6 protein and the protein variant of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 8 is a schematic illustration showing the protein domain structure of wild-type IL-6 protein and the variant of the present invention (SEQ ID NO: 5). Unique region is indicated by U (SEQ ID NO: 6).

FIGs. 9a-b present the nucleic acid sequence (Figure 9a) and amino acid sequence (Figure 9b) of the IL7 T7 variant of the present invention (SEQ ID NO: 11 and 9, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIGs. 9c-d present the nucleic acid sequence (Figure 9c) and amino acid sequence (Figure 9d) of the IL7 T8 variant of the present invention (SEQ ID NO: 15 and 13, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 10 is a schematic illustration depicting a graphical viewer scheme presenting the new variants of IL7 (Transcript\_7 and Transcript\_8) as compared to the wild type mRNA. The ESTs supporting the new variant are indicated. Transcript indicated as "0" represents known mRNA. The color code is as follows: red= genomic DNA; pink= refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same directinality as their annotation; black= ESTs aligned in the opposite directinality to their annotation; grey= ESTs without direction annotation; dark blue= predicted transcripts; turquoise = predicted polypeptide.

FIGs. 11a-b are amino acid sequence alignment between wild-type IL-7 protein and the protein variants (T7 and T8) of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 12 is a schematic illustration showing the protein domain structure of wild-type IL-7 protein and the variants of the present invention (SEQ ID NOs: 9 and 13). Unique regions are indicated by U (SEQ ID NO: 10 and 14).

FIGs. 13a-b present the nucleic acid sequence (Figure 13a) and amino acid sequence (Figure 13b) of the TNFR9 variant of the present invention (SEQ ID NO: 19

and 17, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 14 is a schematic illustration depicting a graphical viewer scheme presenting the new variant of TNFR9 (Transcript\_4) as compared to the wild type mRNA. The ESTs supporting the new variant are indicated. Transcript indicated as "0" represents known mRNA. The color code is as follows: red= genomic DNA; pink= refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same directinality as their annotation; black= ESTs aligned in the opposite directinality to their annotation; grey= ESTs without direction annotation; dark blue= predicted transcripts; turquoise = predicted polypeptide.

FIG. 15 is an amino acid sequence alignment between wild-type TNFR9 protein and the protein variant of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 16 is a schematic illustration showing the protein domain structure of wild-type TNFR9 protein and the variant of the present invention (SEQ ID NO: 17). Unique region is indicated by U (SEQ ID NO: 18).

FIGs. 17a-b present the nucleic acid sequence (Figure 17a) and amino acid sequence (Figure 17b) of the IL-4R T4 variant of the present invention (SEQ ID NO: 23 and 21, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 17c present the nucleic acid sequence of the IL-4R T11 variant of the present invention (SEQ ID NO: 27). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 18 present the amino acid sequence of the IL-4R T11 variant of the present invention (SEQ ID NO: 25). Unique sequence region is highlighted.

FIGs. 19a-b are amino acid sequence alignments between wild-type IL-4R protein and the protein variants of the present invention (Figure 19a - alignment of IL-4R-T4, and Figure 19b alignment of IL-4R-T11), as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.



FIG. 20 is a schematic illustration showing the protein domain structure of wild-type IL-4R protein and the variants of the present invention (SEQ ID NOs: 21 and 25). Unique regions are indicated by U (SEQ ID NOs: 22 and 26).

FIGs. 21a-b present the nucleic acid sequence (Figure 21a) and amino acid sequence (Figure 21b) of the TGR2 variant of the present invention (SEQ ID NO: 31 and 29, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 22 is a schematic illustration depicting a viewer scheme presenting the new variant of TGR2 (Transcript\_7) as compared to the wild type mRNA. The ESTs supporting the new variant are indicated. Transcript indicated as "0" represents known mRNA. The color code is as follows: red= genomic DNA; pink= refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same directinality as their annotation; black= ESTs aligned in the opposite directinality to their annotation; grey= ESTs without direction annotation; dark blue= predicted transcripts; turquoise = predicted polypeptide.

FIG. 23 is an amino acid sequence alignment between wild-type TGR2 protein and the protein variant of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 24 is a schematic illustration showing the protein domain structure of wild-type TGR2 protein and the variant of the present invention (SEQ ID NO: 29). Unique region is indicated by U (SEQ ID NO: 30).

FIGs. 25a-b present the nucleic acid sequence (Figure 25a) and amino acid sequence (Figure 25b) of the ITAV variant of the present invention (SEQ ID NO: 35 and 33, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 26 is a schematic illustration depicting a viewer scheme presenting the new variant of ITAV (Transcript\_3) as compared to the wild type mRNA. The ESTs supporting the new variant are indicated. Transcript indicated as "0" represents known mRNA. The color code is as follows: red= genomic DNA; pink= refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same directinality as their annotation; black= ESTs aligned in the opposite directinality to their annotation;

21

grey= ESTs without direction annotation; dark blue= predicted transcripts; turquoise = predicted polypeptide.

FIG. 27 is an amino acid sequence alignment between wild-type ITAV protein and the protein variant of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand  
5 -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 28 is a schematic illustration showing the protein domain structure of wild-type ITAV protein and the variant of the present invention (SEQ ID NO: 33). Unique region is indicated by U (SEQ ID NO: 34).

10 FIGs. 29a-b present the nucleic acid sequence (Figure 29a) and amino acid sequence (Figure 29b) of the IL-10-R- $\beta$  variant of the present invention (SEQ ID NO: 39 and 37, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 30 is a schematic illustration depicting the viewer scheme presenting the new variant of IL-10-R- $\beta$  (Transcript\_1) as compared to the wild type mRNA. The  
15 ESTs supporting the new variant are indicated. Transcript indicated as "0" represents known mRNA. The color code is as follows: red= genomic DNA; pink= refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same directinality as their annotation; black= ESTs aligned in the opposite directinality to their annotation; grey= ESTs without direction annotation; dark blue= predicted  
20 transcripts; turquoise = predicted polypeptide.

FIG. 31 is an amino acid sequence alignment between wild-type IL-10-R- $\beta$  protein and the protein variant of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -  
25 onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 32 is a schematic illustration showing the protein domain structure of wild-type IL-10-R- $\beta$  protein and the variant of the present invention (SEQ ID NO: 37). Unique region is indicated by U (SEQ ID NO: 38).

FIGs. 33a-b present the nucleic acid sequence (Figure 33a) and amino acid  
30 sequence (Figure 33b) of the INR1 variant of the present invention (SEQ ID NO: 43 and 41, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 34 is a schematic illustration depicting a viewer scheme presenting the new variant of INR1 (Transcript\_11) as compared to the wild type mRNA. The ESTs supporting the new variant are indicated. Transcript indicated as "0" represents known mRNA. The color code is as follows: red= genomic DNA; pink= refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same directinality as their annotation; black= ESTs aligned in the opposite directinality to their annotation; grey= ESTs without direction annotation; dark blue= predicted transcripts; turquoise = predicted polypeptide.

FIG. 35 is an amino acid sequence alignment between wild-type INR1 protein and the protein variant of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap, FIG. 36 is a schematic illustration showing the protein domain structure of wild-type INR1 protein and the variant of the present invention (SEQ ID NO: 41). Unique region is indicated by U (SEQ ID NO: 42).

### DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is of novel soluble polypeptides and polynucleotides encoding same, which can be used for the diagnosis and treatment of a wide range of diseases, such as cancer and inflammatory diseases.

The principles and operation of the present invention may be better understood with reference to the drawings and accompanying descriptions.

Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.

Extracellular proteins including receptors and their corresponding ligands play active roles in the formation, differentiation and maintenance of multicellular organisms. Any fate of an individual cell including proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or the immediate environment. This information is often

transmitted by secreted polypeptides such as, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones, which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins. These secreted polypeptides are normally processed by the cellular secretory pathway  
5 to reach their site of action in the extracellular environment.

Secreted proteins have various industrial applications, including as pharmaceuticals, diagnostics, biosensors and bioreactors. Most protein drugs available at present, such as thrombolytic polynucleotide or polypeptide sequences of this aspect of the present invention, interferons, interleukins, erythropoietins, colony stimulating  
10 factors, and various other cytokines, are secretory proteins. Their receptors, which are membrane proteins, also have potential as therapeutic or diagnostic polynucleotide or polypeptide sequences of this aspect of the present invention. For example, receptor immunoadhesins, for instance, can be employed as therapeutic polynucleotide or polypeptide sequences of this aspect of the present invention to block receptor-ligand  
15 interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.

For these reasons, efforts are being undertaken by both industry and academia to identify novel, native, secreted proteins. Many efforts are focused on the screening  
20 of mammalian recombinant DNA libraries to identify the coding sequences for such proteins. Examples of such screening methods and techniques are described in, for example, Klein et al., Proc. Natl. Acad. Sci. 93:7108-7113 (1996); U.S. Pat. No. 5,536,637

The present inventors have previously designed algorithms which allow for the  
25 mass prediction of yet unknown gene products and for annotating same [see US patent No: 6,625,545; U.S. Pat. Appl. No. 10/426,002; a U.S. patent application entitled METHODS AND SYSTEMS FOR ANNOTATING BIOMOLECULAR SEQUENCES (Attorney Docket No. 26940), filed concurrently herewith, assigned to the same assignee hereof and contains subject matter related, in certain respects, to the  
30 subject matter of the instant application, the teachings of all of which are incorporated herein by reference; and Example 1 of the Examples section which follows].

While applying the above-mentioned algorithms, the present inventors uncovered novel naturally occurring variants of extracellular gene products, which, as

is described in the Examples section which follows, play pivotal roles in disease onset and progression. As such these variants can be used to design therapeutic and diagnostic tools for a wide range of diseases.

***Met splice variant***

5 According to one aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 1, as  
10 determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

As used herein the phrase "an isolated polynucleotide" refers to a single or double stranded nucleic acid sequences which is isolated and provided in the form of an RNA sequence, a complementary polynucleotide sequence (cDNA), a genomic  
15 polynucleotide sequence and/or a composite polynucleotide sequences (e.g., a combination of the above).

As used herein the phrase "complementary polynucleotide sequence" refers to a sequence, which results from reverse transcription of messenger RNA using a reverse transcriptase or any other RNA dependent DNA polymerase. Such a sequence  
20 can be subsequently amplified *in vivo* or *in vitro* using a DNA dependent DNA polymerase.

As used herein the phrase "genomic polynucleotide sequence" refers to a sequence derived (isolated) from a chromosome and thus it represents a contiguous portion of a chromosome.

25 As used herein the phrase "composite polynucleotide sequence" refers to a sequence, which is at least partially complementary and at least partially genomic. A composite sequence can include some exonal sequences required to encode the polypeptide of the present invention, as well as some intronic sequences interposing therebetween. The intronic sequences can be of any source, including of other genes,  
30 and typically will include conserved splicing signal sequences. Such intronic sequences may further include cis acting expression regulatory elements.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 3 or 4.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of a Met gene (Swissprot Locus No. : MET\_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the Met polypeptides of the present invention. Examples include but are not limited to ligand binding, antibody specific recognition, inhibition of cell-proliferation, scattering, angiogenesis, motility, morphogenesis and/or invasion (see Example 2 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 1 or 2.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 3 or 4 under moderate to stringent hybridization conditions.

Moderate to stringent hybridization conditions are characterized by a hybridization solution such as containing 10 % dextrane sulfate, 1 M NaCl, 1 % SDS and  $5 \times 10^6$  cpm  $^{32}\text{P}$  labeled probe, at 65 °C, with a final wash solution of 0.2 x SSC and 0.1 % SDS and final wash at 65°C and whereas moderate hybridization is effected using a hybridization solution containing 10 % dextrane sulfate, 1 M NaCl, 1 % SDS and  $5 \times 10^6$  cpm  $^{32}\text{P}$  labeled probe, at 65 °C, with a final wash solution of 1 x SSC and 0.1 % SDS and final wash at 50 °C.

The present invention also encompasses novel polypeptides (e.g., of the Met gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 1 or 2. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 1 or 2. Finally, the present invention also encompasses fragments of the above

described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 2 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "Met-related diseases", since, without being bound by theory, they are devoid of a transmembrane and intracellular domains while retain the extracellular region of Met (i.e., HGF binding site) and therefore are likely to compete with HGF binding to the functional, membrane bound, Met receptor and as a consequence block Met activation and signaling pathway.

The above-mentioned "Met-related disease" refers to a disease in which Met-activity and/or expression contribute to disease onset and/or progression. Examples of Met-related diseases include, but are not limited to, cancer, such as, hereditary and sporadic papillary renal carcinoma, breast cancer, ovarian cancer, childhood hepatocellular carcinoma, metastatic head and neck squamous cell carcinomas, lung cancer (e.g., non-small cell lung cancer, small cell lung cancer), prostate cancer, pancreatic cancer and gastric cancer, and other diseases such as diabetic retinopathy.

It will be appreciated that the polypeptides of this aspect of the present invention may also have agonistic properties. These include increasing the stability of Met-ligand (e.g., HFG), protection from proteolysis and modification of the pharmacokinetic properties of the ligand (i.e., increasing the half-life of the ligand, while decreasing the clearance thereof). As such, the biomolecular sequences of this aspect of the present invention may be used to treat conditions or diseases in which Met plays a favorable role. Examples include, but are not limited to, regenerative processes such as wound healing and conditions, which require enhanced angiogenesis such as atherosclerotic diseases, ischemic conditions and diabetes. As mentioned the Met ligand is the hepatocyte growth factor, suggesting that the biomolecular sequences of this aspect of the present invention may have hepatoprotective properties and therefore may be used to diseases of the liver such as hepatic cirrhosis and hepatic dysfunction.

Thus, the present invention envisages treatment of the above-mentioned diseases by the provision of polynucleotide or polypeptide sequences of this aspect of the present invention, which are capable of upregulating expression of the

polypeptides of the present invention in a subject in need thereof, as is further described hereinbelow. Such polynucleotide or polypeptide sequences of this aspect of the present invention and administration thereof are further described hereinbelow.

*IL-6 splice variant*

5 According to another aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID  
10 NO: 5, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 7 or 8.

Preferably, the polypeptide of this aspect of the present invention is at least an  
15 active portion of a naturally occurring protein product of an IL-6 gene (Swissprot Locus No. IL6\_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the IL-6 polypeptides of the present invention. Examples include but are not limited antibody  
20 specific recognition and inhibition of IL-6 binding to the receptor (see Example 3 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 5 or 6.

The isolated polynucleotides of this aspect of the present invention can be  
25 qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 7 or 8 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., products of the IL-6 gene) or portions thereof, which are encoded by the isolated polynucleotide  
30 and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 5 or 6. The present invention also



encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 5 or 6. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 3 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "IL-6-related diseases", since, without being bound by theory, the IL-6 splice variant of this aspect of the present invention (SEQ ID NO: 5), contains the N-terminal 157 amino acids of wild-type IL-6, while lacks the last 50 amino acids of the protein, and as such may serve as an antagonist of IL-6 by several mechanisms. For example, this polypeptide variant can exhibit binding only to IL-6R $\alpha$ , and no, or reduced binding to gp130, the second IL-6 receptor subunit. Since gp130 is the signaling subunit of the IL-6R complex, IL-6 splice variant of this aspect of the present invention, will not be able to activate the receptor. Thus it might serve as an antagonist of IL-6 signaling by binding the IL-6 receptor without activating it.

The above-mentioned "IL-6-related disease" refers to a disease in which IL-6-activity and/or expression contributes to disease onset and/or progression. Examples include, but are not limited to, inflammatory, autoimmune, and malignant diseases, such as, rheumatoid arthritis (RA), Castleman's disease, Crohn's disease, multiple myeloma/plasmacytoma, mesangial proliferative glomerulonephritis, psoriasis and Kaposi's sarcoma.

Thus, this aspect of the present invention envisages treatment of the above-mentioned diseases by the provision of polynucleotide or polypeptide sequences of this aspect of the present invention, which are capable of upregulating expression of the polypeptides of the present invention in a subject in need thereof, as is further described hereinbelow. Such polynucleotide or polypeptide sequences of this aspect of the present invention and administration thereof are further described hereinbelow.

*IL-7 splice variants*

According to yet another aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 9 or 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 11, 12, 15 or 16.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of an IL-7 gene (Swissprot Locus No. IL7\_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the IL-7 polypeptides of the present invention. Examples include but are not limited to, antibody specific recognition, inhibition of IL-7 binding to the receptor, enhancement of anti-tumor immunogenic reaction, reduction of tumor-induced suppression of immunogenic reaction, inhibition of cell proliferation (e.g., B-cells, see Example 4 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 9, 10, 13 or 14.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 11, 12, 15 or 16 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., of the IL-7 gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 9, 10, 13 or 14. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50

%, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 9, 10, 13 or 14. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 4 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "IL-7-related diseases", since, without being bound by theory, they may bind only one IL-7 receptor subunit to thereby produce dysfunctional ligand-receptor complexes.

The above-mentioned "IL-7-related disease" refers to a disease in which IL-7-activity and/or expression contributes to disease onset and/or progression. Examples of IL-7-related diseases include, but are not limited to cancer, such as acute and chronic lymphocytic leukemia, acute myelogenous leukemia, Sezary's syndrome, Burkitt's lymphoma and Hodgkin's disease.

It will be appreciated that the polypeptides of this aspect of the present invention may also have agonistic properties, such as by binding to the IL-7 receptor with enhanced affinity as compared to the wild-type IL-7. As such, the biomolecular sequences of this aspect of the present invention may be used to treat conditions or diseases in which IL-7 plays a favorable role. Examples include, but are not limited to, cancer, such as melanoma, renal and colorectal cancer, in which IL-7 plays a therapeutic role by eliciting anti-tumor immunogenic responses. Furthermore, it is well established that IL-7 controls the growth and proliferation of immature B-cells and can stimulate the development of bone marrow cells into T-cells and B-cell precursors. Thus the polypeptides of this aspect of the present invention may be used to establish a spectrum of lymphoid cell types following radiotherapy or chemotherapy.

Thus, this aspect of the present invention envisages treatment of the above-mentioned diseases by the provision of polynucleotide or polypeptide sequences of this aspect of the present invention, which are capable of upregulating expression of the polypeptides of the present invention in a subject in need thereof, as is further described hereinbelow. Such polynucleotide or polypeptide sequences of this aspect of the present invention and administration thereof are further described hereinbelow.

***Tumor necrosis factor receptor 9 (TNR-9)/4-1BBR splice variant***

According to still another aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 19 or 20.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of a TNR9 gene (Swissprot Locus No. TNR9\_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the TNFR9 polypeptides of the present invention. Examples include but are not limited to 4-1BB binding, antibody specific recognition, inhibition of IL-2 production, cell-proliferation and differentiation, clonal expansion and survival of CD38+ cells, signaling (see Example 5 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 17 or 18.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 19 or 20 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., of the TNR9 gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 17 or 18. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 17 or 18. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or  
5 man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 5 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "TNR9-related diseases", since, without being bound by theory, they are devoid of a transmembrane and intracellular  
10 domains while retain the extracellular region of TNR9 and therefore are likely to compete with 4-1BBL binding to the functional, membrane bound, TNR9 receptor and as a consequence block TNR9 activation and signaling pathway.

The above-mentioned "TNR9-related disease" refers to a disease in which TNR9-activity and/or expression contribute to disease onset and/or progression.  
15 Examples of TNR9-related diseases include, but are not limited to, myocardial inflammation, induced by coxackievirus B3, herpetic stromal keratitis (HSK) induced by HSV-1 and inflammatory diseases, such as multiple sclerosis and Crohn's disease as well as prevention of graft rejection and graft-versus-host disease.

It will be appreciated that the polypeptides of this aspect of the present  
20 invention may also have agonistic properties. These include increasing the stability of 4-1BB-ligand, protection from proteolysis and modification of the pharmacokinetic properties of the ligand (i.e., increasing the half-life of the ligand, while decreasing the clearance thereof). As such, the biomolecular sequences of this aspect of the present invention may be used to treat conditions or diseases in which TNR9 plays a  
25 favorable role. Examples include, but are not limited to, cancer, viral infections and autoimmune diseases such as spontaneous systemic lupus erythematosus (SLE), RA, and ulcerative colitis.

Thus, this aspect of the present invention envisages treatment of the above-mentioned diseases by the provision of polynucleotide or polypeptide sequences of  
30 this aspect of the present invention, which are capable of upregulating expression of the polypeptides of the present invention in a subject in need thereof, as is further described hereinbelow. Such polynucleotide or polypeptide sequences of this aspect of the present invention and administration thereof are further described hereinbelow.

*Interleukin 4 receptor (IL4R) splice variants*

According to an additional aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 21 or 25, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 23, 24, 27 or 28.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of an IL-4 receptor gene (Swissprot Locus No. IL4R\_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the IL-4R polypeptides of the present invention. Examples include but are not limited to ligand binding, antibody specific recognition and inhibition of IL-4 signaling (see Example 6 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 21, 22, 25 or 26.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 23, 24, 27 or 28 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., of the IL-4R gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 21, 22, 25 or 26. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 21 or 25, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 21, 22, 25 or 26. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 6 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "IL-4R-related diseases", since, without being bound by theory, they are devoid of a transmembrane and intracellular domains, while still retain a complete CRIA domain of the extracellular region of IL-4R and therefore are likely to compete with IL-4 binding to the functional, membrane-bound, IL-4 receptor and as a consequence block IL-4 activation and signaling pathway.

The above-mentioned "IL-4R-related disease" refers to a disease in which IL-4R-activity and/or expression contribute to disease onset and/or progression. Examples of IL-4R-related diseases include, but are not limited to, asthma and allergic disorders, autoimmune diseases, such as lupus, transplant rejection and graft-versus-host diseases

It will be appreciated that the polypeptides of this aspect of the present invention may also have agonistic properties. These include increasing the stability of IL-4R-ligand (e.g., IL-4), protection from proteolysis and modification of the pharmacokinetic properties of the ligand (i.e., increasing the half-life of the ligand, while decreasing the clearance thereof). As such, the biomolecular sequences of this aspect of the present invention may be used to treat conditions or diseases in which IL-4 plays a favorable role. Examples include, but are not limited to, cancer, such as, leukaemia, kaposi's sarcoma, lymphoma and non-small cell lung cancer, anaemia and rheumatoid arthritis.

Thus, this aspect of the present invention envisages treatment of the above-mentioned diseases by the provision of polynucleotide or polypeptide sequences of this aspect of the present invention, which are capable of upregulating expression of the polypeptides of the present invention in a subject in need thereof, as is further described hereinbelow. Such polynucleotide or polypeptide sequences of this aspect of the present invention and administration thereof are further described hereinbelow.

*Transforming growth factor  $\beta$  receptor type II (TGF- $\beta$ -R/TGR2) splice variant*

According to yet an additional aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 31 or 32.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of a TGR2 gene (Swissprot Locus No. TGR2\_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the TGR2 polypeptides of the present invention. Examples include but are not limited to ligand binding, antibody specific recognition, inhibition of TGR2 signaling such as through the type I receptor and SMAD proteins or through PI3K and p70S6K, tumor suppression and tumor promotion (see Example 7 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 29 or 30.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 31 or 32 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., of the TGR2 gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 29 or 30. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50



%, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 29 or 30. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 7 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "TGR2-related diseases", since, without being bound by theory, they are devoid of a transmembrane and intracellular domains while retain the extracellular region of TGR2 and therefore are likely to compete with TGF- $\beta$  binding to the functional, membrane bound, TGR2 receptor and as a consequence block TGR2 activation and signaling pathway.

The above-mentioned "TGR2-related disease" refers to a disease in which TGR2-activity and/or expression contribute to disease onset and/or progression. Examples of TGR2-related diseases include, but are not limited to, cancer, such as glioblastoma where TGR2 acts as a tumor promoter (see Example 6 of the Examples section), organ remodeling diseases and fibrotic diseases, such as chronic renal disease or pulmonary fibrosis, scleroderma and eye scarring following glaucoma surgery.

It will be appreciated that the polypeptides of this aspect of the present invention may also have agonistic properties. These include increasing the stability of TGF  $\beta$ , protection from proteolysis and modification of the pharmacokinetic properties of the ligand (i.e., increasing the half-life of the ligand, while decreasing the clearance thereof). As such, the biomolecular sequences of this aspect of the present invention may be used to treat conditions or diseases in which TGR2 plays a favorable role, such as in cancer onset where TGR2 plays a protective role, atherosclerosis and other injury-induced hyperplasias such as restenosis, rheumatoid arthritis, psoriasis, multiple sclerosis, osteoporosis and articular cartilage damage, in which tissue repair is achieved by promoting TGF $\beta$ 2 Activity. The polypeptides of this aspect of the present invention may also be used for wound healing.

Thus, this aspect of the present invention envisages treatment of the above-mentioned diseases by the provision of polynucleotide or polypeptide sequences of

this aspect of the present invention, which are capable of upregulating expression of the polypeptides of the present invention in a subject in need thereof, as is further described hereinbelow.

*Integrin- $\alpha$ -V (ITAV) splice variants*

5 According to still an additional aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet  
10 switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 33 or 34.

Preferably, the polypeptide of this aspect of the present invention is at least an  
15 active portion of a naturally occurring protein product of a ITAV gene (Swissprot Locus No. ITAV\_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the ITAV polypeptides of the present invention. Examples include but are not limited to ligand  
20 (e.g., extracellular matrix proteins, fibronectin) or receptor-partner binding , antibody specific recognition, inhibition of cell survival, proliferation and migration (see Example 8 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 33 or 34..

25 The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 35 or 36 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., of the  
30 ITAV gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel

polypeptides are set forth in SEQ ID NO: 33 or 34. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 33 or 34. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 8 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "ITAV-related diseases", since, without being bound by theory, they are devoid of a transmembrane and intracellular domains while retain the extracellular region of ITAV and therefore are likely to compete with ligand binding to the functional, membrane bound, ITAV receptor and as a consequence block ITAV activation and signaling pathway. Alternatively these polypeptides can dimerize with a second receptor subunit to produce a dysfunctional heterodimeric complexes thereby blocking signaling.

The above-mentioned "ITAV-related disease" refers to a disease in which ITAV-activity and/or expression contributes to disease onset and/or progression. Examples of ITAV-related diseases include, but are not limited to, ocular diseases(e.g., persistent corneal epithelial defect), cancer (e.g., breast cancer, renal cancer, cervical cancer, colon cancer, prostate cancer, bladder cancer, lung cancer and melanoma), cardiovascular diseases (e.g., stroke and heart failure, atherosclerosis, restenosis, ischemia and reperfusion injury), immunological related diseases (e.g., immunodeficiency, allergies, asthma, psoriasis, RA and inflammatory bowel diseases e.g., Chron's disease), metabolism related diseases, such as diabetes and diabetes related retinopathy, osteoporosis, sepsis and wound healing.

Thus, this aspect of the present invention envisages treatment of the above-mentioned diseases by the provision of agents, which are capable of upregulating expression of the polypeptides of the present invention in a subject in need thereof. Such agents and administration thereof are further described hereinbelow.

***Interleukin-10 receptor  $\beta$  chain (IL-10-R  $\beta$ ) splice variant***

According to a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 39.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of an IL-10-R $\beta$  gene (Swissprot Locus No. I10S\_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the IL-10-R $\beta$  polypeptides of the present invention. Examples include, but are not limited to, ligand binding, antibody specific recognition, regulation of IL-10R signaling (e.g., STAT activation) and regulation of immune responses (see Example 9 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 37 or 38.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 39 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., of the IL-10-R $\beta$  gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 37 or 38. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 37 or 38, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 37 or 38. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or  
5 man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 9 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "IL-10-R $\beta$ -related diseases", due to their enhanced agonistic properties. These include increasing the stability of the  
10 ligand (e.g., IL-10), protection from proteolysis and modification of the pharmacokinetic properties of the ligand (i.e., increasing the half-life of the ligand, while decreasing the clearance thereof) to thereby increase the biological effects of the IL-10 signaling cascade. As such, the biomolecular sequences of this aspect of the present invention may be used to treat conditions or diseases in which IL-10R  
15 signaling plays a favorable role. Examples include, but are not limited to, inflammatory diseases, such as, psoriasis, inflammatory bowel diseases, Crohn's disease, colitis ulcerative, multiple sclerosis, RA, transplant rejection, allergic contact dermatitis, hepatitis C infection; HIV infection and atherosclerosis.

It will be appreciated, however, that since the polypeptide sequences of this  
20 aspect of the present invention are devoid of a transmembrane and intracellular domains while retain the extracellular region of IL-10-R $\beta$  (i.e., IL-10 binding site), they are most likely to compete with IL-10 binding to the functional, membrane bound, IL-10-R $\beta$  receptor and as a consequence block IL-10R activation and signaling pathway. Thus, due to their predicted antagonistic effects, the biomolecular  
25 sequences of this aspect of the present invention may be used to treat diseases which depend on IL-10R (i.e., activity and/or expression) for their onset or progression. Examples include, but are not limited to, cancer, such as lymphoma, melanoma and carcinoma, and infection with visceral leishmaniasis.

Thus, this aspect of the present invention envisages treatment of the above-  
30 mentioned diseases by the provision of agents, which are capable of upregulating expression of the polypeptides of the present invention in a subject in need thereof. Such agents and administration thereof are further described hereinbelow.

*Interferon- $\alpha/\beta$ -receptor-1-INR1 splice variant*

According to yet a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 43 or 40.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of an INR1 gene (Swissprot Locus No. INR1\_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the INR1 polypeptides of the present invention. Examples include but are not limited to ligand binding, antibody specific recognition, modulation of immune responses (see Example 10 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 41 or 42.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 43 or 40 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., of the INR1 gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 41 or 42. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO:

41 or 42. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

5 As is mentioned hereinabove and in Example 10 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "INR1-related diseases", due to their enhanced agonistic properties. These include increasing the stability of the ligand (e.g., interferon), protection from proteolysis and modification of the  
10 pharmacokinetic properties of the ligand (i.e., increasing the half-life of the ligand, while decreasing the clearance thereof).

Thus, the biomolecular sequences may be used to treat a number of diseases in which INR1 plays a favorable role. Examples of such diseases include, but are not limited to, cancer, such as, solid tumors (e.g., glioblastoma, renal cell carcinoma,  
15 melanoma) and hematological malignancies [e.g., chronic myelogenous leukemia (CML), multiple myeloma, non-Hodgkin's lymphoma and hairy cell leukemia], viral infections (e.g., hepatitis B/C, herpes and human papilloma virus) and autoimmune diseases such as multiple sclerosis.

As mentioned hereinabove, the polypeptide sequences of the present invention  
20 can be used in a number of therapeutic applications. In such applications it is highly desirable to employ the minimal and most efficacious peptide regions, which still exert inhibitory function. Identification of such peptide regions can be effected using various approaches, including, for example, display techniques.

Thus, according to still a further aspect of the present invention there is  
25 provided a display library comprising a plurality of display vehicles (such as phages, viruses or bacteria) each displaying at least 6, at least 7, at least 8, at least 9, at least 10, 10-15, 12-17, 15-20, 15-30 or 20-50 consecutive amino acids derived from the polypeptide sequences of the present invention.

Methods of constructing such display libraries are well known in the art. Such  
30 methods are described in, for example, Young AC, *et al.*, "The three-dimensional structures of a polysaccharide binding antibody to *Cryptococcus neoformans* and its complex with a peptide from a phage display library: implications for the identification of peptide mimotopes" J Mol Biol 1997 Dec 12;274(4):622-34; Giebel

LB *et al.* "Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities" *Biochemistry* 1995 Nov 28;34(47):15430-5; Davies EL *et al.*, "Selection of specific phage-display antibodies using libraries derived from chicken immunoglobulin genes" *J Immunol Methods* 1995 Oct 12;186(1):125-35;  
5 Jones C RT *al.* "Current trends in molecular recognition and bioseparation" *J Chromatogr A* 1995 Jul 14;707(1):3-22; Deng SJ *et al.* "Basis for selection of improved carbohydrate-binding single-chain antibodies from synthetic gene libraries" *Proc Natl Acad Sci U S A* 1995 May 23;92(11):4992-6; and Deng SJ *et al.* "Selection of antibody single-chain variable fragments with improved carbohydrate binding by  
10 phage display" *J Biol Chem* 1994 Apr 1;269(13):9533-8, which are incorporated herein by reference.

Peptide sequences which exhibit high therapeutic activity, such as by competing with wild type signaling proteins of the same signaling pathway, can be also uncovered using computational biology. Software programs useful for displaying  
15 three-dimensional structural models, such as RIBBONS (Carson, M., 1997. *Methods in Enzymology* 277, 25), O (Jones, TA. *et al.*, 1991. *Acta Crystallogr.* A47, 110), DINO (DINO: Visualizing Structural Biology (2001) <http://www.dino3d.org>); and QUANTA, INSIGHT, SYBYL, MACROMODE, ICM, MOLMOL, RASMOL and GRASP (reviewed in Kraulis, J., 1991. *Appl Crystallogr.* 24, 946) can be utilized to  
20 model interactions between the polypeptides of the present invention and prospective peptide sequences to thereby identify peptides which display the highest probability of binding for example to a respective ligand (e.g., IL-10). Computational modeling of protein-peptide interactions has been successfully used in rational drug design, for further detail, see Lam *et al.*, 1994. *Science* 263, 380; Wlodawer *et al.*, 1993. *Ann Rev*  
25 *Biochem.* 62, 543; Appelt, 1993. *Perspectives in Drug Discovery and Design* 1, 23; Erickson, 1993. *Perspectives in Drug Discovery and Design* 1, 109, and Mauro MJ. *et al.*, 2002. *J Clin Oncol.* 20, 325-34.

It will be appreciated that peptides identified according to the teachings of the present invention may be degradation products, synthetic peptides or recombinant  
30 peptides as well as peptidomimetics, typically, synthetic peptides and peptoids and semipeptoids which are peptide analogs, which may have, for example, modifications rendering the peptides more stable while in a body or more capable of penetrating into cells. Such modifications include, but are not limited to N terminus modification, C



terminus modification, peptide bond modification, including, but not limited to, CH<sub>2</sub>-NH, CH<sub>2</sub>-S, CH<sub>2</sub>-S=O, O=C-NH, CH<sub>2</sub>-O, CH<sub>2</sub>-CH<sub>2</sub>, S=C-NH, CH=CH or CF=CH, backbone modifications, and residue modification. Methods for preparing peptidomimetic compounds are well known in the art and are specified, for example, in Quantitative Drug Design, C.A. Ramsden Gd., Chapter 17.2, F. Choplin Pergamon Press (1992), which is incorporated by reference as if fully set forth herein. Further details in this respect are provided hereinunder.

Peptide bonds (-CO-NH-) within the peptide may be substituted, for example, by N-methylated bonds (-N(CH<sub>3</sub>)-CO-), ester bonds (-C(R)H-C-O-O-C(R)-N-), ketomethylen bonds (-CO-CH<sub>2</sub>-),  $\alpha$ -aza bonds (-NH-N(R)-CO-), wherein R is any alkyl, e.g., methyl, carba bonds (-CH<sub>2</sub>-NH-), hydroxyethylene bonds (-CH(OH)-CH<sub>2</sub>-), thioamide bonds (-CS-NH-), olefinic double bonds (-CH=CH-), retro amide bonds (-NH-CO-), peptide derivatives (-N(R)-CH<sub>2</sub>-CO-), wherein R is the "normal" side chain, naturally presented on the carbon atom.

These modifications can occur at any of the bonds along the peptide chain and even at several (2-3) at the same time.

Natural aromatic amino acids, Trp, Tyr and Phe, may be substituted for synthetic non-natural acid such as Phenylglycine, TIC, naphthylelanine (Nol), ring-methylated derivatives of Phe, halogenated derivatives of Phe or o-methyl-Tyr.

In addition to the above, the peptides of the present invention may also include one or more modified amino acids or one or more non-amino acid monomers (e.g. fatty acids, complex carbohydrates etc).

As used herein in the specification and in the claims section below the term "amino acid" or "amino acids" is understood to include the 20 naturally occurring amino acids; those amino acids often modified post-translationally *in vivo*, including, for example, hydroxyproline, phosphoserine and phosphothreonine; and other unusual amino acids including, but not limited to, 2-aminoadipic acid, hydroxylysine, isodesmosine, nor-valine, nor-leucine and ornithine. Furthermore, the term "amino acid" includes both D- and L-amino acids.

Tables 1 and 2 below list naturally occurring amino acids (Table 1) and non-conventional or modified amino acids (Table 2) which can be used with the present invention.

Table 1

<i>Amino Acid</i>	<i>Three-Letter Abbreviation</i>	<i>One-letter Symbol</i>
alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid	Asp	D
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic Acid	Glu	E
glycine	Gly	G
Histidine	His	H
isoleucine	Ile	I
leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
tryptophan	Trp	W
tyrosine	Tyr	Y
Valine	Val	V
Any amino acid as above	Xaa	X

Table 2

<i>Non-conventional amino acid</i>	<i>Code</i>	<i>Non-conventional amino acid</i>	<i>Code</i>
$\alpha$ -aminobutyric acid	Abu	L-N-methylalanine	Nmala
$\alpha$ -amino-	Mgab	L-N-methylarginine	Nmarg
$\alpha$ -methylbutyrate			
aminocyclopropane-	Cpro	L-N-methylasparagine	Nmasn
carboxylate		L-N-methylaspartic acid	Nmasp
aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
aminonorbomyl-	Norb	L-N-methylglutamine	Nmgin
carboxylate		L-N-methylglutamic acid	Nmglu
cyclohexylalanine	Chexa	L-N-methylhistidine	Nmhis
cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
D-alanine	Dal	L-N-methylleucine	Nmleu
D-arginine	Darg	L-N-methyllysine	Nmlys
D-aspartic acid	Dasp	L-N-methylmethionine	Nmmet
D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
D-isoleucine	Dile	L-N-methylproline	Nmpro
D-leucine	Dleu	L-N-methylserine	Nmser
D-lysine	Dlys	L-N-methylthreonine	Nmthr
D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
D-ornithine	Dom	L-N-methyltyrosine	Nmtyr
D-phenylalanine	Dphe	L-N-methylvaline	Nmval
D-proline	Dpro	L-N-methylethylglycine	Nmetg
D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug
D-threonine	Dthr	L-norleucine	Nle
D-tryptophan	Dtrp	L-norvaline	Nva
D-tyrosine	Dtyr	$\alpha$ -methyl-aminoisobutyrate	Maib
D-valine	Dval	$\alpha$ -methyl- $\gamma$ -aminobutyrate	Mgab
D- $\alpha$ -methylalanine	Dmala	$\alpha$ -methylcyclohexylalanine	Mchexa
D- $\alpha$ -methylarginine	Dmarg	$\alpha$ -methylcyclopentylalanine	Mcpen
D- $\alpha$ -methylasparagine	Dmasn	$\alpha$ -methyl- $\alpha$ -naphthylalanine	Manap

D- $\alpha$ -methylaspartate	Dmasp	$\alpha$ -methylpenicillamine	Mpen
D- $\alpha$ -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
D- $\alpha$ -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
D- $\alpha$ -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
D- $\alpha$ -methylisoleucine	Dmile	N-amino- $\alpha$ -methylbutyrate	Nmaabu
D- $\alpha$ -methylleucine	Dmleu	$\alpha$ -naphthylalanine	Anap
D- $\alpha$ -methyllysine	Dmlys	N-benzylglycine	Nphe
D- $\alpha$ -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
D- $\alpha$ -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
D- $\alpha$ -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
D- $\alpha$ -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
D- $\alpha$ -methylserine	Dmser	N-cyclobutylglycine	Ncbut
D- $\alpha$ -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
D- $\alpha$ -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
D- $\alpha$ -methyltyrosine	Dmtyr	N-cyclodecylglycine	Ncdec
D- $\alpha$ -methylvaline	Dmval	N-cyclododecylglycine	Ncdod
D- $\alpha$ -methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
D- $\alpha$ -methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
D- $\alpha$ -methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
D- $\alpha$ -methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
D- $\alpha$ -methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
D-N-methylleucine	Dnmleu	N-(3-indolylethyl)glycine	Nhtrp
D-N-methyllysine	Dnmlys	N-methyl- $\gamma$ -aminobutyrate	Nmgabu
N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
N-(2-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nva
D-N-methyltyrosine	Dnmtyr	N-methyl- $\alpha$ -naphthylalanine	Nmanap
D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
$\gamma$ -aminobutyric acid	Gabu	N-(p-hydroxyphenyl)glycine	Nhtyr
L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
L-ethylglycine	Etg	penicillamine	Pen
L-homophenylalanine	Hphe	L- $\alpha$ -methylalanine	Mala
L- $\alpha$ -methylarginine	Marg	L- $\alpha$ -methylasparagine	Masn
L- $\alpha$ -methylaspartate	Masp	L- $\alpha$ -methyl- <i>t</i> -butylglycine	Mtbug
L- $\alpha$ -methylcysteine	Mcys	L-methylethylglycine	Metg
L- $\alpha$ -methylglutamine	Mgln	L- $\alpha$ -methylglutamate	Mglu
L- $\alpha$ -methylhistidine	Mhis	L- $\alpha$ -methylhomo phenylalanine	Mhphe
L- $\alpha$ -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
D-N-methylisoleucine	Dnmile	N-(imidazolethyl)glycine	Nhis
D-N-methylleucine	Dnmleu	N-(3-indolylethyl)glycine	Nhtrp
D-N-methyllysine	Dnmlys	N-methyl- $\gamma$ -aminobutyrate	Nmgabu
N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe

N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
D-N-methyltyrosine	Dnmtyr	N-methyl- $\alpha$ -naphthylalanine	Nmanap
D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
$\gamma$ -aminobutyric acid	Gabu	N-( <i>p</i> -hydroxyphenyl)glycine	Nhtyr
L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
L-ethylglycine	Etg	penicillamine	Pen
L-homophenylalanine	Hphe	L- $\alpha$ -methylalanine	Mala
L- $\alpha$ -methylarginine	Marg	L- $\alpha$ -methylasparagine	Masn
L- $\alpha$ -methylaspartate	Masp	L- $\alpha$ -methyl- <i>t</i> -butylglycine	Mtbug
L- $\alpha$ -methylcysteine	Mcys	L-methylethylglycine	Metg
L- $\alpha$ -methylglutamine	Mgln	L- $\alpha$ -methylglutamate	Mglu
L- $\alpha$ -methylhistidine	Mhis	L- $\alpha$ -methylhomophenylalanine	Mhphe
L- $\alpha$ -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
L- $\alpha$ -methylleucine	Mleu	L- $\alpha$ -methyllysine	Mlys
L- $\alpha$ -methylmethionine	Mmet	L- $\alpha$ -methylnorleucine	Mnle
L- $\alpha$ -methylnorvaline	Mnva	L- $\alpha$ -methylornithine	Morn
L- $\alpha$ -methylphenylalanine	Mphe	L- $\alpha$ -methylproline	Mpro
L- $\alpha$ -methylserine	mser	L- $\alpha$ -methylthreonine	Mthr
L- $\alpha$ -methylvaline	Mtrp	L- $\alpha$ -methyltyrosine	Mtyr
L- $\alpha$ -methylleucine	Mval Nnbhm	L-N-methylhomophenylalanine	Nmhph
N-(N-(2,2-diphenylethyl))		N-(N-(3,3-diphenylpropyl))	
carbamylmethyl-glycine	Nnbhm	carbamylmethyl(1)glycine	Nnbhe
1-carboxy-1-(2,2-diphenyl ethylamino) cyclopropane	Nmbc		

Table 2 Cont.

Since the peptides of the present invention are preferably utilized in therapeutics which require the peptides to be in soluble form, the peptides of the present invention preferably include one or more non-natural or natural polar amino acids, including but not limited to serine and threonine which are capable of increasing peptide solubility due to their hydroxyl-containing side chain.

The peptides of the present invention are preferably utilized in a linear form, although it will be appreciated that in cases where cyclicization does not severely interfere with peptide characteristics, cyclic forms of the peptide can also be utilized.

The peptides of present invention can be biochemically synthesized such as by using standard solid phase techniques. These methods include exclusive solid phase synthesis, partial solid phase synthesis methods, fragment condensation, classical solution synthesis. These methods are preferably used when the peptide is relatively

short (i.e., 10 kDa) and/or when it cannot be produced by recombinant techniques (i.e., not encoded by a nucleic acid sequence) and therefore involves different chemistry.

Solid phase peptide synthesis procedures are well known in the art and further described by John Morrow Stewart and Janis Dillaha Young, Solid Phase Peptide  
5 Syntheses (2nd Ed., Pierce Chemical Company, 1984).

Synthetic peptides can be purified by preparative high performance liquid chromatography [Creighton T. (1983) Proteins, structures and molecular principles. WH Freeman and Co. N.Y.] and the composition of which can be confirmed via amino acid sequencing.

10 In cases where large amounts of the peptides of the present invention are desired, the peptides of the present invention can be generated using recombinant techniques such as described by Bitter et al., (1987) Methods in Enzymol. 153:516-544, Studier et al. (1990) Methods in Enzymol. 185:60-89, Brisson et al. (1984) Nature 310:511-514, Takamatsu et al. (1987) EMBO J. 6:307-311, Coruzzi et al.  
15 (1984) EMBO J. 3:1671-1680 and Brogli et al., (1984) Science 224:838-843, Gurley et al. (1986) Mol. Cell. Biol. 6:559-565 and Weissbach & Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp 421-463.

Briefly, polynucleotides encoding the polypeptides of the present invention are first cloned into an appropriate nucleic acid construct (i.e., vector).

20 To enable cellular expression of the proteins of the present invention, the nucleic acid construct of the present invention further includes at least one cis acting regulatory element. As used herein, the phrase "cis acting regulatory element" refers to a polynucleotide sequence, preferably a promoter, which binds a trans acting regulator and regulates the transcription of a coding sequence located downstream  
25 thereto.

Any available promoter can be used by the present methodology dependent on the host cell (e.g., eukaryotic, prokaryotic).

The nucleic acid construct of the present invention can further include an enhancer, which can be adjacent or distant to the promoter sequence and can function  
30 in up regulating the transcription therefrom.

The constructs of the present methodology preferably further include an appropriate selectable marker and/or an origin of replication. Preferably, the construct utilized is a shuttle vector, which can propagate both in *E. coli* (wherein the

construct comprises an appropriate selectable marker and origin of replication) and be compatible for propagation in cells, or integration in a gene and a tissue of choice. The construct according to the present invention can be, for example, a plasmid, a bacmid, a phagemid, a cosmid, a phage, a virus or an artificial chromosome.

5        Other then containing the necessary elements for the transcription and translation of the inserted coding sequence, the expression construct of the present invention can also include sequences engineered to enhance stability, production, purification, yield or toxicity of the expressed peptide. For example, the expression of a fusion protein or a cleavable fusion protein comprising Met variant of the  
10        present invention and a heterologous protein can be engineered. Such a fusion protein can be designed so that the fusion protein can be readily isolated by affinity chromatography; e.g., by immobilization on a column specific for the heterologous protein. Where a cleavage site is engineered between the Met moiety and the heterologous protein, the Met moiety can be released from the chromatographic  
15        column by treatment with an appropriate enzyme or agent that disrupts the cleavage site [e.g., see Booth et al. (1988) *Immunol. Lett.* 19:65-70; and Gardella et al., (1990) *J. Biol. Chem.* 265:15854-15859].

As mentioned hereinabove, a variety of prokaryotic or eukaryotic cells can be used as host-expression systems to express the polypeptides of the present invention.  
20        These include, but are not limited to, microorganisms, such as bacteria transformed with a recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vector containing the coding sequence; yeast transformed with recombinant yeast expression vectors containing the coding sequence; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco  
25        mosaic virus, TMV) or transformed with recombinant plasmid expression vectors, such as Ti plasmid, containing the coding sequence. Mammalian expression systems can also be used to express the polypeptides of the present invention.

Examples of bacterial constructs include the pET series of *E. coli* expression vectors [Studier et al. (1990) *Methods in Enzymol.* 185:60-89].

30        In yeast, a number of vectors containing constitutive or inducible promoters can be used, as disclosed in U.S. Pat. Application No: 5,932,447. Alternatively, vectors can be used which promote integration of foreign DNA sequences into the yeast chromosome.

In cases where plant expression vectors are used, the expression of the coding sequence can be driven by a number of promoters. For example, viral promoters such as the 35S RNA and 19S RNA promoters of CaMV [Brisson et al. (1984) Nature 310:511-514], or the coat protein promoter to TMV [Takamatsu et al. (1987) EMBO J. 6:307-311] can be used. Alternatively, plant promoters such as the small subunit of RUBISCO [Coruzzi et al. (1984) EMBO J. 3:1671-1680 and Brogli et al., (1984) Science 224:838-843] or heat shock promoters, e.g., soybean hsp17.5-E or hsp17.3-B [Gurley et al. (1986) Mol. Cell. Biol. 6:559-565] can be used. These constructs can be introduced into plant cells using Ti plasmid, Ri plasmid, plant viral vectors, direct DNA transformation, microinjection, electroporation and other techniques well known to the skilled artisan. See, for example, Weissbach & Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp 421-463.

Other expression systems such as insects and mammalian host cell systems which are well known in the art and are further described hereinbelow can also be used by the present invention.

Constructs encoding the polypeptides of the present invention are transformed into an appropriate host cell. Transformed cells are cultured under conditions, which allow for the expression of high amounts of recombinant polypeptide. Such conditions include, but are not limited to, media, bioreactor, temperature, pH and oxygen conditions that permit protein production. "Media" refers to any medium in which a cell is cultured to produce the recombinant polypeptide of the present invention. Such a medium typically includes an aqueous solution having assimilable carbon, nitrogen and phosphate sources, and appropriate salts, minerals, metals and other nutrients, such as vitamins. Cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes, and petri plates. Culturing can be carried out at a temperature, pH and oxygen content appropriate for a recombinant cell. Such culturing conditions are well known to one of ordinary skill in the art.

Recovery of the recombinant polypeptide is effected following an appropriate time in culture. The phrase "recovering the recombinant polypeptide" refers to collecting the whole fermentation medium containing the polypeptide and need not imply additional steps of separation or purification. Notwithstanding the above,

polypeptides of the present invention can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, 5 concanavalin A chromatography, chromatofocusing and differential solubilization.

As mentioned hereinabove, the biomolecular sequences of the present invention can be used to treat subjects with the above-described diseases.

The subject according to the present invention is a mammal, preferably a human which is diagnosed with one of the diseases described hereinabove, or 10 alternatively is predisposed to having one of the diseases described hereinabove.

As used herein the term "treating" refers to preventing, curing, reversing, attenuating, alleviating, minimizing, suppressing or halting the deleterious effects of the above-described diseases.

Treating, according to the present invention, can be effected by specifically 15 upregulating the expression of at least one of the polypeptides of the present invention in the subject.

Upregulating expression of the polypeptides of the present invention in a subject may be effected via the administration of at least one of the exogenous polynucleotide sequences of the present invention (e.g., SEQ ID NOs: 3, 7, 11, 15, 19, 20 23, 27, 31, 35, 39 or 43) ligated into a nucleic acid expression construct designed for expression of coding sequences in eukaryotic cells (e.g., mammalian cells). Accordingly, the exogenous polynucleotide sequence may be a DNA or RNA sequence encoding the variants of the present invention or active portions thereof.

It will be appreciated that the nucleic acid construct can be administered to 25 the individual employing any suitable mode of administration, described hereinbelow (i.e., in-vivo gene therapy). Alternatively, the nucleic acid construct is introduced into a suitable cell via an appropriate gene delivery vehicle/method (transfection, transduction, homologous recombination, etc.) and an expression system as needed and then the modified cells are expanded in culture and returned to the individual 30 (i.e., ex-vivo gene therapy).

Preferably, the promoter utilized by the nucleic acid construct of the present invention is active in the specific cell population transformed. Examples of cell type-specific and/or tissue-specific promoters include promoters, such as albumin that is



liver specific [Pinkert et al., (1987) *Genes Dev.* 1:268-277], lymphoid specific promoters [Calame et al., (1988) *Adv. Immunol.* 43:235-275]; in particular promoters of T-cell receptors [Winoto et al., (1989) *EMBO J.* 8:729-733] and immunoglobulins; [Banerji et al. (1983) *Cell* 33729-740], neuron-specific promoters such as the neurofilament promoter [Byrne et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477], pancreas-specific promoters [Edlunch et al. (1985) *Science* 230:912-916] or mammary gland-specific promoters such as the milk whey promoter (U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166).

Examples of suitable constructs include, but are not limited to, pcDNA3, pcDNA3.1 (+/-), pGL3, PzeoSV2 (+/-), pDisplay, pEF/myc/cyto, pCMV/myc/cyto each of which is commercially available from Invitrogen Co. ([www.invitrogen.com](http://www.invitrogen.com)). Examples of retroviral vector and packaging systems are those sold by Clontech, San Diego, Calif., including Retro-X vectors pLNCX and pLXSN, which permit cloning into multiple cloning sites and the transgene is transcribed from CMV promoter. Vectors derived from Mo-MuLV are also included such as pBabe, where the transgene will be transcribed from the 5'LTR promoter.

Currently preferred in vivo nucleic acid transfer techniques include transfection with viral or non-viral constructs, such as adenovirus, lentivirus, Herpes simplex I virus, or adeno-associated virus (AAV) and lipid-based systems. Useful lipids for lipid-mediated transfer of the gene are, for example, DOTMA, DOPE, and DC-Chol [Tonkinson et al., *Cancer Investigation*, 14(1): 54-65 (1996)]. The most preferred constructs for use in gene therapy are viruses, most preferably adenoviruses, AAV, lentiviruses, or retroviruses. A viral construct such as a retroviral construct includes at least one transcriptional promoter/enhancer or locus-defining element(s), or other elements that control gene expression by other means such as alternate splicing, nuclear RNA export, or post-translational modification of messenger. Such vector constructs also include a packaging signal, long terminal repeats (LTRs) or portions thereof, and positive and negative strand primer binding sites appropriate to the virus used, unless it is already present in the viral construct. In addition, such a construct typically includes a signal sequence for secretion of the peptide from a host cell in which it is placed. Preferably the signal sequence for this purpose is a mammalian signal sequence or the signal sequence of the polypeptide variants of the present invention. Optionally, the construct may also include a signal that directs

polyadenylation, as well as one or more restriction sites and a translation termination sequence. By way of example, such constructs will typically include a 5' LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3' LTR or a portion thereof. Other vectors can be used that are non-viral, such as cationic lipids, polylysine, and dendrimers.

It will be appreciated that the present methodology may also be effected by specifically upregulating the expression of the splice variants of the present invention endogenously in the subject. Agents for upregulating endogenous expression of specific splice variants of a given gene include antisense oligonucleotides, which are directed at splice sites of interest, thereby altering the splicing pattern of the gene. This approach has been successfully used for shifting the balance of expression of the two isoforms of Bcl-x [Taylor (1999) *Nat. Biotechnol.* 17:1097-1100; and Mercatante (2001) *J. Biol. Chem.* 276:16411-16417]; IL-5R [Karras (2000) *Mol. Pharmacol.* 58:380-387]; and c-myc [Giles (1999) *Antisense Acid Drug Dev.* 9:213-220].

For example, interleukin 5 and its receptor play a critical role as regulators of hematopoiesis and as mediators in some inflammatory diseases such as allergy and asthma. Two alternatively spliced isoforms are generated from the IL-5R gene, which include (i.e., long form) or exclude (i.e., short form) exon 9. The long form encodes for the intact membrane-bound receptor, while the shorter form encodes for a secreted soluble non-functional receptor. Using 2'-O-MOE-oligonucleotides specific to regions of exon 9, Karras and co-workers (supra) were able to significantly decrease the expression of the wild type receptor and increase the expression of the shorter isoforms. Design and synthesis of oligonucleotides which can be used according to the present invention are described hereinbelow and by Sazani and Kole (2003) *Progress in Molecular and Subcellular Biology* 31:217-239.

Alternatively or additionally, upregulation may be effected by administering to the subject at least one of the polypeptides of the present invention (e.g., recombinant or synthetic) or an active portion thereof, as described hereinabove. However, since the bioavailability of large polypeptides is relatively small due to high degradation rate and low penetration rate, administration of polypeptides is preferably confined to small peptide fragments (e.g., about 100 amino acids).

The agents of the present invention (e.g., polynucleotides, polypeptides, oligonucleotides) can be provided to the subject *per se*, or as part of a pharmaceutical composition where they are mixed with a pharmaceutically acceptable carrier.

As used herein a "pharmaceutical composition" refers to a preparation of one  
5 or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

Herein the term "active ingredient" refers to the preparation accountable for the  
10 biological effect (e.g., polynucleotides, polypeptides, oligonucleotides of the present invention).

Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically acceptable carrier" which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does  
15 not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases. One of the ingredients included in the pharmaceutically acceptable carrier can be for example polyethylene glycol (PEG), a biocompatible polymer with a wide range of solubility in both organic and aqueous media (Mutter et al. (1979).

Herein the term "excipient" refers to an inert substance added to a  
20 pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

25 Techniques for formulation and administration of drugs may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.

Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including  
30 intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections. Alternately, one may administer a preparation in a local rather than systemic manner,

for example, via injection of the preparation directly into a specific region of a patient's body.

Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving,  
5 granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the present invention may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing  
10 of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For injection, the active ingredients of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer. For transmucosal  
15 administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be  
20 formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in  
25 particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added,  
30 such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic,

talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

5        Pharmaceutical compositions, which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the  
10        active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.

15        For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

20        For administration by nasal inhalation, the active ingredients for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro- tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

25        The preparations described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

30        Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame

oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which  
5 increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.

Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.

The preparation of the present invention may also be formulated in rectal  
10 compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.

Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically  
15 effective amount means an amount of active ingredients effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.

Determination of a therapeutically effective amount is well within the capability of those skilled in the art.

For any preparation used in the methods of the invention, the therapeutically  
20 effective amount or dose can be estimated initially from in vitro assays. For example, a dose can be formulated in animal models and such information can be used to more accurately determine useful doses in humans.

Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures *in vitro*, in cell cultures or  
25 experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g.,  
30 Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.1).

Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment

lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.

The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.

Compositions including the preparation of the present invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.

Pharmaceutical compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.

It will be appreciated that treatment of the above-described diseases according to the present invention may be combined with other treatment methods known in the art (i.e., combination therapy). Thus, treatment of malignancies using the agents of the present invention may be combined with, for example, radiation therapy, antibody therapy and/or chemotherapy.

It will be appreciated that since abnormal expression (i.e., upregulation or downregulation as compared to normal state) of these biomolecular sequences may contribute to disease onset or progression or be present during the course of the disease, such biomolecular sequences can also be used as valuable diagnostic markers.

Thus, the present invention also envisages determining a level of a biomolecular sequence of the present invention (i.e., a polynucleotide or a polypeptide) in a biological sample obtained from the subject. Wherein the level determined can be correlated with predisposition to, or presence or absence of the

above-described corresponding disease, thereby diagnosing predisposition to, or presence of such disease in the subject.

As used herein the term "diagnosing" refers to classifying a disease or a symptom, determining a severity of the disease, monitoring disease progression and therapeutic treatment, forecasting an outcome of a disease and/or prospects of recovery.

As used herein, the term "level" refers to expression levels of RNA and/or protein or to DNA copy number of the variants of the present invention.

A level correlatable with predisposition to, or presence or absence of a disease can be a level of a variant of the present invention in a pathological sample which is different (i.e., increased or decreased) from the level of the same variant in a normal healthy sample obtained from a similar tissue or cellular origin.

As used herein "a biological sample" refers to a sample of tissue or fluid isolated from the subject, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, tumors, organs, and also samples of in vivo cell culture constituents.

Numerous well known tissue or fluid collection methods can be utilized to collect the biological sample from the subject in order to determine the level of DNA, RNA and/or polypeptide of the variants of the present invention in the subject.

Examples include, but are not limited to, fine needle biopsy, needle biopsy, core needle biopsy and surgical biopsy.

Regardless of the procedure employed, once a biopsy is obtained the level of the variants of the present invention can be determined and a diagnosis can thus be made.

Determining a level of the variants of the present invention can be effected using various biochemical and molecular approaches used in the art for determining gene amplification, and/or level of gene expression.

Determining the level of the variants of the present invention in normal tissues of the same origin is preferably effected along side to detect an elevated expression and/or amplification. Additionally or alternatively, determining the level of wild-type gene product (e.g., c-Met) is preferably effected along side.



Typically, detection of a nucleic acid of interest in a biological sample is effected by hybridization-based assays using an oligonucleotide probe.

The term "oligonucleotide" refers to a single stranded or double stranded oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-  
5 occurring bases, sugars and covalent internucleoside linkages (e.g., backbone) as well as oligonucleotides having non-naturally-occurring portions which function similarly to respective naturally-occurring portions. For example, an oligonucleotide probe which can be utilized by the present invention is a single stranded polynucleotide  
10 which includes a sequence complementary to a unique sequence region of a variant of the present invention (e.g., SEQ ID NO: 4).

Oligonucleotides designed according to the teachings of the present invention can be generated according to any oligonucleotide synthesis method known in the art such as enzymatic synthesis or solid phase synthesis. Equipment and reagents for  
15 executing solid-phase synthesis are commercially available from, for example, Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the capabilities of one skilled in the art and can be accomplished via established methodologies as detailed in, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989);  
20 "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988) and "Oligonucleotide Synthesis" Gait, M. J., ed. (1984) utilizing solid phase chemistry, e.g. cyanoethyl phosphoramidite followed by  
25 deprotection, desalting and purification by for example, an automated trityl-on method or HPLC.

The oligonucleotide of the present invention is of at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 22, at least 25, at least 30 or at least 40; bases specifically  
30 hybridizable with the variants of the present invention.

The oligonucleotides of the present invention may comprise heterocyclic nucleosides consisting of purines and the pyrimidines bases, bonded in a 3' to 5' phosphodiester linkage.

Preferably used oligonucleotides are those modified in either backbone, internucleoside linkages or bases, as is broadly described hereinunder. These can be efficiently used for in-vivo diagnosis procedures.

Specific examples of preferred oligonucleotides useful according to this aspect of the present invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. Oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone, as disclosed in U.S. Pat. NOs: 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms can also be used.

Alternatively, modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts, as disclosed in U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240;

5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623, 070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439.

Other oligonucleotides which can be used according to the present invention, are those modified in both sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for complementation with the appropriate polynucleotide target. An example for such an oligonucleotide mimetic, includes peptide nucleic acid (PNA). A PNA oligonucleotide refers to an oligonucleotide where the sugar-backbone is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The bases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Other backbone modifications, which can be used in the present invention are disclosed in U.S. Pat. No: 6,303,374.

Oligonucleotides of the present invention may also include base modifications or substitutions. As used herein, "unmodified" or "natural" bases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified bases include but are not limited to other synthetic and natural bases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further bases include those disclosed in U.S. Pat. No: 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, pages 289-302,

Crooke, S. T. and Lebleu, B. , ed., CRC Press, 1993. Such bases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2 °C. [Sanghvi YS et al. (1993) Antisense Research and Applications, CRC Press, Boca Raton 276-278] and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

It will be appreciated that oligonucleotides of the present invention may include further modifications which increase bioavailability, therapeutic efficacy and reduce cytotoxicity. Such modifications are described in Younes (2002) Current Pharmaceutical Design 8:1451-1466.

Hybridization based assays which allow the detection of the variants of the present invention (i.e., DNA or RNA) in a biological sample rely on the use of oligonucleotide which can be 10, 15, 20, or 30 to 100 nucleotides long preferably from 10 to 50, more preferably from 40 to 50 nucleotides. It will be appreciated, though, that the length of the oligonucleotide of the present invention will greatly depend on the length and composition of the unique nucleic acid sequence region of the variant.

Hybridization of short nucleic acids (below 200 bp in length, e.g. 17-40 bp in length) can be effected using the following exemplary hybridization protocols which can be modified according to the desired stringency; (i) hybridization solution of 6 x SSC and 1 % SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS, 100 µg/ml denatured salmon sperm DNA and 0.1 % nonfat dried milk, hybridization temperature of 1 - 1.5 °C below the  $T_m$ , final wash solution of 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS at 1 - 1.5 °C below the  $T_m$ ; (ii) hybridization solution of 6 x SSC and 0.1 % SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS, 100 µg/ml denatured salmon sperm DNA and 0.1 % nonfat dried milk, hybridization temperature of 2 - 2.5 °C below the  $T_m$ , final wash solution of 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS at 1 - 1.5 °C below the  $T_m$ , final wash solution of 6 x SSC, and final wash at 22 °C; (iii) hybridization

solution of 6 x SSC and 1 % SDS or 3 M TMACl, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS, 100 µg/ml denatured salmon sperm DNA and 0.1 % nonfat dried milk, hybridization temperature.

The detection of hybrid duplexes can be carried out by a number of methods. Typically, hybridization duplexes are separated from unhybridized nucleic acids and the labels bound to the duplexes are then detected. Such labels refer to radioactive, fluorescent, biological or enzymatic tags or labels of standard use in the art. A label can be conjugated to either the oligonucleotide probes or the nucleic acids derived from the biological sample (target).

For example, oligonucleotides of the present invention can be labeled subsequent to synthesis, by incorporating biotinylated dNTPs or rNTP, or some similar means (e.g., photo-cross-linking a psoralen derivative of biotin to RNAs), followed by addition of labeled streptavidin (e.g., phycoerythrin-conjugated streptavidin) or the equivalent. Alternatively, when fluorescently-labeled oligonucleotide probes are used, fluorescein, lissamine, phycoerythrin, rhodamine (Perkin Elmer Cetus), Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, FluorX (Amersham) and others [e.g., Kricka et al. (1992), Academic Press San Diego, Calif] can be attached to the oligonucleotides.

Traditional hybridization assays include PCR, RT-PCR, real-time PCR, RNase protection, in-situ hybridization, primer extension, Southern blot, Northern Blot and dot blot analysis.

Those skilled in the art will appreciate that wash steps may be employed to wash away excess target DNA or probe as well as unbound conjugate. Further, standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the oligonucleotide primers and probes.

It will be appreciated that a variety of controls may be usefully employed to improve accuracy of hybridization assays. For instance, samples may be hybridized to an irrelevant probe and treated with RNase A prior to hybridization, to assess false hybridization.

It will be appreciated that antisense oligonucleotides may be employed to quantify expression of a splice isoform of interest. Such detection is effected at the pre-mRNA level. Essentially the ability to quantitate transcription from a splice site of interest can be effected based on splice site accessibility. Oligonucleotides may

compete with splicing factors for the splice site sequences. Thus, low activity of the antisense oligonucleotide is indicative of splicing activity [see Sazani and Kole (2003), supra].

Polymerase chain reaction (PCR)-based methods may be used to identify the presence of mRNAs of the variants of the present invention. For PCR-based methods a pair of oligonucleotides is used, which is specifically hybridizable with the polynucleotide sequences described hereinabove in an opposite orientation so as to direct exponential amplification of a portion thereof (including the hereinabove described sequence alteration) in a nucleic acid amplification reaction.

The polymerase chain reaction and other nucleic acid amplification reactions are well known in the art and require no further description herein. The pair of oligonucleotides according to this aspect of the present invention are preferably selected to have compatible melting temperatures ( $T_m$ ), e.g., melting temperatures which differ by less than that 7 °C, preferably less than 5 °C, more preferably less than 4 °C, most preferably less than 3 °C, ideally between 3 °C and 0 °C.

Hybridization to oligonucleotide arrays may be also used to determine expression of the variants of the present invention. Such screening has been undertaken in the BRCA1 gene and in the protease gene of HIV-1 virus [see Hacia et al., (1996) Nat Genet 1996;14(4):441-447; Shoemaker et al., (1996) Nat Genet 1996;14(4):450-456; Kozal et al., (1996) Nat Med 1996;2(7):753-759].

The nucleic acid sample, which includes the candidate region to be analyzed is isolated, amplified and labeled with a reporter group. This reporter group can be a fluorescent group such as phycoerythrin. The labeled nucleic acid is then incubated with the probes immobilized on the chip using a fluidics station. For example, Manz et al. (1993) Adv in Chromatogr 1993; 33:1-66 describe the fabrication of fluidics devices and particularly microcapillary devices, in silicon and glass substrates.

Once the reaction is completed, the chip is inserted into a scanner and patterns of hybridization are detected. The hybridization data is collected, as a signal emitted from the reporter groups already incorporated into the nucleic acid, which is now bound to the probes attached to the chip. Since the sequence and position of each probe immobilized on the chip is known, the identity of the nucleic acid hybridized to a given probe can be determined.

It will be appreciated that when utilized along with automated equipment, the above described detection methods can be used to screen multiple samples for the above-mentioned diseases both rapidly and easily.

The presence of the variants of the present invention may also be detected at the protein level. Numerous protein detection assays are known in the art, examples include, but are not limited to, chromatography, electrophoresis, immunodetection assays such as ELISA and western blot analysis, immunohistochemistry and the like, which may be effected using antibodies specific to the variants of the present invention.

Preferably used are antibodies which specifically interact with the polypeptides of the present invention and not with the protein or other isoforms thereof, for example. Such antibodies are directed, for example, to the unique sequence portions of the polypeptide variants of the present invention (e.g., SEQ ID NOs: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42) or to unique sequences, which bridge the common portion, which is shared with the wild-type sequence, and the unique sequence regions.

Preferably, the antibody of this aspect of the present invention specifically binds at least one epitope of the polypeptide variants of the present invention. As used herein, the term "epitope" refers to any antigenic determinant on an antigen to which the paratope of an antibody binds.

Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or carbohydrate side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.

The term "antibody" as used in this invention includes intact molecules as well as functional fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv that are capable of binding to macrophages. These functional antibody fragments are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab', the fragment of an antibody molecule that can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (3) (Fab')<sub>2</sub>, the

fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab')<sub>2</sub> is a dimer of two Fab' fragments held together by two disulfide bonds; (4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (5) Single chain antibody ("SCA"), a genetically engineered molecule containing the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.

Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (See for example, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference). It will be appreciated that the polypeptides of the present invention may be coupled with a carrier protein with high antigenicity, or the polypeptides are administered together with a suitable adjuvant. Examples of carrier proteins include hemocyanin of Fissurellidae, keyhole limpet hemocyanin, bovine serum albumin, bovine thyroalbumin, or the like. Examples of adjuvants include Complete Freund's Adjuvant, hydroxylated aluminum gel, pertussis vaccine, or the like.

Antibody fragments according to the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in *E. coli* or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')<sub>2</sub>. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. Pat. Nos. 4,036,945 and 4,331,647, and references contained therein, which patents are hereby incorporated by reference in their entirety. See also Porter, R. R. [Biochem. J. 73: 119-126 (1959)]. Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain



fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

Fv fragments comprise an association of VH and VL chains. This association  
5 may be noncovalent, as described in Inbar *et al.* [Proc. Nat'l Acad. Sci. USA 69:2659-62 (1972)]. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene  
10 comprising DNA sequences encoding the VH and VL domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as *E. coli*. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by [Whitlow and  
15 Filpula, *Methods* 2: 97-105 (1991); Bird *et al.*, *Science* 242:423-426 (1988); Pack *et al.*, *Bio/Technology* 11:1271-77 (1993); and U.S. Pat. No. 4,946,778, which is hereby incorporated by reference in its entirety.

Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition  
20 units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick and Fry [*Methods*, 2: 106-10 (1991)].

Humanized forms of non-human (e.g., murine) antibodies are chimeric  
25 molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab').sub.2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by  
30 residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are

found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones *et al.*, Nature, 321:522-525 (1986); Riechmann *et al.*, Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones *et al.*, Nature, 321:522-525 (1986); Riechmann *et al.*, Nature 332:323-327 (1988); Verhoeyen *et al.*, Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks *et al.*, J. Mol. Biol., 222:581 (1991)]. The techniques of Cole *et al.* and Boerner *et al.* are also available for the preparation of human monoclonal antibodies (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner *et al.*, J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introduction of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including

gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks *et al.*, Bio/Technology 10,: 779-783 (1992); Lonberg *et al.*, Nature 368: 856-859 (1994); Morrison, Nature 368 812-13 (1994); Fishwild *et al.*, Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14: 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13, 65-93 (1995).

The diagnostic reagents described hereinabove can also be included in kits. For example a kit for diagnosing predisposition to, or presence of the above-described diseases in a subject can include an antibody directed at the unique amino acid sequence of the Met variant (SEQ ID NO: 2) in a one container and a solid phase for attaching multiple biological samples packaged in a second container with appropriate buffers and preservatives and used for diagnosis. It will be appreciated that such a kit can also include reagents which detect the level of the wild-type gene (e.g., c-Met).

As used herein the term "about" refers to  $\pm 10\%$ .

Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

## EXAMPLES

Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.

Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook *et al.*, (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel *et al.*, "Current Protocols in Molecular Biology", John Wiley and

Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998);  
5 methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods  
10 in Cellular Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); "Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., Eds. (1984); "Animal Cell Culture" Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To  
20 Methods And Applications", Academic Press, San Diego, CA (1990); Marshak et al., "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the  
25 convenience of the reader. All the information contained therein is incorporated herein by reference.

### EXAMPLE 1

#### *Description of the methodology undertaken to uncover the biomolecular sequences of the present invention and uses therefor*

30 Human ESTs and cDNAs were obtained from NCBI GenBank version 126 (Oct 15 2001, [www.ncbi.nlm.nih.gov/dbEST](http://www.ncbi.nlm.nih.gov/dbEST)) and aligned to the human genome (NCBI assembled genomic sequence from Oct. 2001) using the LEADS clustering

and assembly system as described in U.S. Pat. No. 6,625,545 and U.S. Pat. Appl. No. 10/426,002.

5 Briefly, the software cleans the expressed sequences from repeats, vectors and immunoglobulins. It then aligns the expressed sequences to the genome taking alternatively splicing into account and clusters overlapping expressed sequences into “clusters” that represent genes or partial genes.

These were annotated using the GeneCarta (Compugen, Tel-Aviv, Israel) platform. The GeneCarta platform includes a rich pool of annotations, sequence information (particularly of spliced sequences), chromosomal information, 10 alignments, and additional information such as SNPs, gene ontology terms, expression profiles, functional analyses, detailed domain structures, known and predicted proteins and detailed homology reports.

Brief description of the methodology used to obtain annotative sequence information is summarized infra (for detailed description see U.S. Pat. Appl. 15 10/426,002).

*The ontological annotation approach* - An ontology refers to the body of knowledge in a specific knowledge domain or discipline such as molecular biology, microbiology, immunology, virology, plant sciences, pharmaceutical chemistry, medicine, neurology, endocrinology, genetics, ecology, genomics, proteomics, 20 cheminformatics, pharmacogenomics, bioinformatics, computer sciences, statistics, mathematics, chemistry, physics and artificial intelligence.

An ontology includes domain-specific concepts – referred to, herein, as sub-ontologies. A sub-ontology may be classified into smaller and narrower categories. The ontological annotation approach is effected as follows.

25 First, biomolecular (i.e., polynucleotide or polypeptide) sequences are computationally clustered according to a progressive homology range, thereby generating a plurality of clusters each being of a predetermined homology of the homology range.

30 Progressive homology is used to identify meaningful homologies among biomolecular sequences and to thereby assign new ontological annotations to sequences, which share requisite levels of homologies. Essentially, a biomolecular sequence is assigned to a specific cluster if displays a predetermined homology to at least one member of the cluster (i.e., single linkage). A “progressive homology

range” refers to a range of homology thresholds, which progress via predetermined increments from a low homology level (e.g. 35 %) to a high homology level (e.g. 99 %).

Following generation of clusters, one or more ontologies are assigned to each cluster. Ontologies are derived from an annotation preassociated with at least one biomolecular sequence of each cluster; and/or generated by analyzing (e.g., text-mining) at least one biomolecular sequence of each cluster thereby annotating biomolecular sequences.

*The hierarchical annotation approach* - “Hierarchical annotation” refers to any ontology and subontology, which can be hierarchically ordered, such as, a tissue expression hierarchy, a developmental expression hierarchy, a pathological expression hierarchy, a cellular expression hierarchy, an intracellular expression hierarchy, a taxonomical hierarchy, a functional hierarchy and so forth.

The hierarchical annotation approach is effected as follows.

First, a dendrogram representing the hierarchy of interest is computationally constructed. A “dendrogram” refers to a branching diagram containing multiple nodes and representing a hierarchy of categories based on degree of similarity or number of shared characteristics.

Each of the multiple nodes of the dendrogram is annotated by at least one keyword describing the node, and enabling literature and database text mining, such as by using publicly available text mining software. A list of keywords can be obtained from the GO Consortium ([www.geneontology.org](http://www.geneontology.org)). However, measures are taken to include as many keywords, and to include keywords which might be out of date. For example, for tissue annotation, a hierarchy is built using all available tissue/libraries sources available in the GenBank, while considering the following parameters: ignoring GenBank synonyms, building anatomical hierarchies, enabling flexible distinction between tissue types (normal versus pathology) and tissue classification levels (organs, systems, cell types, etc.).

In a second step, each of the biomolecular sequences is assigned to at least one specific node of the dendrogram.

The biomolecular sequences can be annotated biomolecular sequences, unannotated biomolecular sequences or partially annotated biomolecular sequences.

Annotated biomolecular sequences can be retrieved from pre-existing annotated databases as described hereinabove.

For example, in GenBank, relevant annotational information is provided in the definition and keyword fields. In this case, classification of the annotated biomolecular sequences to the dendrogram nodes is directly effected. A search for suitable annotated biomolecular sequences is performed using a set of keywords which are designed to classify the biomolecular sequences to the hierarchy (i.e., same keywords that populate the dendrogram)

In cases where the biomolecular sequences are unannotated or partially annotated, extraction of additional annotational information is effected prior to classification to dendrogram nodes. This can be effected by sequence alignment, as described hereinabove. Alternatively, annotational information can be predicted from structural studies. Where needed, nucleic acid sequences can be transformed to amino acid sequences to thereby enable more accurate annotational prediction.

Finally, each of the assigned biomolecular sequences is recursively classified to nodes hierarchically higher than the specific nodes, such that the root node of the dendrogram encompasses the full biomolecular sequence set, which can be classified according to a certain hierarchy, while the offspring of any node represent a partitioning of the parent set.

For example, a biomolecular sequence found to be specifically expressed in "rhabdomyosarcoma", will be classified also to a higher hierarchy level, which is "sarcoma", and then to "Mesenchymal cell tumors" and finally to a highest hierarchy level "Tumor". In another example, a sequence found to be differentially expressed in endometrium cells, will be classified also to a higher hierarchy level, which is "uterus", and then to "women genital system" and to "genital system" and finally to a highest hierarchy level "genitourinary system". The retrieval can be performed according to each one of the requested levels.

*Annotating gene expression according to relative abundance* - Spatial and temporal gene annotations are also assigned by comparing relative abundance in libraries of different origins. This approach can be used to find genes, which are differentially expressed in tissues, pathologies and different developmental stages. In principal, the presentation of a contig in at least two tissues of interest is determined and significant over or under representation of the contig in one of the at least two

tissues is assessed to identify differential expression. Significant over or under representation is analyzed by statistical pairing.

Annotating spatial and temporal expression can also be effected on splice variants. This is effected as follows. First, a contigue which includes exonal sequence presentation of the at least two splice variants of the gene of interest is obtained. This  
5 contigue is assembled from a plurality of expressed sequences;

Then, at least one contigue sequence region, unique to a portion (i.e., at least one and not all) of the at least two splice variants of the gene of interest, is identified . Identification of such unique sequence region is effected using computer alignment  
10 software.

Finally, the number of the plurality of expressed sequences in the tissue having the at least one contigue sequence region is compared with the number of the plurality of expressed sequences not-having the at least one contigue sequence region, to thereby compare the expression level of the at least two splice variants of the gene  
15 of interest in the tissue.

Data concerninng therapies, indications and possible pharmacological activities of the polypeptides of the present invention was obtained from PharmaProject (PJB Publications Ltd 2003 <http://www.pjbpubs.com/cms.asp?pageid=340>) and public databases, including LocusLink ([http://www.genelynx.org/cgi-](http://www.genelynx.org/cgi-bin/resource?res=locuslink)  
20 [bin/resource?res=locuslink](http://www.genelynx.org/cgi-bin/resource?res=locuslink)) and Swissprot (<http://www.ebi.ac.uk/swissprot/index.html>). Functional structural analysis of the polypeptides of the present invention was effected using Interpro domain analysis software (Interpro default parameters, the analyses that were run are HMMPfam, HMMSmart, ProfileScan, FprintScan, and BlastProdom). Subecllular localization  
25 was analysed using ProLoc software (Einat Hazkani-Covo, Erez Y. Levanon, Galit Rotman, Dan Graur, Amit Novik. Evolution of multicellularity in metazoa: comparative analysis of the subcellular localization of proteins in Saccharomyces, Drosophila and Caenorhabditis. Cell Biology International (in press).

## EXAMPLE 2

### *Met- Hepatocyte growth factor receptor*

The protein product of c-met oncogene (Swissprot Locus No. MET\_HUMAN), is a tyrosine kinase receptor for hepatocyte growth factor (HGF,



Swissprot Locus No. HGF\_HUMAN), also known as scatter factor (SF). HGF/SF was identified independently as both a growth factor for hepatocytes and as a fibroblast-derived cell motility factor, or scatter factor. The mature HGF is a disulfide-linked heterodimer composed of an  $\alpha$ -chain and a  $\beta$ -chain deriving from a pre-pro HGF polypeptide that is proteolytically cleaved to yield the mature active HGF. HGF is produced predominantly by mesenchymal cells and acts primarily on Met-expressing epithelial cells in an endocrine and/or paracrine fashion. The HGF/SF-Met complex induces a wide range of biological events, including proliferation, scattering, invasion, branching morphogenesis, transformation and angiogenesis. This wide array of biological processes is mediated by the HGF-Met signaling involving interactions between mesenchymal and epithelial cells. Such paracrine signaling is vital to embryogenesis and contributes to kidney and mammary gland formation, migration and development of muscle and neuronal precursors, and liver and placenta development.

Binding of HGF to the extracellular domain of Met triggers autophosphorylation of specific tyrosine residues in the intracellular region of Met. Specifically, phosphorylation of two tyrosine residues (Tyr1234 and Tyr1235) located within the activation loop of the tyrosine kinase domain activates the intrinsic kinase activity of the receptor, while phosphorylation of two tyrosine residues (Tyr1349 and Tyr1356) located in the C-terminus of Met activates a multisubstrate docking site, recruiting downstream signaling molecules and adaptor proteins thereby amplifying the cellular responses from HGF to multiple distinctive pathways.

While HGF/SF-Met signaling plays a key role during normal development (embryonic development, wound healing and tissue regeneration) this signaling pathway has been implicated in tumor development and progression. In particular, abnormal HGF-Met signaling was shown to play a significant role in promoting tumor cell invasion and metastasis. c-Met mutations have been described in hereditary and sporadic human papillary renal carcinomas and have been reported in ovarian cancer, childhood hepatocellular carcinoma, metastatic head and neck squamous cell carcinomas, and gastric cancer. c-Met is also over-expressed in both small cell lung cancer and non-small cell lung cancer. In view of its critical role in oncogenesis, various inhibition strategies have been employed to therapeutically target Met receptor tyrosine kinase.

***Chromosomal location and structural information***

The human Met gene, which includes 21 exons, is located on chromosome 7 band 7q21–q31 and spans more than 120 kb in length.

The primary Met transcript produces a 150 kDa polypeptide (1390 amino acids) that is partially glycosylated to produce a 170 kDa precursor protein. This 170 kDa precursor is further glycosylated and then cleaved into a 50 kDa  $\alpha$ -chain and a 140 kDa  $\beta$ -chain which are disulfide-linked. The  $\alpha$ -subunit of the mature Met heterodimer is highly glycosylated and is entirely extracellular, while the  $\beta$ -subunit contains a large extracellular region, a membrane spanning segment, and an intracellular tyrosine kinase domain.

Met is the prototypic member of a subfamily of heterodimeric receptor tyrosine kinases which include Met, Ron, and Sea. Members of the Met receptor subfamily have been shown to share homology with semaphorins and semaphorin receptors (plexin), which play a role in cell scattering. All semaphorins contain a conserved 500 amino acid extracellular domain (Sema domain) in which resides the cysteine-rich Met related sequence (MRS) which minimal consensus is C-X(5–6)-C-X(2)-C-X(6–8)-C-X(2)-C-X(3–5)-C. The extracellular portions of Met, Ron, and Sea contain a region of homology to semaphorins including the N-terminal Sema domain and the MRS. Other domains identified in the extracellular portion of Met are the PSI domain and the IPT/TIG repeat domain. The PSI domain is found in plexins, semaphorins and integrins while the IPT repeats (also known as TIG domains) are found within immunoglobulin, plexins and transcription factors. The C-terminus intracellular tyrosine kinase domain shares homology with Ron and Sea.

***Biological function***

1. Proliferation- Aside from hepatocytes, HGF is also an important growth factor for cells of various origins, including epithelial cells, neurons and placental cytotrophoblasts. The mitogenic effect of HGF is also crucial in regenerative processes following tissue injury.

2. Scattering- The process of cell scattering can be divided into three phases, essentially, cell spreading, cell–cell dissociation, and cell migration. As mentioned above, HGF was discovered as a secretory product of fibroblasts and smooth muscle cells that induces dissociation and motility of epithelial cells. HGF/SF

is able to induce cell dissociation and mutual repulsion in a similar manner to semaphorins.

3.     Angiogenesis- HGF acts as a potent angiogenic molecule by directly acting on vascular endothelial cells. HGF stimulation of vascular endothelial cells promotes migration, proliferation, protease production, invasion, and organization into capillary-like tubes. HGF can also promote the expression of angiogenic factors by tumor cells. HGF induces a dose-dependent increase in the angiogenic cytokines IL-8 and vascular endothelial growth factor (VEGF) produced by head and neck squamous cell carcinoma cell lines.

4.     Cell motility- The key events regulating cell motility are polymerization of actin, formation of actin stress fibers, and focal adhesion formation. Many studies have shown that HGF-Met signaling increases the motility of epithelial cells.

5.     Morphogenesis- HGF has been shown to induce branching morphogenesis of kidney, mammary and bile ductular cells. In response to HGF, Met expressing cells form branches in three-dimensional matrigel or tubule-like structures in collagen gels. This process is mediated through changes in cell shape, asymmetric polarization of the cells in the direction of branching, branch elongation, cell-cell contact, cell-ECM communication, ECM remodeling, controlled proteolysis and cell motility.

6.     Invasion and metastasis- HGF/SF-Met signaling has been strongly implicated in the promotion of the invasive/metastatic tumor phenotype. An HGF stimulated pathway involving MAPK1/2 signaling is important in the up-regulation of expression of the serine protease urokinase (uPA) and its receptor (uPAR), resulting in an increase of uPA on the cell surface. Certain components of the ECM can be directly degraded by uPA, and more importantly, uPA cleaves plasminogen into the broader-specificity protease plasmin, which is able to efficiently degrade several ECM and basement membrane (BM) components. Plasmin also activates metalloproteinases, which have potent ECM/BM degrading abilities. HGF has been reported to promote attachment of tumor cells to endothelium, an important step in the metastatic cascade. This activity may be mediated by HGF induced up-regulation of CD44 expression on endothelium cells, and an induced integrin expression on tumor cells.

***Abnormal activity and/or expression of Met-HGF in cancer***

Aberrant c-Met signaling has been described in a variety of human cancers (solid tumors and hematologic malignancies). Mutations in c-Met, over-expression of c-Met and/or HGF, and expression of c-Met and HGF by the same cell can all contribute to tumorigenesis. Cell lines with uncontrolled c-Met activation via one of these mechanisms are both highly invasive and metastatic. Increased c-Met and/or HGF expression by human tumor cells is often associated with high tumor grade and poor prognosis.

***References:***

- Maulik et al. 2002. Cytokine and Growth Factor Reviews. 13:41-59.
- Zhang et al. 2003. Journal of Cellular Biochemistry. 88:408-417.
- Furge et al. 2000. Oncogene. 19:5582-5589.
- To et al. 1998. Oncology Reports. 5:1013-1024.
- Trusolino et al. 1998. The FASEB Journal. 12:1267-1280.
- Comoglio et al. 2002. The Journal of Clinical Investigation. Vol. 109, No. 7, Pp. 857-862.
- Danilkovitch-Miagkova et al. 2002. The Journal of Clinical Investigation. Vol. 109, No. 7, Pp. 863-867.
- Wajih et al. 2002. Circulation Research. 90:46-52.
- Mark et al. 1992. The Journal of Biological Chemistry. Vol 267, No. 36, Pp. 26166-26171.

***Met splice variant-structure***

The present inventors have uncovered a novel splice variant of Met (SEQ ID NOs: 1, 3, Figures 1a,b-4) by LEADS clustering and assembly algorithm and the annotation process, as described above (Example 1). This splice variant results from alternative splicing of the c-Met gene, thereby causing an extension of exon 12 (the last exon before the transmembrane region encoding exon) leading to an insertion of a stop codon and the generation of a truncated Met protein which terminates just before the transmembrane domain. Met splice variant has an open reading frame (ORF) of 934 amino acids: 910 amino acids of the wild-type (w.t.) Met protein and a unique sequence of 24 amino acids at the C-terminus of the protein. It contains nearly the complete extracellular portion of Met (910 amino acids of 933 of the w.t protein) and therefore comprises all its structural domains (the Sema, PSI and TIG domains). It is

predicated to be a secreted protein since it retains the original N-terminal signal peptide (amino acids 1-24) and lacks the transmembrane domain (amino acids 933-955 of the w.t.).

*Therapeutic and diagnostic applications for the Met splice variant of the present invention*

Met splice variant of the present invention can serve as a antagonist (i.e., inhibitor) of Met-HGF interaction. It contains the extracellular region of Met, the HGF binding site, and therefore it is likely to bind HGF. Met extracellular region has been shown previously to bind HGF with a high affinity (comparable to the membrane bound receptor). Met splice variant can inhibit Met-HGF signaling by competing with the membrane-bound receptor for the ligand-HGF, thus preventing HGF binding to the cell surface receptor and as a consequence blocking Met activation and its signaling pathway.

Because of the overwhelming evidence favoring the role of aberrant HGF-Met signaling in the pathogenesis of various human cancers, endogenous and exogenous inhibitors of this signaling pathway such as Met splice variant may be used as valuable therapeutic tools in the treatment of cancers such as, hereditary and sporadic papillary renal carcinoma, breast cancer, ovarian cancer, childhood hepatocellular carcinoma, metastatic head and neck squamous cell carcinomas, lung cancer (e.g., non-small cell lung cancer, small cell lung cancer), prostate cancer, pancreatic cancer, gastric cancer and other diseases such as diabetic retinopathy.

In addition to its therapeutic potential, Met splice variant may be used for diagnosing cancer. Aberrant c-Met signaling, which results from mutations in the Met sequence or over-expression of c-Met, has been described in a variety of human cancers. Furthermore, increased c-Met expression by human tumor cells is often associated with high tumor grade and poor prognosis.

**EXAMPLE 3**

*Interleukin-6 (IL-6)*

**Background**

IL-6 (Swissprot Locus No. IL6\_HUMAN) was originally identified as an antigen-nonspecific B-cell differentiation factor in culture media of mitogen- or

antigen-stimulated peripheral blood mononuclear cells that induced B cells to produce immunoglobulins and was named B-cell stimulatory factor 2 (BSF-2).

IL-6 is a pleiotropic cytokine with a wide range of biological activities in immune regulation, hematopoiesis, inflammation, and oncogenesis. The cytokine is produced by various types of lymphoid and nonlymphoid cells, such as T cells, B cells, monocytes, fibroblasts, keratinocytes, endothelial cells, mesangial cells, and several tumor cells. It induces growth of T cells and differentiation of cytotoxic T cells by augmenting the expression of IL-2 receptor and IL-2. IL-6 acts synergistically with IL-3 to support the formation of multilineage blast cell colonies in hematopoiesis. It also induces differentiation of macrophages, megakaryocytes and osteoclasts. In the acute-phase reaction, this cytokine stimulates hepatocytes to produce acute-phase proteins such as C-reactive protein (CRP), fibrinogen,  $\alpha_1$ -antitrypsin and serum amyloid A and it simultaneously suppresses albumin production. It causes leukocytosis and fever when administered in vivo and also acts as a growth factor for renal mesangial cells, epidermal keratinocytes and various types of tumor cells, for example, in plasmacytoma, multiple myeloma and renal cell carcinoma.

Although IL-6 has pleiotropic effects on various target cells, some of these biological activities are also mediated by other cytokines, such as leukemia inhibitory factor (LIF) and oncostatin M (OSM). The pleiotropy and redundancy of IL-6 functions can be explained by the unique composition of its receptor signaling system. Two components of IL-6 receptor (IL-6R) were identified, an 80-kDa IL-6-binding protein ( $\alpha$  chain) and a common 130-kDa signal transducer known as gp130 ( $\beta$  chain). The gp130 subunit is shared by receptors for other cytokines of the IL-6 superfamily, such as ciliary neurotrophic factor (CNTF), LIF, OSM, IL-11, and cardiotrophin-1 receptors. Although IL-6 cannot directly bind to gp130, it can bind to IL-6R to thereby generate the high-affinity complex of IL-6/IL-6R/gp130. Mutagenesis studies have identified three distinct regions on the surface of IL-6 which specifically interact with the respective receptors: site I interacts with IL-6R $\alpha$ ; site II, which is common to all IL-6-type cytokines, interacts with the cytokine-binding module of gp130 and site III interacts with the second signaling receptor (another gp130, in the case of IL-6). The signal transduction through gp130 is mediated by two pathways: the JAK-STAT

(Janus family tyrosine kinase–signal transducer and activator of transcription) pathway and the Ras mitogen-activated protein kinase (MAPK) pathway.

### *Clinical application*

IL-6 have been shown to play key roles in various disease conditions, such as inflammatory, autoimmune, and malignant diseases. Uncontrolled IL-6 overproduction appears to be responsible for the clinical symptoms and abnormal laboratory findings in Rheumatoid arthritis (RA). The ability of IL-6 to induce differentiation of B-cells suggests that overproduction of IL-6 is responsible for the increase in serum  $\gamma$ -globulin and the emergence of rheumatoid factors in RA. As a hepatocyte-stimulating factor, IL-6 causes an increase in CRP, serum amyloid A, and erythrocyte sedimentation rate and a decrease in serum albumin. On the other hand, IL-6 as a megakaryocyte differentiation factor causes thrombocytosis. The ability of IL-6 in the presence of soluble IL-6R to induce bone absorption, suggests that IL-6 may be involved in the osteoporosis and destruction of bone and cartilage associated with RA. In fact, a large amount of IL-6 has been observed in both sera and synovial fluids from the affected joints of patients with RA. Blockade of the IL-6 signaling may thus constitute a new therapeutic strategy for RA. In addition to RA, IL-6 was found to be involved in various diseases such as Castleman's disease, Crohn's disease, multiple myeloma/plasmacytoma, mesangial proliferative glomerulonephritis, psoriasis and Kaposi's sarcoma. Thus RA and these other diseases could be targets for IL-6 inhibitors.

### *References*

- Simpson et al. 1997. Protein Science. 6:929-955.  
Jones et al. 2001. The FASEB Journal. 15:43-58.  
Hirano T. 1998. Intern. Rev. Immunol. Vol. 16, Pp. 249-284.  
Heinrich et al. 2003. Biochemical Society. 374 :1-20.  
Bihl et al. 2002. American Journal Of Respiratory Cell and Molecular Biology. Vol. 27, pp. 48-56.  
Naka et al. 2002. Arthritis Research. Vol 4 Suppl 3:S233-S242.

### *IL-6 splice variant-structure*

A novel splice variant of IL-6 (SEQ ID NOs: 5 and 7, Figures 5a-b-8) was uncovered by LEADS clustering and assembly algorithm and the annotation process, as described above (Example 1). IL-6 splice variant results from alternative splicing

of the IL-6 gene, thus causing an extension of exon 4, leading to an insertion of a stop codon and the generation of a truncated protein. IL-6 splice variant encodes a 198 amino acids long protein which contains the N-terminal signal sequence (residues 1-29), most of the IL6/GCSF/MGF family domain and a unique sequence of 41 amino acids at the C-terminus of the protein.

***Therapeutic applications for the IL-6 splice variant of the present invention***

The IL-6 splice variant of the present invention contains the N-terminus 157 amino acids of the wild-type while lacking the last 50 amino acids of the protein. This splice variant may serve as an antagonist of IL-6 by several mechanisms. For example, it can bind only to IL-6R $\alpha$  while abolishing the binding to gp130. Since gp130 is the signaling subunit of the IL-6R complex, such variant will not be able to activate the receptor. By binding to the receptor without activating it, IL-6 splice variant might have the potential to serve as an antagonist of IL-6 signaling.

Disregulation of IL-6 production has been implicated in the pathogenesis of a variety of diseases, including plasmacytoma/myeloma and several chronic inflammatory proliferative diseases. Blocking of IL-6 signaling by inhibitors such as this IL-6 splice variant can thus have an important therapeutic potential for the treatment of Rheumatoid arthritis, Castleman's disease, Crohn's disease, multiple myeloma/plasmacytoma, mesangial proliferative glomerulonephritis, psoriasis and Kaposi's sarcoma.

***EXAMPLE 4***

***Interleukin-7 (IL-7)***

***Background***

The IL-7 cytokine (Swissprot Locus No. IL7\_HUMAN) was originally identified as a growth factor for murine B cell progenitors and was isolated from bone marrow stromal cells. Subsequently, it was demonstrated that IL-7 plays a crucial role in normal B and T cell lymphopoiesis. It acts as a differentiation and proliferation factor of B cells and as a survival factor of activated T cells. Receptors for IL-7 have been found on cells of both the lymphoid and myeloid lineages. A heterodimeric IL-7R complex is composed of two subunits, a unique  $\alpha$  subunit and a p64  $\gamma$  subunit, which is common to the receptors for IL-2, IL-4, IL-9 and IL-15. While IL-7R expression is important for early pre-B and pro-B cell development, mature B cells



lack expression of high affinity receptor and demonstrate no proliferative response to IL-7. In addition to its expression on immature B cells, IL-7R has been identified also on thymocyte and on most mature T cells, wherein the receptor is transiently down-regulated upon activation. IL-7 signaling involves a number of nonreceptor tyrosine kinase pathways that associate with the cytoplasmic tail of the receptor. These include the Janus kinase/signal transducer and activator of transcription (Jak/STAT) pathway, phosphatidylinositol 3-kinase (PI3-kinase), and Src family tyrosine kinases.

### *Clinical applications*

Due to the numerous effects of IL-7 on mature T cells it may modulate immune responses in infectious or cancerous disease. Systemic administration of IL-7 can be used as an anti-cancer therapy by enhancing the immune responses against tumor through a variety of mechanisms. In addition, IL-7 combined with other factors, such as GM-CSF, can enhance the generation of mature monocyte-derived dendritic cells. Furthermore, IL-7, along with other cytokines, may contribute to the induction of a type 1 immune response and LAK cells. Finally, by diminishing TGF- $\beta$  production, IL-7 can potentially down-regulate one mechanism through which tumors suppress local immune responses. In contrast, IL-7 stimulates the growth of pre-B and T acute lymphoblastic leukemia cells in vitro. It also induces proliferation of chronic lymphocytic leukemia cells and acute myelogenous leukemia cells, as well as cells from patients with Sezary syndrome. IL-7R is expressed on the majority of neoplastic lymphoid cells and on a subset of myeloid neoplasms. The demonstration of IL-7 secretion by neoplastic B lymphocytes from patients with Burkitt's lymphoma, Sezary leukemia cells, Hodgkin's lymphoma cells and normal keratinocytes suggests the possibility of both autocrine and paracrine growth-stimulatory mechanisms for IL-7 in neoplastic diseases. Therefore inhibiting IL-7 signaling might have a therapeutic potential in cancer therapy.

### *References*

Cosenza et al. 2000. Protein Science. 9:916-926.

VanderSpek et al. 2002. Cytokine. Vol. 17, No. 5, Pp. 227-233.

Gorgun et al. 2002. Cytokine. Vol. 20, No. 1, Pp 17-22.

Fry et al. 2002. Blood. Vol. 99, No. 11, Pp. 3892-3904.

***Splice variant structure***

The present inventors uncovered two novel splice variants of IL-7, variant T7 (SEQ ID NOs: 9, 11) and variant T8 (SEQ ID NO: 13, 15) by applying LEADS clustering and assembly algorithm and the annotation process, as described above  
5 (Example 1).

IL-7 splice variant T7 (see Figures 9a-b-12) results from alternative splicing of the IL-7 gene, involving the skipping of exon 6 (the last exon of wild-type IL-7) into a new last exon and 3' UTR, and the generation of a protein with a different C-terminus. IL-7 splice variant T7 encodes a 167 amino acids long protein which  
10 contains the N-terminal signal sequence (residues 1-27), an almost the complete IL-7/IL-9 family domain and a unique sequence of 29 amino acids at the C-terminus.

IL-7 splice variant T8 (see Figures 9c-d-12) results from alternative splicing of the IL-7 gene, involving the skipping of exon 6 (the last exon of wild-type IL-7) into a new last exon and 3' UTR, and the generation of a protein with a different C-terminus. IL-  
15 7 splice variant T8 encodes a 157 amino acids long protein which contains the N-terminal signal sequence (residues 1-27), most of the IL-7/IL-9 family domain and a unique sequence of 19 amino acids at the C-terminus.

***Therapeutic applications for the IL-7 splice variants of the present invention***

IL-7 splice variants contain the N-terminus 138 amino acids of the wild-type  
20 IL-7 and a unique sequences at the C terminus of the proteins. These splice variants can modulate IL-7 signaling and therefore may be used as valuable therapeutic tools in the treatment of cancers, such as acute and chronic lymphocytic leukemia, acute myelogenous leukemia, Sezary's syndrome, Burkitt's lymphoma and Hodgkin's disease, and in constructing a spectrum of lymphoid cell types following radiotherapy  
25 or chemotherapy.

***EXAMPLE 5******Tumor necrosis factor receptor-9/ 4-1BBR******Background***

30 T cells receiving signals via the Ag-specific TCR require a second, costimulatory signal to stabilize cytokine mRNA and induce the expression of anti-apoptotic proteins. The most well-studied costimulatory pathway involves the binding of two members of the Ig supergene family B7-1 (CD80) and B7-2 (CD86), present

on APCs, to T cell counter receptors CD28, and CTLA-4(CD152). Similarly, members of the nerve growth factor/TNF superfamily can function as costimulatory molecules. These include 4-1BB receptor (CDw137), CD30, OX40, and CD40 ligand (CD154). The 4-1BB receptor (Swissprot Locus No. TNR9\_HUMAN) is an inducible type I membrane protein expressed on activated cytolytic and helper T cells as well as NK cells.

The ligand for 4-1BB receptor is 4-1BB ligand (4-1BBL), which is expressed on activated APCs including activated B cells, activated macrophages and mature dendritic cells. This expression pattern suggested that pairing of 4-1BBR and 4-1BBL is important for interactions between APCs and T cells, which play a role in the process of antigen presentation. Signals delivered by the 4-1BB receptor can induce T cells to produce IL-2, proliferate and differentiate, as well as protect T cells from activation-induced cell death. Despite the expression of 4-1BBR on both CD4+ and CD8+ T cells, 4-1BBR has been reported to predominantly affect CD8+ T cell responses. 4-1BBR was shown to regulate both clonal expansion and survival of CD8+ T cells. As is the case for other TNFR superfamily members, 4-1BBR uses adaptor molecules called tumor necrosis factor receptor-associated factors (TRAFs) to transduce a downstream signal. The cytoplasmic domain of 4-1BBR is able to associate specifically with TRAF1, TRAF2, and TRAF3. Accumulating evidence indicates that there exists a signal transduction pathway via the 4-1BB ligand as well as via the 4-1BB receptor. 4-1BBR is able to replace CD28 in stimulating high-level IL-2 production by resting T cells in the absence of CD28. Since 4-1BBR must be up-regulated before providing costimulatory signals for T cells, in contrast to CD28 which is expressed constitutively, 4-1BBR may play a major role in the later stages of the immune response. Thus, it is plausible to hypothesize that CD28 and 4-1BBR play sequentially differential roles in the stages of the immune response: CD28 is more important in the induction stages of the immune response while 4-1BBR is more important in perpetuating the immune response. This task of 4-1BBR may be achieved by providing a survival signal as well as a costimulatory signal for T cells.

#### *Clinical applications*

Administration of agonistic anti-4-1BBR antibodies has been shown to eradicate established large tumors in mice. Interestingly, anti-4-1BBR-mediated tumor elimination is a complex process which requires CD4 + T cells and NK cells as

well as CD8 + T cells. Thus, it seems that the immune response induced by anti-4-1BB antibodies augment tumor-specific cytotoxic activity of CD8 + T cells, which is regulated by CD4 + T cells and NK cells. Similarly, the introduction of 4-1BBL into tumor cells confers full immunogenicity and thus enhances the amplification of an anti-tumor immune response. Although 4-1BB was shown to effect CD8+ cells preferentially, there is accumulating evidence that 4-1BBR is implicated in immune responses mediated by CD4+ T cells, including alloimmune responses and inflammation. As with CD8+ T cells, signaling through 4-1BBR appears to promote cell proliferation and survival of CD4+ T cells. This suggested that intervention in the 4-1BBR costimulatory pathway could provide an immunotherapeutic approach to the treatment of inflammatory diseases. It has been shown that in vivo blocking of 4-1BB/4-1BBL interactions, by administration of anti 4-1BBL monoclonal antibody, significantly decrease the myocardial inflammation, induced by coxsackievirus B3, and prevented the herpetic stromal keratitis (HSK) induced by HSV-1. Contrary to these observations, administration of agonistic anti-4-1BBR monoclonal antibody blocked the disease progression of spontaneous systemic lupus erythematosus (SLE). In general, it was suggested that agonistic anti 4-1BBR monoclonal antibody may be a valid therapeutic approach to treat Th2-mediated autoimmune diseases such as SLE, RA, ulcerative colitis, whereas tools to block the 4-1BBR costimulatory pathway such as anti 4-1BBL monoclonal antibody may provide immuno-therapy to treat Th1-mediated inflammatory diseases such as MS and Crohn's disease and to prevent rejection of organ transplant. Agonistic anti 4-1BBR monoclonal antibody may also be used as an immunotherapeutic agent to eradicate tumor or viral infection.

### *References*

- Blazar et al. 2001. The Journal of Immunology. 166:3174-3183.
- Seo et al. 2003. The Journal of Immunology. 171:576-583.
- Croft M. 2003. Cytokine and Growth Factor Reviews. 14:265-273.
- Vinay et al. 1998. Seminars in Immunology. 10:481-489.
- Croft M. 2003. Nature Reviews Immunology. 3:609-620.
- Aggarwal B.B. 2003. Nature Reviews Immunology. 3:745-755.
- Kwon et al. 2003. Experimental and Molecular Medicine. Vol. 35, No. 1 Pp. 8-16.
- Kwon et al. 2000. Molecules and Cells. Vol. 10, No. 2, Pp. 119-126.

***TNR9-splice variant structure***

The present inventors uncovered novel splice variants of TNR9 (SEQ ID NOs: 17, 19, Figures 13a-b-16) by applying LEADS clustering and assembly algorithm and the annotation process, as described above (Example 1).

5 This TNR9 (4-1BBR) splice variant results from alternative splicing of the TNR9 gene, thus introducing a new exon 5a (between exons 5 and 6) and a 3' UTR, leading to an insertion of a stop codon and the generation of a truncated protein. TNR9 splice variant encodes a 153 amino acids long protein which contains the N-terminal signal sequence (residues 1-17), one of the TNFR cys rich repeats (residues 10 47-86) and a unique sequence of 15 amino acids at the C-terminus of the protein. It is predicated to be a secreted protein due to the fact that it lacks the transmembrane domain.

***Therapeutic applications for the TNR9 splice variants of the present invention***

15 TNR9 splice variant can serve as a antagonist of TNR9 (4-1BBR)/4-1BBL interaction. It contains part of the extracellular region of TNR9, thus may be capable of inhibiting TNR9 signaling by competing with the membrane-bound receptor for the ligand-4-1BBL, thus preventing its binding to the cell surface receptor and as a consequence blocking TNR9 activation and its signaling pathway.

20 Inhibitors of TNR9 signaling pathway, such as this TNR9 splice variant, could have an important therapeutic potential for the treatment of inflammatory diseases such as MS and Crohn's disease, myocardial inflammation, induced by coxsackievirus B3, herpetic stromal keratitis (HSK) induced by HSV-1 and to prevent rejection of organ transplant and graft-vs-host disease.

25

***EXAMPLE 6******Interleukin-4 receptor (IL-4R)******Background***

30 IL-4 is a pleiotropic and multifunctional cytokine produced by activated T cells, mast cells and basophils. IL-4 plays a critical role in regulating the outcome of an immune response by facilitating Th2 cell differentiation and suppressing the differentiation of IFN- $\gamma$ -producing CD4 + T cells, thereby favoring humoral immune responses. The other important function of IL-4 is the regulation of immunoglobulin

class-switching. It induces class-switching to IgE and IgG4 in human B cells, suggesting a preeminent role of IL-4 in the regulation of allergic conditions. IL-4 also exerts a wide variety of other effects on hematopoietic and nonhematopoietic cells. It enhances the expression of CD23 and class II MHC molecules in B cells and upregulates surface expression of the receptor complex for IL-4. On vascular endothelial cells, IL-4 together with TNF induces the expression of VCAM-1 (vascular cell adhesion molecule 1) and downregulates the expression of E-selectin, thereby changing the adhesive characteristics of endothelial cells and facilitating tissue infiltration by allergic inflammatory cells, such as eosinophils. IL-4 receptors are expressed on hematopoietic cells and a range of nonhematopoietic cells including epithelial, endothelial, muscle, fibroblast and liver cells. On hematopoietic cells, the receptor complex for IL-4 is composed of a 140 kDa high-affinity ligand-binding chain, the IL-4-receptor  $\alpha$  chain (IL-4R $\alpha$ ) and the so-called common  $\gamma$  chain ( $\gamma$ C) that is shared by IL-2, IL-7, IL-9 and IL-15. In contrast, IL-13R $\alpha$ 1 is the predominant accessory chain of the receptor complex for IL-4 in non-hematopoietic cells. Furthermore, the receptor complex for IL-13 consists of various combinations of the IL-4R $\alpha$ , IL-13R $\alpha$ 1 and IL-13R $\alpha$ 2. This may explain the redundancy in biological responses mediated by IL-4 and IL-13. Both IL-4 and IL-13 have been implicated in allergic diseases, probably through redundant and independent pathways. Although homodimerized IL-4R $\alpha$  can generate biological signals within the cell, physiologic signaling requires heterodimerization of IL-4R $\alpha$  and the accessory chain ( $\gamma$ C). Neither IL-4R $\alpha$  nor  $\gamma$ C contains intrinsic kinase activities; rather the IL-4R requires receptor-associated kinases for the initiation of signal transduction. Three members of the Janus kinase (Jak) family- Jak-1, Jak-2 and Jak-3 have been shown to be activated in response to IL-4R engagement and to associate with the components of the receptor complex for IL-4. Jak-1 has been proposed to bind IL-4R $\alpha$  whereas Jak-3 associates with the  $\gamma$ C chain. IL-4-IL-4R engagement results in tyrosine phosphorylation of Jak-1 and Jak-3, leading to tyrosine phosphorylation of IL-4R $\alpha$  itself, a process that occurs immediately after IL-4R engagement. Five conserved tyrosine residues (Tyr497, Tyr575, Tyr603, Tyr631 and Tyr713) that can potentially be phosphorylated are present in the cytoplasmic domain of IL-4R $\alpha$ . After tyrosine phosphorylation, these conserved tyrosine residues become potential docking sites for downstream

signaling molecules containing Src-homology-domain 2 (SH2) or phosphotyrosine-binding domains.

### *References*

Mueller et al. 2002. Biochimica et Biophysica Acta. 1592:237-250.

5 Nelms et al. 1999. Annu. Rev. Immunol. 17:701-738.

Pan et al. 1999. Current Opinion in Immunology. 11:615-620.

Gessner et al. 1999/2000. Immunobiology. 201, 285-307.

### *IL-4R splice variants-structure*

The present inventors uncovered novel isoforms of IL-4R as further described  
10 hereinbelow, by applying LEADS clustering and assembly algorithm and the annotation process, as described above (Example 1).

IL-4R splice variant T4 (SEQ ID NO: 21, 23, Figures 17a-b-20) results from alternative splicing of the IL-4R gene, introducing a novel exon 4a (between exons 4 and 5), leading to an insertion of a stop codon and the generation of a truncated  
15 protein. IL-4R splice variant T4 encodes a 131 amino acids long protein which contains the N-terminal signal sequence (residues 1-25), the complete CRIA domain of IL-4R and a unique sequence of 10 amino acids at the C-terminus of the protein. It is predicated to be a secreted protein due to the fact that it has lost its transmembrane domain.

20 IL-4R splice variant T11 (SEQ ID NOs: 25, 27, Figures 17c, 18-20) results from alternative splicing of the IL-4R gene, thus causing the extension of exon 6 (the last exon before the exon that encodes the transmembrane domain), leading to an insertion of a stop codon and the generation of a truncated IL4R which ends just before the transmembrane domain. IL-4R splice variant T11 encodes a 229 amino  
25 acids long protein which contains the N-terminal signal sequence (residues 1-25), the complete CRIA domain of IL-4R and a unique sequence of 6 amino acids at the C-terminus of the protein. It is predicated to be a secreted protein due to the fact that it has lost its transmembrane domain.

*Therapeutic applications for the IL-4R splice variants of the present*  
30 *invention*

Since IL-4R $\alpha$  is an independent high affinity IL-4 binding subunit, IL-4R $\alpha$  splice variants, which are secreted forms of the receptor can serve as antagonists of IL-4/IL-4R interaction. They all contain the complete CRIA domain of IL-4R $\alpha$  while

T11 splice variant even contains the whole extracellular region of IL-4R $\alpha$  and therefore they can inhibit IL-4/IL4R signaling by competing with the membrane-bound receptor for the ligand, thus preventing IL-4R activation. It has been previously reported that the recombinant extracellular domain of IL-4R blocks IL-4 functions in vitro and in vivo, first shown in a murine model of allotransplantation.

IL-4-IL4R signaling pathways play a major role in the pathogenesis of allergic diseases. Moreover, naturally occurring mutations of the IL-4R $\alpha$  chain have been identified and implicated in a genetic predisposition for atopic asthma. Blocking of IL-4 signaling could therefore have an important therapeutic potential for the treatment of asthma and other allergic disorders. In addition to its role in allergic disorders, IL-4R signaling was shown to be involved in autoimmune diseases and in organ transplantation. Recently, it has been shown that IL-4 may serve multiples roles in the development of lupus. Evidence for a novel role for IL-4 in the development of lupus nephritis comes from recent studies, which suggest that IL-4 may directly promote extracellular matrix deposition in the glomeruli. Blockage of IL-4 signaling may ameliorate glomerulosclerosis and prevent the development of end-stage renal disease and in general might have a therapeutic potential in the treatment of lupus. Thus, in addition to their therapeutic potential in the treatment of asthma and other allergic disorders, IL-4R $\alpha$  splice variants may be used in the treatment of autoimmunity diseases such as lupus, in organ transplant rejection and graft-vs-host diseases.

### EXAMPLE 7

#### *Transforming growth factor $\beta$ receptor type II (TGF- $\beta$ -R/TGR2)*

##### *Background*

TGF- $\beta$  belongs to a large family of growth and differentiation factors. It is a potent growth inhibitor of all epithelial and hematopoietic cells and can also induce apoptosis. Three isoforms of TGF- $\beta$ , designated TGF- $\beta_{1,3}$ , with about 70% amino acid sequence identity have been identified in mammals. TGF- $\beta$  signals through two related transmembrane ser/thr kinase receptors, the type I and type II receptors (TGR1 and TGR2). Signaling is initiated when TGF- $\beta$  binds to the type II receptor (TGR2, Swissprot Locus No. TGR2\_HUMAN) which is followed by recruitment of the type I receptor into a heteromeric complex. Within the complex the type II receptor



transphosphorylates and activates the type I receptor kinase which targets downstream signaling components of the pathway. Proteins belong to the SMAD family of intracellular mediators are the only downstream substrates of the type I receptor kinase. Two member of the SMAD family, namely, Smad 2 and Smad 3, are directly phosphorylated by the type I receptor, leading to association of these receptor-regulated SMADs and Smad 4, followed by translocation of the heteromeric complex to the nucleus. In the nucleus, these complexes of SMADs can interact with DNA and with specific DNA binding transcription factors to elicit gene response to TGF- $\beta$ . In addition to the SMADs, the activated receptor complex can signal through phosphatidylinositol 3-kinase (PI3K), protein phosphatase 2A/p70 S6 kinase (PP2A/p70S6K), and various mitogen-activated protein kinase (MAPK) pathways. Since TGF- $\beta$  inhibits cell growth, escape from the growth inhibition by TGF- $\beta$  results in uncontrolled cell growth. Mutations in the extracellular domain of the type II receptor were identified in hereditary non-polyposis colon cancer (HNPCC) and in several transformed cells. In addition to defects in the type II receptor, alterations in the type I receptor have been found in prostate, colon and gastric cancer cells, which are insensitive to TGF- $\beta$ .

#### *Clinical applications*

Although TGF- $\beta$  can be tumor suppressive, there is increasing evidence that TGF- $\beta$  secretion by tumor cells and/or stromal cells within the peritumoral microenvironment can contribute to tumor maintenance and progression. The effect of TGF- $\beta$  is considered to be biphasic: It acts early as a tumor suppressor, probably by inhibiting the proliferation of nontransformed cells and it acts later as tumor promoter, by downregulating cellular adhesion molecules, elevating the expression of metalloproteases, increasing motility and angiogenesis and causing local and systemic immunosuppression, all of which contribute to tumor progression and metastasis. In support of this view, elevated levels of TGF- $\beta$  are often observed in advanced carcinomas and have been correlated with diseases progression. The potential tumor promoting effects of TGF- $\beta$  provide novel molecular targets for interventions. Several approaches have been proposed, including the use of blocking antibodies against TGF- $\beta$ 1, TGF- $\beta$ 2, and TGF- $\beta$ 3, using the extracellular domains of the type II and III TGF- $\beta$  receptors, which would sequester TGF- $\beta$  isoforms at tumor sites and prevent

binding to cognate receptors and, using adenovirus encoding inhibitors of TGF- $\beta$  signaling.

### *References*

- Dumont et al. 2000. Breast Cancer Res. 2:125-132.
- 5 Miyazono K. 1997. International Journal of Hematology. 65:97-104.
- Brattain et al. 1996. Current Opinion in Oncology. 8:49-53.
- Wrana J.L. 1998. Mineral and Electrolyte Metabolism. 24:120-130.
- Moustakas et al. 2001. Journal of Cell Science 114:4359-4369.
- Akhurst R.J. 2002. The Journal of Clinical Investigation. Vol. 109, No. 12, Pp.
- 10 1533-1536.
- Attisano et al. 2002. Science. 296:1646-1647.

### *Splice variant structure*

The present inventors uncovered a novel isoform of TGR2 (SEQ ID NOs: 29 and 31, Figures 21a-b-24) by applying LEADS clustering and assembly algorithm and the annotation process, as described above (Example 1).

15

This TGR2 splice variant results from alternative splicing of the TGR2 gene, thus causing the extension of exon 3 (the last exon before the exon that encodes the transmembrane domain) leading to an insertion of a stop codon and the generation of a truncated TGR2 protein which ends just before the transmembrane domain. TGR2 splice variant encodes a 176 amino acids long protein which contains the N-terminal signal sequence (residues 1-23), the complete TGF- $\beta$ R/ activinR domain and a unique sequence of 25 amino acids at the C-terminus of the protein. It is predicated to be a secreted protein due to the fact that it retains the original N-terminal signal peptide and lacks the transmembrane domain.

20

### *Therapeutic applications for the TGR2 splice variant of the present invention*

25

Since TGR2 splice variant encodes a soluble receptor which contains the complete TGF- $\beta$ R/ activinR domain, it is expected to bind TGF- $\beta$  and thus can inhibit TGF- $\beta$ /TGR2 signaling by competing with the membrane-bound receptor on the ligand, thus preventing TGF- $\beta$  from binding to the cell surface receptor and activating it. A soluble form of TGR2 has been previously shown to bind TGF- $\beta$  and to inhibit its signaling in vitro and in vivo. A chimeric Fc:TGR2 protein was shown to be very attractive because of its high affinity for TGF- $\beta$  and its effectiveness in a number of

30

animal models. Fc:TGR2 was efficient in reducing tumor metastasis in models of breast cancer and melanoma, whether delivered genetically (transgenic mice) or administered as an injectable circulating drug. Similarly, TGR2 splice variant may be efficient in cancer therapy. In addition to cancer, TGR2 may be used for the treatment of other diseases including organ remodeling diseases/fibrotic diseases, such as chronic renal disease or pulmonary fibrosis, scleroderma and eye's scarring following glaucoma surgery.

### EXAMPLE 8

#### *Integrin $\alpha$ -V - ITAV*

##### *Background*

The integrin family is composed of 15  $\alpha$  and 8  $\beta$  subunits that form over twenty different  $\alpha\beta$  heterodimeric combinations on cell surfaces. Integrins recognize extracellular matrix (ECM) proteins and cell surface immunoglobulin family molecules through short peptide sequences. Several integrins (e.g.,  $\alpha_v\beta_3$ ,  $\alpha_5\beta_1$ ,  $\alpha_{IIb}\beta_3$ ) interact strongly with the tripeptide Arg-Gly-Asp (RGD) sequence within the context of specific ECM or cell surface proteins. While some integrins recognize only a single ECM protein ligand (e.g.  $\alpha_5\beta_1$  recognizes only fibronectin), others can bind several ligands (e.g.,  $\alpha_v\beta_3$  binds vitronectin, fibronectin, osteopontin, fibrinogen, denatured or proteolysed collagen and other matrix proteins). The integrin-mediated adhesion of cells to the ECM leads to bi-directional intracellular signaling events that can regulate cell survival, proliferation and migration. In contrast, inhibition of integrin-ligands interactions suppresses cellular growth or induces apoptotic cell death. Integrin  $\alpha_v\beta_3$ , the most promiscuous member of the integrin family, is not widely expressed in normal tissue. It is not generally expressed on epithelial cells and is expressed only at low levels on resting vascular and uterine smooth muscle as well as endothelium and on certain activated leukocytes, macrophages and osteoclasts. Although  $\alpha_v\beta_3$  is not highly expressed on normal cells, it is expressed on tumor cells including late-stage glioblastomas, ovarian carcinoma and melanomas. It contributes to the progression of melanoma by regulating melanoma cell proliferation, survival and metastases. The  $\alpha_v\beta_3$  on endothelium cells can take part in the angiogenic process in several ways. It regulates cell adhesion to the matrix, transmit signals to the nucleus of the cell and is pro-angiogenic by co-operating with VEGFR-2, a pro-angiogenic

receptor through the activation of cell signalling and the regulation of cell cycle gene expression. The two  $\beta$  chains identified with  $\alpha_v$  and angiogenesis are  $\beta_3$  and  $\beta_5$ . These subunits share 53% homology, however their ligand specificities are different.  $\alpha_v\beta_3$  prefers to bind to osteopontin while  $\alpha_v\beta_5$  prefers vitronectin. Two different cytokine-dependent pathways participate in the activation of these two integrins. The  $\alpha_v\beta_3$  pathway involves basic FGF (FGF-2) or TNF- $\alpha$ , whereas  $\alpha_v\beta_5$  uses VEGF, TGF- $\alpha$ , or PMA. Since the integrin  $\alpha_v$  subunit is widely expressed on most cell types and associates with several different  $\beta$  subunits, the expression of  $\alpha_v\beta_3$  is likely to be regulated by  $\beta$  transcription. There are additional  $\alpha_v$  integrin complexes associated with angiogenesis and blood vessels. They include  $\alpha_v\beta_1$  associated with brain blood vessels and with squamous cell carcinoma cell migration;  $\alpha_v\beta_8$ , identified on tumor cells; and  $\alpha_v\beta_6$  which induces secretion of MMP-2 in colon cancer and is important in the progression of this disease.

#### *Clinical applications*

The role of integrins in pathological processes in both acute and chronic diseases include ocular, cancer (primary tumors and metastasis), cardiovascular (stroke and heart failure) and inflammatory conditions (rheumatoid arthritis). The  $\alpha_v$  integrin has been found to be associated with multiple tumor types, including melanoma, breast, renal, cervical, colon, prostate, bladder, and lung carcinoma. Antibodies to  $\alpha_v$  prevent human melanoma tumor formation in nude mice and antagonists of  $\alpha_v\beta_3$  potentially inhibit angiogenesis in a number of animal models. Thus, blocking the  $\alpha_v$  integrin serves as an important therapeutic strategy in cancer therapy. Inhibitors of integrin function include blocking monoclonal antibody and peptide antagonist, which mimics the RGD ligand recognition domain common to  $\alpha_v$  integrin ligands, are in phase II clinical trials.

#### *References*

- Kerr et al. 2000. Exp.Opin. Invest. Drugs 9(6) :1271-1279.  
Tucker G.C. 2003. Current Opinion in Investigational Drugs. 4(6):722-731.  
Mould et al. 2000. The Journal of Biological Chemistry. Vol. 275, No. 27, Pp. 20324-20336.

***ITAV- splice variant structure***

The present inventors uncovered a novel isoform of ITAV (SEQ ID NOs: 33 and 35, Figures 25a-b-28) by applying LEADS clustering and assembly algorithm and the annotation process, as described above (Example 1).

5 The ITAV splice variant T3 results from alternative splicing of the ITAV gene, causing an extension of exon 24, leading to the insertion of a stop codon and the generation of a truncated ITAV protein which ends before the transmembrane domain. ITAV splice variant T3 has an ORF of 815 amino acids: 811 amino acids of the wild-type protein and a unique sequence of 4 amino acids at the C-terminus. It  
10 contains most of the extracellular region of ITAV (811 amino acids out of 993 of the wild-type), including the five integrin alpha repeats. It is predicated to be a secreted protein due to the fact that it retains the original N-terminal signal peptide (amino acids 1-30) and lacks the transmembrane domain (amino acids 993-1016 of the wild-type).

***Therapeutic applications for the ITAV splice variant of the present invention***

15 ITAV splice variant T3 can serve as an antagonist of a variety of integrin interactions. It contains most of the extracellular region of ITAV and therefore is likely to bind the ligands. This splice variant can inhibit integrin signaling by competing with the membrane-bound receptor for the different ligands, thus  
20 preventing their binding to the cell surface receptor and as a consequence block integrin activation and signaling pathway. Alternatively, it can compete with the wild-type membrane ITAV for binding of the  $\beta$  subunit, thus preventing the heterodimerization of  $\alpha_v$  with the  $\beta$  subunit and the subsequent signaling.

Because of the overwhelming evidence favoring the role of  $\alpha_v$  integrin in the  
25 pathogenesis of a wide array of diseases as cancer, cardiovascular and inflammation, inhibitors of this molecule, such as the ITAV splice variant of the present invention, may have an important therapeutic potential. ITAV splice variant can play a critical role in the treatment of the following pathological conditions: cancer (in general, but in particular colon and melanoma); cardiovascular diseases, such as atherosclerosis, restenosis, ischemia and reperfusion injury; immunological related diseases such as  
30 immunodeficiency, allergies, asthma, psoriasis, RA and inflammatory bowel diseases/chronic's disease; metabolism related diseases, such as diabetes and diabetes related retinopathy; osteoporosis, sepsis and wound healing.

**EXAMPLE 9*****Interleukin-10 receptor  $\beta$  chain******Background***

IL-10 was first described as a cytokine that is produced by T helper 2 (Th2) cells that inhibits interferon (IFN)- $\gamma$  synthesis in Th1 cells. It is a homodimer, produced mainly by macrophages, which has a crucial role in immunoregulation. Its expression is regulated by several endogenous and exogenous factors such as endotoxin, tumor necrosis factor (TNF)- $\alpha$ , catecholamines, and cAMP-elevating agents. IL-10 activity is mediated by its specific cell surface receptor complex, which is expressed on a variety of cells, in particular immune cells. The IL-10 receptor is composed of two different chains,  $\alpha$  and  $\beta$  (CRFB4), both members of the class II cytokine receptor family. These receptors are transmembrane glycoproteins whose extracellular domains consist of about 210 amino acids comprising two tandem fibronectin type III domains and having several conserved amino acid important for the secondary structure. The interaction of IL-10R with IL-10 seems to be highly complex. The IL-10R $\beta$  chain (Swissprot Locus No. I10S\_HUMAN) is essential for IL-10-mediated effects as CRFB4-deficient mice display the same phenotype as IL-10 deficient mice.

Interestingly, in cells which express IL-10R $\beta$  exclusively, no IL-10/IL-10R complexes are formed, suggesting that only IL-10/IL-10R $\alpha$  complexes interact with the  $\beta$ -chain. However in cells expressing both the IL-10R $\alpha$  and  $\beta$  chains the characteristic STAT transcription factor activation pattern for IL-10 signaling is observed. . The IL-10/IL-10R interaction activates the tyrosine kinases Jak1 and Tyk2, which are associated with the IL-10R $\alpha$  and IL-10R $\beta$ 2, respectively. The receptor engagement and tyrosine phosphorylation activates the cytoplasmically localized inactive transcription factors STAT 1, 3, and 5, resulting in their translocation to the nucleus and downstream gene activation. IL-10 signaling results in the inhibition of immune functions. It controls inflammatory processes by suppressing the expression of proinflammatory cytokines, chemokines, adhesion molecules, as well as antigen-presenting and costimulatory molecules in monocytes/macrophages, neutrophils, and T cells. As all of these inflammatory proteins are transcriptionally controlled by NF- $\kappa$ B it wasn't surprising to find out that IL-10 exerts a significant part of its anti-inflammatory properties by inhibiting this

transcription factor. Antigen-presenting cells and lymphocytes are the primary targets of IL-10. Direct effects on these populations explains the major immunological impact of this cytokine, including the regulation of the Th1/Th2 balance. IL-10 reverses the Th1 cytokine pattern present. It promotes the development of a type 2 cytokine pattern by inhibiting the IFN- $\gamma$  production of T lymphocytes particularly via the suppression of IL-12 synthesis in accessory cells. According to this, IL-10 costimulates the proliferation and differentiation of B cells, which is important in the adequate defense against intestinal parasites, neutralization of bacterial toxins, and in local mucosa defense. Moreover, IL-10 suppresses the production of proinflammatory cytokines as IL-1 $\beta$ , IL-6, IL-8, G-CSF, GM-CSF, TNF $\alpha$  while enhances the production of anti-inflammatory mediators such as IL-1RA and soluble TNF $\alpha$  receptors. In addition it inhibits the capacity of monocytes/macrophages and dendritic cells to present antigen to T cells. This is realized by down-regulation of cell surface levels of MHC class II, of costimulatory molecules such as CD86 and of some adhesion molecules such as CD58.

#### *Clinical applications*

Its considerable anti-inflammatory effects and ability to act as a main suppressor of cellular immunity raises the question of the IL-10 expression under pathophysiological conditions. Both overexpression (e.g., in lymphoma, melanoma, carcinoma) as well as IL-10 deficiency were found (e.g., in inflammatory bowel disease, psoriasis) and seems to have a pathophysiological significance. IL-10 overexpression in different malignancies might contribute to tumor development, in particular, by suppressing the antitumor immune response. Moreover, IL-10 might even be a tumor cell growth factor in certain tumors such as B cell lymphoma and melanoma. In contrast to several malignancies, where there is an overexpression of IL-10, a relative deficiency is considered to be of pathophysiological relevance in chronic inflammatory disorders characterized by the predominance of a type 1 cytokine pattern. These included psoriasis, inflammatory bowel disease such as Crohn's diseases, multiple sclerosis, rheumatoid arthritis, transplant rejection, and allergic contact dermatitis. The immunomodulatory properties of IL-10 and the promising results from IL-10 delivery on the course of several inflammatory diseases in experimental models induced the interest on clinical application of IL-10. So far human recombinant IL-10 (ilodecakin/Tenovil; Schering-Plough Research, Kenilworth,

NJ) has been tested in healthy volunteers, patients with Crohn's disease, rheumatoid arthritis, psoriasis, hepatitis C infection, HIV infection, and for the inhibition of therapy associated cytokine releases in organ transplantation and Jarisch-Herxheimer reaction. Application of IL-10 in humans seems to be safe and immunologically active. The clinical effects of recombinant IL-10, however, have been quite heterogeneous in different entities. Whereas almost no effect was seen in rheumatoid arthritis and CD, significant response was observed in psoriasis.

### ***References***

Asadullah et al. 2003. Pharmacol Rev. 55:241-269.

Kotenko S.V. 2002. Cytokine & Growth Factor Reviews. 13:223-240.

Walter M.R. 2002. Immunologic Research. 26/1-3:303-308.

Moore et al. 2001. Annu. Rev. Immunol. 19:683-765.

### ***IL-10-R $\beta$ - splice variant structure***

The present inventors uncovered a novel isoform of IL-10R $\beta$  (SEQ ID Nos. 37 and 39, Figures 29a-b-32). IL-10-R $\beta$  splice variant results from alternative splicing of the IL-10-R $\beta$  gene, thus causing the skipping of exon 6 (the exon which encodes the transmembrane domain), leading to the insertion of a stop codon and the generation of a truncated protein. IL-10-R $\beta$  splice variant encodes a 222 amino acids long protein which contains the N-terminal signal sequence (residues 1-17), the complete 2 fibronectin type III domains and a unique sequence of 7 amino acids at the C-terminus of the protein. It is predicated to be a secreted protein due to the fact that it has lost its transmembrane domain.

### ***Therapeutic applications for the IL-10-R $\beta$ splice variant of the present invention***

IL-10 exhibits low in-vivo half life. Therefore extension its half life has a therapeutic advantage. Soluble receptors have been shown to exhibit agonistic properties including, increasing the molecular internal stability of the ligand, protection from proteolysis and modification of the pharmacokinetic properties of the ligand, namely, increasing its in vivo half-life while decreasing its clearance. IL-10-R $\beta$  splice variant which encodes a soluble receptor might serve as an agonist, increase IL-10 half-life in vivo and therefore enhancing its biological effect. Thus, this splice variant may have an important therapeutic potential for the treatment of the following pathological conditions: inflammatory diseases, such as, psoriasis,



inflammatory bowel diseases (Crohn's disease), colitis ulcerative, multiple sclerosis, RA, transplant rejection and allergic contact dermatitis; hepatitis C infection; HIV infection and atherosclerosis.

5

**EXAMPLE 10*****Interferon- $\alpha/\beta$ -receptor-1- IFNAR1-INR1******Background***

Type I interferons (IFNs), initially identified for their ability to protect cells from viral infections, are truly pleiotropic cytokines. They are also implicated in both  
10 normal and neoplastic cell growth regulation and in modulating both innate and adaptive immune responses to microbial challenge. All type I IFNs, IFN- $\alpha$ s, IFN- $\beta$ , IFN- $\omega$ ,

IFN- $\kappa$ , and IFN- $\tau$ , are functionally active as monomers and activate a specific receptor complex composed of two major subunits, IFNAR-1/INR1 and IFNAR-  
15 2/INR2. The high affinity interaction between IFN- $\alpha/\beta$  and its specific cell surface receptor leads to receptor aggregation and the activation of receptor-associated cytoplasmic tyrosine kinases of the Jak family- Jak1 and Tyk2. These in turn phosphorylate intracellular tyrosine residues of the IFNAR-1 and IFNAR-2 chains, that serve as recruitment sites for the signal transducers and activators of transcription  
20 (STAT) proteins, Stat 1-5. Once associated with the activated receptor, the STAT become phosphorylated, then form both homodimers and heterodimers, which translocate to the nucleus and bind specific DNA sequences within the promoter regions of IFN-sensitive genes (ISG). The Jak-Stat pathway is an essential signaling pathway for the transcription of many ISGs, whose protein products mediate specific  
25 IFN-dependent biologic responses. IFNs mediate a critical role in innate cellular defense against viral infection. Mice deficient in IFN- $\beta$  or in IFNAR-1 are highly susceptible to viral infections. The antiviral activity of IFNs include inhibition of viral replication and protein synthesis and the induction of viral mRNA degradation. In addition to their antiviral activity, IFNs exhibit growth inhibitory activity, either by  
30 mediating cell death (through caspases) or by modulating the expression of proteins regulating cell cycle entry and exit, hence mediating growth arrest. IFNs are also involved in the regulation of immune response towards viral or tumor challenge. A well-characterized function of IFNs is their ability to upregulate MHC class I

expression and consequently promote CD8<sup>+</sup> T cell responses. Moreover, IFNs can regulate the expression of key cytokines that influence T cell responses, namely, IL-12, IL-15 and IFN- $\gamma$  and of CC- chemokines. IFNs- $\alpha/\beta$  regulate the functions of immune cells from different lineages including NK cells, dendritic cells and B/T lymphocytes.

### *Clinical application*

Due to their growth inhibitory activity and the modulation of immune responses, type I interferons have been used as therapeutic agents against a variety of solid tumors and hematological malignancies. IFN- $\alpha$  has been approved for the treatment of chronic myelogenous leukemia (CML), multiple myeloma and hairy cell leukemia.

At this time, IFN- $\alpha$  is the treatment of choice for CML patients not eligible for allogeneic bone marrow transplantation. In addition, it may have the potential therapeutic value in the treatment of several lymphomas. Apart from the widespread therapeutic indications for IFNs in the treatment of neoplasias, their efficacy as therapeutic agents for the treatment of viral infections and autoimmune diseases has been proved. IFN- $\alpha$  is the treatment of choice for hepatitis B and C infections and accumulating evidence supports the use of IFN- $\beta$  for the treatment of multiple sclerosis.

### *References*

Deonarain et al. 2002. Current Pharmaceutical Design. Vol. 8, No. 24, Pp. 2131-2137.

Brierley et al. 2002. Journal of Interferon and Cytokine Research. 22:835-845.

### *INR1-splice variant structure*

The present inventors uncovered a novel isoform of INR1 (SEQ ID NOs: 41 and 43, Figures 33a-b-35). INR1 splice variant 11 results from alternative splicing of the INR1 gene, thus causing an extension of exon 9, leading to an insertion of a stop codon and the generation of a truncated protein. INR1 splice variant T11 encodes a 441 amino acids long protein which contains the N-terminal signal sequence (residues 1-27), the complete extracellular portion of the wild-type INR1 (up to amino acid 427), including the four fibronectin type III-like domains and a unique sequence of 10 amino acids at the C-terminus of the protein. It is predicted to be a secreted protein since it does not contain the transmembrane domain (residues 437-457).

*Therapeutic applications for the INR1 splice variant of the present invention*

Although the activity and specificity of function make the IFNs potentially therapeutic agents, they are not ideal drugs, exhibiting low stability in vivo. Thus, there is an intense interest in developing alternative or improved molecules that demonstrate IFNs function but have superior pharmacological properties. For example, PEGylation of type I IFNs extends the serum half-life and duration of therapeutic activity. PEGylation of IFN- $\alpha$  and IFN- $\beta$  increased their serum half-life by 6 and 5 fold, respectively, however the PEGylated form of IFN- $\beta$  exhibited less efficient systemic distribution with some evidence of induction of neutralizing antibodies. As opposed to their well-characterized function as competitive inhibitors (antagonists), soluble receptors have been shown to exhibit agonistic properties. These include increasing the molecular internal stability of the ligand, protection from proteolysis and modification of the pharmacokinetic properties of the ligand, namely, increasing its in vivo half-life while decreasing its clearance.

INR1 splice variants which encode soluble receptors might serve as agonists, increase IFNs half-life in vivo and therefore enhance their biological effect. Thus, this splice variant may have an important therapeutic potential for the treatment of the following pathological conditions: cancer, such as, solid tumors (e.g., glioblastoma, renal cell carcinoma, melanoma) and hematological malignancies (e.g., chronic myelogenous leukemia (CML), multiple myeloma, non-Hodgkin's lymphoma and hairy cell leukemia), viral infections (e.g., hepatitis B/C, herpes and human papilloma virus) and autoimmune diseases such as multiple sclerosis.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad

scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein

5 by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.

## WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.
2. The isolated polynucleotide of claim 1, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 3.
3. The isolated polynucleotide of claim 1, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 4.
4. The isolated polynucleotide of claim 1, wherein said polypeptide is as set forth in SEQ ID NO: 1.
5. The isolated polynucleotide of claim 1, wherein said polypeptide is as set forth in SEQ ID NO: 2.
6. An isolated polynucleotide as set forth in SEQ ID NO: 4.
7. An isolated polynucleotide as set forth in SEQ ID NO: 3.
8. An isolated polypeptide as set forth in SEQ ID NO: 1.
9. An isolated polypeptide as set forth in SEQ ID NO: 2.
10. A nucleic acid construct comprising the isolated polynucleotide of claim 1.
11. The nucleic acid construct of claim 10, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

12. The nucleic acid construct of claim 10, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
13. A host cell comprising the nucleic acid construct of claim 10.
14. An isolated polypeptide comprising an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.
15. An antibody or an antibody fragment being capable of specifically binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.
16. An oligonucleotide specifically hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.
17. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.
18. A method of treating Met-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters, thereby treating the Met-related disease in a subject.

19. The method of claim 18, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

20. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

21. The isolated polynucleotide of claim 20, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 8.

22. The isolated polynucleotide of claim 20, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 7.

23. The isolated polynucleotide of claim 20, wherein said polypeptide is as set forth in SEQ ID NO: 5.

24. The isolated polynucleotide of claim 20, wherein said polypeptide is as set forth in SEQ ID NO: 6.

25. An isolated polynucleotide as set forth in SEQ ID NO: 8.

26. An isolated polynucleotide as set forth in SEQ ID NO: 7.

27. An isolated polypeptide as set forth in SEQ ID NO: 5.

28. An isolated polypeptide as set forth in SEQ ID NO: 6.

29. A nucleic acid construct comprising the isolated polynucleotide of claim 20.

30. The nucleic acid construct of claim 29, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
31. The nucleic acid construct of claim 29, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
32. A host cell comprising the nucleic acid construct of claim 29.
33. An isolated polypeptide comprising an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.
34. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.
35. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.
36. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.
37. A method of treating an IL-6-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5 as determined using the



LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters, thereby treating the IL-6-related disease in the subject.

38. The Method of claim 37, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

39. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

40. The isolated polynucleotide of claim 39, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 11.

41. The isolated polynucleotide of claim 39, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 12.

42. The isolated polynucleotide of claim 39, wherein said polypeptide is as set forth in SEQ ID NO: 9.

43. The isolated polynucleotide of claim 39, wherein said polypeptide is as set forth in SEQ ID NO: 10.

44. An isolated polynucleotide as set forth in SEQ ID NO: 11.

45. An isolated polynucleotide as set forth in SEQ ID NO: 12.

46. An isolated polypeptide as set forth in SEQ ID NO: 10.

47. An isolated polypeptide as set forth in SEQ ID NO: 9.

48. A nucleic acid construct comprising the isolated polynucleotide of claim 39.

49. The nucleic acid construct of claim 48, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

50. The nucleic acid construct of claim 48, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

51. A host cell comprising the nucleic acid construct of claim 48.

52. An isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

53. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

54. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

55. A pharmaceutical composition comprising a therapeutically effective amount of a IL-7 polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

56. A method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

57. The method of claim 56, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

58. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

59. The isolated polynucleotide of claim 58, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 15.

60. The isolated polynucleotide of claim 58, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 16.

61. The isolated polynucleotide of claim 58, wherein said polypeptide is as set forth in SEQ ID NO: 13.

62. The isolated polynucleotide of claim 58, wherein said polypeptide is as set forth in SEQ ID NO: 14.

63. An isolated polynucleotide as set forth in SEQ ID NO: 15.

64. An isolated polynucleotide as set forth in SEQ ID NO: 16.

65. An isolated polypeptide as set forth in SEQ ID NO: 13.
66. An isolated polypeptide as set forth in SEQ ID NO: 14.
67. A nucleic acid construct comprising the isolated polynucleotide of claim 58.
68. The nucleic acid construct of claim 67, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
69. The nucleic acid construct of claim 67, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
70. A host cell comprising the nucleic acid construct of claim 67.
71. An isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.
72. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.
73. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.
74. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 85 % identical to

SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

75. A method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

76. The method of claim 75, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

77. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

78. The isolated polynucleotide of claim 77, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 19.

79. The isolated polynucleotide of claim 77, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 20.

80. The isolated polynucleotide of claim 77, wherein said polypeptide is as set forth in SEQ ID NO: 17.

81. The isolated polynucleotide of claim 77, wherein said polypeptide is as set forth in SEQ ID NO: 18.

82. An isolated polynucleotide as set forth in SEQ ID NO: 19.
83. An isolated polynucleotide as set forth in SEQ ID NO: 20.
84. An isolated polypeptide as set forth in SEQ ID NO: 17.
85. An isolated polypeptide as set forth in SEQ ID NO: 18.
86. A nucleic acid construct comprising the isolated polynucleotide of claim 77.
87. The nucleic acid construct of claim 86, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
88. The nucleic acid construct of claim 86, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
89. A host cell comprising the nucleic acid construct of claim 86.
90. An isolated polypeptide comprising an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.
91. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.
92. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 60 % identical to SEQ ID NO: 17, as

determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

93. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

94. A method of treating TNFR9-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

95. The method of claim 94, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

96. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

97. The isolated polynucleotide of claim 96, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 27.

98. The isolated polynucleotide of claim 96, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 28.

99. The isolated polynucleotide of claim 96, wherein said polypeptide is as set forth in SEQ ID NO: 25.
100. The isolated polynucleotide of claim 96, wherein said polypeptide is as set forth in SEQ ID NO: 26.
101. An isolated polynucleotide as set forth in SEQ ID NO: 27.
102. An isolated polynucleotide as set forth in SEQ ID NO: 28.
103. An isolated polypeptide as set forth in SEQ ID NO: 25.
104. An isolated polypeptide as set forth in SEQ ID NO: 26.
105. A nucleic acid construct comprising the isolated polynucleotide of claim 96.
106. The nucleic acid construct of claim 105, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
107. The nucleic acid construct of claim 105, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
108. A host cell comprising the nucleic acid construct of claim 105.
109. An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.
110. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25,



116

as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

111. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

112. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

113. A method of treating IL-4R-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

114. The method of claim 113, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

115. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

116. The isolated polynucleotide of claim 115, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 24.

117

117. The isolated polynucleotide of claim 115, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 23.

118. The isolated polynucleotide of claim 115, wherein said polypeptide is as set forth in SEQ ID NO: 21.

119. The isolated polynucleotide of claim 115, wherein said polypeptide is as set forth in SEQ ID NO: 22.

120. An isolated polynucleotide as set forth in SEQ ID NO: 23.

121. An isolated polynucleotide as set forth in SEQ ID NO: 24.

122. An isolated polypeptide as set forth in SEQ ID NO: 21.

123. An isolated polypeptide as set forth in SEQ ID NO: 22.

124. A nucleic acid construct comprising the isolated polynucleotide of claim 115.

125. The nucleic acid construct of claim 124, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

126. The nucleic acid construct of claim 124, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

127. A host cell comprising the nucleic acid construct of claim 124.

128. An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

129. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

130. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

131. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

132. A method of treating IL-4R-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

133. The method of claim 132, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

134. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

135. The isolated polynucleotide of claim 134, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 31.

136. The isolated polynucleotide of claim 134, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 32.

137. The isolated polynucleotide of claim 134, wherein said polypeptide is as set forth in SEQ ID NO: 29.

138. The isolated polynucleotide of claim 134, wherein said polypeptide is as set forth in SEQ ID NO: 30.

139. An isolated polynucleotide as set forth in SEQ ID NO: 31.

140. An isolated polynucleotide as set forth in SEQ ID NO: 32.

141. An isolated polypeptide as set forth in SEQ ID NO: 29.

142. An isolated polypeptide as set forth in SEQ ID NO: 30.

143. A nucleic acid construct comprising the isolated polynucleotide of claim 134.

144. The nucleic acid construct of claim 143, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

145. The nucleic acid construct of claim 143, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

146. A host cell comprising the nucleic acid construct of claim 143.

147. An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

148. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

149. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

150. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

151. A method of treating TGR2-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

152. The method of claim 151, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

121

153. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

154. The isolated polynucleotide of claim 153, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 35.

155. The isolated polynucleotide of claim 153, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 36.

156. The isolated polynucleotide of claim 153, wherein said polypeptide is as set forth in SEQ ID NO: 33.

157. The isolated polynucleotide of claim 153, wherein said polypeptide is as set forth in SEQ ID NO: 34.

158. An isolated polynucleotide as set forth in SEQ ID NO: 35.

159. An isolated polynucleotide as set forth in SEQ ID NO: 36.

160. An isolated polypeptide as set forth in SEQ ID NO: 33.

161. An isolated polypeptide as set forth in SEQ ID NO: 34.

162. A nucleic acid construct comprising the isolated polynucleotide of claim 153.

163. The nucleic acid construct of claim 162, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

164. The nucleic acid construct of claim 162, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

165. A host cell comprising the nucleic acid construct of claim 162.

166. An isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

167. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

168. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

169. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

170. A method of treating ITAV-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

123

171. The method of claim 170, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

172. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

173. The isolated polynucleotide of claim 172, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 39.

174. The isolated polynucleotide of claim 172, wherein said polypeptide is as set forth in SEQ ID NO: 37.

175. The isolated polynucleotide of claim 172, wherein said polypeptide is as set forth in SEQ ID NO: 38.

176. An isolated polynucleotide as set forth in SEQ ID NO: 39.

177. An isolated polypeptide as set forth in SEQ ID NO: 37.

178. An isolated polypeptide as set forth in SEQ ID NO: 38.

179. A nucleic acid construct comprising the isolated polynucleotide of claim 172.

180. The nucleic acid construct of claim 179, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.



124

181. The nucleic acid construct of claim 179, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

182. A host cell comprising the nucleic acid construct of claim 179.

183. An isolated polypeptide comprising an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

184. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

185. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

186. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

187. A method of treating IL10-R-B-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

188. The method of claim 187, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

189. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

190. The isolated polynucleotide of claim 189, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 43.

191. The isolated polynucleotide of claim 189, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 40.

192. The isolated polynucleotide of claim 189, wherein said polypeptide is as set forth in SEQ ID NO: 41.

193. The isolated polynucleotide of claim 189, wherein said polypeptide is as set forth in SEQ ID NO: 42.

194. An isolated polynucleotide as set forth in SEQ ID NO: 43.

195. An isolated polynucleotide as set forth in SEQ ID NO: 40.

196. An isolated polypeptide as set forth in SEQ ID NO: 41.

197. An isolated polypeptide as set forth in SEQ ID NO: 42.

198. A nucleic acid construct comprising the isolated polynucleotide of claim 189.

199. The nucleic acid construct of claim 189, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

200. The nucleic acid construct of claim 189, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

201. A host cell comprising the nucleic acid construct of claim 198.

202. An isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

203. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

204. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

205. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

206. A method of treating INR1-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41 as determined using the

LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

207. The method of claim 206, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

1/39

MET\_T9 (SEQ ID NO: 3)

gaattccgcccctcgccgcccgcggcgccccgagcgctttgtgagcagatgcggagccgag  
tggagggcgcgagccagatgcggggcgacagctgacttgctgagaggaggcggggaggcg  
cggagcgcgctgtggtccttgcgcccgtgacttctccactgggttcctgggcaccgaaa  
ataaacctctcataATGaaggcccccgctgtgcttgacactggcatcctcgctcctgt  
ttaccttgggtgcagaggagcaatggggagtgtaaagaggcactagcaaagtcggagatga  
atgtgaatatgaagtatcagcttcccaacttcaccgcggaaacacccatccagaatgtca  
ttctacatgagcatcacatttttcttgggtgccactaactacatttatgttttaaatgagg  
aagaccttcagaaggttgctgagtacaagactgggcctgtgctggaacacccagattgtt  
tcccatgtcaggactgcagcagcaaagccaatttatcaggaggtgtttggaaagataaca  
tcaacatggctctagttgtcgacacctactatgatgatcaactcattagctgtggcagcg  
tcaacagagggacctgccagcgacatgtctttccccacaatcatactgctgacatacagt  
cggaggttcactgcatatttctccccacagatagaagagcccagccagtgctcctgactgtg  
tggtgagcgccctgggagccaaagtccctttcatctgtaaaggaccgggttcacaaacttct  
ttgtaggcaataaccataaattcttcttattttcccagatcatccattgcattcgatatcag  
tgagaaggctaaaggaaacgaaagatgggttttatgtttttgacggaccagtcctacattg  
atgttttaccttgattcagagattcttacccttaagtagtgcattgccttggaaagca  
acaatttttatttacttcttgacgggtccaaaggaaactctagatgctcagacttttcaca  
caagaataatcaggttctgttccataaactctggattgcattcctacatggaaatgcctc  
tggagtgtatttctcacagaaaagagaaaaaagagatccacaaagaagggaagtgtttaata  
tacttcaggctgcgtatgtcagcaagcctggggcccagcttgctagacaaataggagcca  
gcctgaatgatgacattcttttcgggggtgttcgcacaaagcaagccagattctgccgaac  
caatggatcgatctgccatgtgtgcattccctatcaaatatgtcaacgacttcttcaaca  
agatcgtcaacaaaaacaatgtgagatgtctccagcatttttacggacccaatcatgagc  
actgctttaataggacacttctgagaaattcatcaggctgtgaagcgcgccgtgatgaat  
atcgaacagagtttaccacagctttgcagcgcgcttgacttattcatgggtcaattcagcg  
aagtcctcttaacatctatatccaccttcattaaaggagacctcaccatagctaattcttg  
ggacatcagagggctcgcttcagtcagggttggtttctcgatcaggaccatcaaccctc  
atgtgaattttctcgactcccacccagtgctccagaagtgttggtggagcatacat  
taaaccaaaaatggctacacactgggttatcactgggaagaagatcacgaagatcccatga  
atggcttgggctgcagacatttccagtcctgcagtcattgcctctctgccccaccctttg  
ttcagtgtggctggtgccacgacaaatgtgtgcgatcggaggaatgcctgagcgggacat  
ggactcaacagatctgtctgcctgcaatctacaaggttttcccaaatagtgcaccccttg  
aaggagggacaaggctgaccatatgtggctgggactttggatttcggaggaataataaat  
ttgatttaaagaaaactagagttctccttggaatgagagctgcaccttgactttaagt  
agagcacgatgaatacattgaaatgcacagttggtcctgccatgaataagcatttcaata  
tgtccataattatttcaaattggccacgggacaacacaatacagtagatttctcctatgtgg  
atcctgtataaacaagtatttgcgggaaatacggctcctatggctggtggcactttactta  
ctttaactggaaattacctaacaacagtggaattcttagacacatttcaattggtggaaaaa  
catgtactttaaaaagtgtgtcaaacagttattcttgaatgtttataccccagcccaacca  
tttcaactgagtttgctgtttaaattgaaaattgacttagccaaccgagagacaagcatct  
tcagttaccgtgaagatcccattgtctatgaaattcatccaaccaaattctttattagtg  
gtgggagcacaataacaggtgttgggaaaaacctgaattcagttagtgtcccgagaatgg  
tcataaatgtgcatgaagcaggaaggaaactttacagtggtcatgtcaacatcgctctaatt  
cagagataatctgttgtaacctccttccctgcaacagctgaatctgcaactccccctga  
aaaccaaagcctttttcatgttagatgggatcctttccaaatactttgatctcatttatg  
tacataatcctgtgtttaagccttttgaaaagccagtgatgatctcaatgggcaatgaaa  
atgtactggaaattaagggaatgatattgaccctgaagcagttaaaggtgaagtgttaa  
aagttggaaataagagctgtgagaatatcacattacattctgaagccgttttatgcacgg  
tccccaatgacctgctgaaattgaacagcgagctaaatatagaggtgggattcctgcatt  
cctctcatgatgtaataaagggaagccagtgtaattatgttattctcagggctaaaaaTAA  
tcattaaagctcatttatgtgtgggttttggctcatcaactc ;

Fig. 1a

2/39

**MET T9 (SEQ ID NO: 1)**

MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAETPIQNVLHE  
HHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINM  
ALVVDITYYDDQLISCGSVNRGTCQRHVFPNHNTADIQSEVHCIFSPQIEEPSQCPDCVV  
SALGAKVLSSVKDRFINFFVGNTINSSYFPDHPHLSISVRRLKETKDGFMFLTDQSYID  
VLPEFRDSYPIKYVHAFESNNFIYFLTVQRETLDQTFHTRIIRFCSINSGLHSYMEMP  
LECILTEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSA  
EPMDRSAMCAFPKIYVNDFFNKIVNKNNVRCLQHFYGNHEHCFNRTLRLNSSGCEARR  
DEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGP  
STPHVNFLLDSDHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRHFQSCSQCLS  
APPFVQCGWCHDKCVRSEECISGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGF  
RRNNKFDLKKTRVLLGNESTLTLSSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTQY  
STFSYVDPVITSISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLKSVSNSILE  
CYTPAQTISTEFAVKLKIDLANRETSIFSREDPIVYEIHPTKSFISSGGSTITGVGKNL  
NSVSVPRMVINVHEAGRNFTVACQHRNSSEIICCTTPSLQQLNLQLPLKTKAFFMLDGI  
LSKYFDLIYVHNPVFKPFKPMISMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENI  
HLHSEAVLCTVPNDLLKLNSELNIEVGFLHSSHDVNKEASVIMLFSGLK

**Fig. 1b**

3/39

Met-Hepatocyte growth factor receptor-




Fig. 2

hsu08818\_t9.pfs

4/39

Sequence name: /dir/tp/CGC/DATA/analysis\_db/sw.fasta:MET\_HUMAN

## Sequence documentation:

Hepatocyte growth factor receptor precursor (EC 2.7.1.112) (Met proto-oncogene tyrosine kinase) (c-met) (HGF receptor) (HGF-SF receptor).  
Homo sapiens (Human). P08581; O60366; Q9UPL8;

Alignment of: HSU08818\_T9 x MET\_HUMAN ..

```
1 MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAET 50
|
|
1 MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAET 50

51 PIQNVILHEHHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFCPCQD 100
|
|
51 PIQNVILHEHHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFCPCQD 100

101 CSSKANLSGGVWVDNINMALVVDTYDDQLISCGSVNRGTCQRHVFPNH 150
|
|
101 CSSKANLSGGVWVDNINMALVVDTYDDQLISCGSVNRGTCQRHVFPNH 150

151 TADIQSEVHCIFSPQIEEPSQCPDCVVSALGAKVLSSVKDRFINFFVGNT 200
|
|
151 TADIQSEVHCIFSPQIEEPSQCPDCVVSALGAKVLSSVKDRFINFFVGNT 200

201 INSSYFPDHPLHSISVRRLKETKDGMFLTDQSYIDVLPEFRDSYPIKYV 250
|
|
201 INSSYFPDHPLHSISVRRLKETKDGMFLTDQSYIDVLPEFRDSYPIKYV 250

251 HAFESNNFIYFLTVQRETLDQTFHTRIIRFCSINSGLHSYMEMPLECIL 300
|
|
251 HAFESNNFIYFLTVQRETLDQTFHTRIIRFCSINSGLHSYMEMPLECIL 300

301 TEKRKKRSTKKEVFNILOAAYVSKPGAQLARQIGASLNDDILFGVFAQSK 350
|
|
301 TEKRKKRSTKKEVFNILOAAYVSKPGAQLARQIGASLNDDILFGVFAQSK 350

351 PDSAEPMDRSAMCAFPPIKYVNDFFNKIVNKNVRCLOHFYGPNEHCENR 400
|
|
351 PDSAEPMDRSAMCAFPPIKYVNDFFNKIVNKNVRCLOHFYGPNEHCENR 400

401 TLLRNSSGCEARRDEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGD 450
|
|
401 TLLRNSSGCEARRDEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGD 450

451 TIANLGTSEGRFMQVVVSRSGPSTPHVNFLLDSHPVSPEVIVEHTLNQNG 500
|
|
451 TIANLGTSEGRFMQVVVSRSGPSTPHVNFLLDSHPVSPEVIVEHTLNQNG 500

501 YTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGWCHDKCVRSEE 550
|
|
501 YTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGWCHDKCVRSEE 550

551 CLSGTWTQQICLPAIYKVPNSAPLEGGTRLTICGWDFGFRNNKFDLKK 600
```

Fig. 3



601	TRVLLGNESCTLTLSSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYS	650
601	TRVLLGNESCTLTLSSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYS	650
651	TF SYVDPVIT SIS PKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLK	700
651	TF SYVDPVIT SIS PKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLK	700
701	SVSNSILECYTPAQTISTEFAVKLKIDLANRETSIFS YREDPIVYEIHPT	750
701	SVSNSILECYTPAQTISTEFAVKLKIDLANRETSIFS YREDPIVYEIHPT	750
751	KSFISGGSTITGVGKNLNSVSVPRMVINVHEAGRNETVACQHRNSNSEIIC	800
751	KSFISGGSTITGVGKNLNSVSVPRMVINVHEAGRNETVACQHRNSNSEIIC	800
801	CTT PSLQQNLQLPLKTKAFFMLDGILSKYFDLIYVHNPFVKPF EK PVMI	850
801	CTT PSLQQNLQLPLKTKAFFMLDGILSKYFDLIYVHNPFVKPF EK PVMI	850
851	SMGNENVLEIKGNDIDPEAVKGEVLKVG NKS CENIHLHSEAVLCTVENDL	900
851	SMGNENVLEIKGNDIDPEAVKGEVLKVG NKS CENIHLHSEAVLCTVENDL	900
901	LKLNSELNIEVGFLHSSHDVNKEASVIMLFSGLK	934
901	LKLNSELNIE.....	910

**SUBSTITUTE SHEET (RULE 26)**




Fig. 4

7/39

IL6 T6 (SEQ ID NO: 7)

ccatgttttggttaaataagtgttttggtgttgcaaggggtctggtttcagcctgaagcca  
tctcagagctgtctgggtctctggagactggagggacaacctagtctagagcccatttgc  
atgagaccaagga~~t~~cctcctgcaagagacaccatcctgaggggaagagggcttctgaacca  
gcttgacccaataaagaattcttgggtgccgacgcggaagcagattcagagcctagagcc  
gtgcctgcgtccgtagtttcttcttagcttcttttgatttcaaatacaagacttacagggga  
gagggagcgataaacacaaaactctgcaagatgccacaaggtcctcctttgacatcccaa  
caaagaggactggagatgtctgaggctcattctgcccctcgagcccaccgggaacgaaaga  
gaagctctatctcccctccaggagcccagct~~ATG~~aactccttctccacaagcgccttcgg  
tccagttgccttctcccctggggctgctcctgggtgttgctgctgccttcccctgccccagt  
acccccaggagaagattccaaagatgtagccgccccacacagacagccactcacctcttc  
agaacgaattgacaaaacaaattcgggtacatcctcgacggcatctcagccctgagaaagga  
gacatgtaacaagagtaacatgtgtgaaagcagcaaagaggcactggcagaaaaacaacct  
gaaccttccaaagatggctgaaaaagatggatgcttccaatctggattcaatgaggagac  
ttgcctgggtgaaaatcatcactgggtcttttgaggtttgaggtatacctagagtacctcca  
gaacagatttgagagtagtgaggaacaagccagagctgtgcagatgagtacaaaagtcct  
gatccagttcctgcagaaaaagggtgggtgtgtcctcattccctcaacttggtgtggggga  
agacagggtcaaagacagtgctcctggacaactcagggatgcaatgccacttccaaaagag  
aaggctacacgtaaaca~~aa~~agagtc~~TCG~~agaaatagtttctgattgttattgttaaattctt  
tttttggttggttggttggttggtctctctctgcaaaggacatcaa


Fig. 5a

IL-6 T6 (SEQ ID NO: 5)

MNSFSTSAFGPVA~~F~~SLG~~L~~LLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYI  
LDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGC~~F~~QSGFNEETCLVKIITGLL  
EFEVYLEYLQNR~~F~~ESSEEQARAVQ~~M~~STKVLIQFLQKKVGVSSFPQLGVGEDRLKDSVLDN  
SGMQCHFQKRRLHVN~~K~~RV

Fig. 5b

## Interleukin 6



9/39

s56892\_p6(t6).pfs

Sequence name: /dir/tp/CGC/DATA/analysis\_db/sw.fasta:IL6\_HUMAN

Sequence documentation:

Interleukin-6 precursor (IL-6) (B-cell stimulatory factor 2) (BSF-2) (Interferon beta-2) (Hybridoma growth factor) (CTL differentiation factor) (CDF). Homo sapiens (Human). P05231; Q9UCU2; Q9UCU3; Q9UCU4;

Alignment of: S56892\_P6 x IL6\_HUMAN ..

```

      1 MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSS 50
      |||
      1 MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSS 50

    51 ERIDKQIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDG 100
      |||
    51 ERIDKQIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDG 100

   101 CFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFSSEEQARAVQMSTKVL 150
      |||
   101 CFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFSSEEQARAVQMSTKVL 150

   151 IQFLQKKVGVSSFPQLGVGEDRLKDSVLDNSGMQCHFQKRRLHVNKRV 198
      |||
   151 IQFLQKK..... 157

```

Fig. 7

## IL-6 structure




Fig. 8

10/39

**IL-7 T7 (SEQ ID NO: 11)**

aagacgaatagttttagtttatttagccaattcagataaatgtgcacgtggaagtcatagtt  
aaatattatcgtcagtttccacgtcctgcgtttaatttggggtttgattttccaaataca  
acacttaccagattaggtggaccacaggaattatttttcccttgaggtctcacctgagcag  
gtgcatgtacagcagacggagcagaaagagactgattagagaggttggagtggttagaggg  
cgtgaccctcttaatcattcttcacttccttttttaaagacgacttggcatcgtccacc  
acatccgcggcaacgcctccttgggtgtcgtccgcttccaataaccagcttgcgtcctgc  
acacttgtggcttccgtgcacacattaacaactcatgggttctagctcccagtcgccaagc  
gttgccaaggcgttgagagatcatctgggaagtccttttaccagaattgctttgattcag  
gccagctggtttttccctgcggtgattcggaaattcgcgaattcctctggctcctcatccag  
gtgcgcgggaagcaggtgcccaggagagaggggataatgaagattccatgctgatgatcc  
caaagattgaacctgcagaccaagcgcgaagtagaaactgaaagtacactgctggcggat  
cctacggaagttatggaaaaggcaaagcgcagagccacgcccgtagtgtgtgccgcccccc  
ttgggatggatgaaactgcagtcgcggcgtgggtaagaggaaccagctgcagagatcacc  
ctgcccacacagactcggcaactccgcggaagaccagggctcctgggagtactatgggc  
ggtgagagcttgctcctgctccagttgcggtcatcatgactacgcccgcctcccgcagac  
ccttccatgtttcttttaggtatatctttggacttcctccctgatccttggtctgtt  
gccagtagcatcatctgattgtgatattgaaggtaaagatggcaaacaatatgagagtg  
tctaattggtcagcatcgatcaattattggacagcatgaaagaaattggtagcaattgcct  
gaataatgaatttaacttttttaaagacatatctgtgatgctaataagggaaggtatggt  
tttattccgtgctgctcgcaagttgaggcaatttcttaaaatgaatagcactgggtgattt  
tgatctccacttattaaaagtttcagaaggcacaacaataactggtgaactgcactggcca  
ggttaaaggaagaaaaccagctgccctgggtgaagcccaaccaacaaagagtttgctc  
aggactacagaagcagttcacattttacagatcaaacggacgacacacacattctttcca  
ctgcaaatgtcctttctccactcaggaaggtatcagtttctccaaataaattgtatcaact  
tgagggcagacacttaattacatcttattatctcgatcccatcattgcataatccagaaa  
gagcacataaagcgtttttcaatgcttatttttagttgatggactatttggttctttggtt  
tgaccaataagactgaataaagataactgaggggaaaaaaattaacaactaatcaggaaa  
taaacttttttcggatttatgaaataatttggttgacatgctctacaggagtgacctaac  
atacctaattggtaactaaaactgttctctttaattacaaaattcccagcatctatcctac  
tatgatactatctgaagataggcaccaataatacaaatgtttatccaaa

Fig. 9a

**IL-7 T7 (SEQ ID NO: 9)**

MFHVSFRYIFGLPPLIILVLLPVASSDCDIEGKDGKQYESVLMVSIQLLDSMKEIGSNCL  
NNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDFDLHLLKVSEGTTILLNCTGQ  
VKGRKPAALGEAQPTKSLSSGLQKQFTFYRSNGRHTSHFCKLSFLH

Fig. 9b

11/39

**IL7-T8** (SEQ ID NO: 15)

aagacgaatagttttgattttattagccaattcagataaatgtgcacgtggaagtcatagtt  
aaatattatcggtcagtttccacgtcctgcgtttaatttggggtttgattttccaaataca  
acacttaccagattaggtggacccacaggattatttttccttgaggtctcacctgagcag  
gtgcatgtacagcagacggagcagaaagagactgattagagaggttggagtggtagaggg  
cgtgaccctcttaatcattcttcacttccttttttaaagacgacttggcatcgccacc  
acatccgcggaacgcctccttggtgtcggtccgcttccaataaccagcttgcgctcctgc  
acacttggtggttccgtgcacacattaacaactcatggttctagctcccagtcgccaagc  
gttgccaaggcggttgagagatcatctgggaagtcttttaccagaattgctttgattcag  
gccagctggttttctgcggtgattcggaattcgcggaattcctctggtcctcatccag  
gtgcgcggaagcaggtgcccaggagagaggggataatgaagattccatgctgatgatcc  
caaagattgaacctgcagaccaagcgcaagtagaaactgaaagtacactgctggcggtat  
cctacggaagttaggaaaaggcaaagcgagagccacgcccgtagtgtgtgcccgcctccc  
ttgggatggatgaaactgcagtcgcggtggtggttaagaggaaccagctgcagagatcacc  
ctgcccacacagactcggaactccgcggaagaccagggtcctgggagtgactatgggc  
ggtgagagcttgctcctgctccagttgcggtcatcatgactacgcccgcctcccgcagac  
cattgcttccatggtttcttttaggtatatctttggacttccctcccctgatccttggtctggt  
gccagtagcatcatctgattgtgatattgaaggtaaagatggcaacaatatgagagtggt  
tctaattggtcagcatcgatcaattattggacagcatgaaagaaattggtagcaattgcct  
gaataatgaatttaacttttttaaagacatatctgtgatgctaataaggaaggatggt  
tttattccgtgctgctcgcaagttgaggcaatttctttaaataagtagcactggtgattt  
tgatctccacttatttaaagtttcagaaggcacaacaatactgttgaaactgcactggcca  
ggttaaaggaagaaaaccagctgccctgggtgaagcccaaccaacaaagagtttggtgga  
actgatcattccttcatgtatgcctccactgctcagctcaacaagtaactcttaataacc  
taccacctgttatctctgggagagggacatatgtttgccaatttctatcttcaatgctta  
tcacaaattttcttatatttgaaataatctgattcaaatagagaactttaacctaataactt  
taattggaaagacaatcttataaaaatcttataacatatc

Fig. 9c

**IL7 T8** (SEQ ID NO: 13)

MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDQYESVLMVSIQLLDSMKEIGSNCL  
NNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDFDLHLLKVSEGTITLLNCTGQ  
VKGRKPAALGEAQPTKSLVELIIPSCMPPLLSSTNS

Fig. 9d




Fig. 10



13/39

humil7a\_p4(t7).pfs

Sequence name: /dir/tp/CGC/DATA/analysis\_db/sw.fasta:IL7\_HUMAN

Sequence documentation:

Interleukin-7 precursor (IL-7). Homo sapiens (Human). P13232;

Alignment of: HUMIL7A\_P4 x IL7\_HUMAN ..

```

      1 MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIQQLLD 50
      ||||||||||||||||||||||||||||||||||||||||||||||||
      1 MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIQQLLD 50

     51 SMKEIGSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDF 100
      ||||||||||||||||||||||||||||||||||||||||||||||||
     51 SMKEIGSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDF 100

    101 DLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSLSSGLQKQFTFYR 150
      ||||||||||||||||||||||||||||||||||||||||||||||||
    101 DLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSL..... 138

    151 SNGRHTHSFHCKLSFLH 167

    138 ..... 138

```

Fig. 11a

humil7a\_p5 (t8).pfs

Sequence name: /dir/tp/CGC/DATA/analysis\_db/sw.fasta:IL7\_HUMAN

Sequence documentation:

Interleukin-7 precursor (IL-7). Homo sapiens (Human). P13232;

Alignment of: HUMIL7A\_P5 x IL7\_HUMAN ..

```

      1 MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIQQLLD 50
      ||||||||||||||||||||||||||||||||||||||||||||||||
      1 MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIQQLLD 50

     51 SMKEIGSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDF 100
      ||||||||||||||||||||||||||||||||||||||||||||||||
     51 SMKEIGSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDF 100

    101 DLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSLVELIIPSCMPPL 150
      ||||||||||||||||||||||||||||||||||||||||||||||||
    101 DLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSL..... 138

    151 LSSTSNS 157

    138 ..... 138

```

Fig. 11b

14/39

## IL-7 structure




Fig. 12

15/39

**TNFR9 T4 (SEQ ID NO: 19)**

gagaccaaggagtggaagttctccggcagccctgagatctcaagagtga  
 catttgtgagaccagctaatttgattaaaattctcttggaatcagctttgctagtatcat  
 acctgtgccagatttcattcATGggaaacagctgttacaacatagtagccactctgttgct  
 ggtcctcaactttgagaggacaagatcattgcaggatccttgtagtaactgccagctgg  
 tacattctgtgataataacaggaatcagatttgcagtcctctgctccaaatagtttctc  
 cagcgcagggtggacaaaggacctgtgacatatgcaggcagtgtaaagggtgttttcaggac  
 caggaaggagtggtcctccaccagcaatgcagagtggtgactgcaactccagggtttcactg  
 cctgggggcaggatgcagcatgtgtgaacaggattgtaaacaagggtcaagaactgacaaa  
 aaaagggttgtaaagactgttgctttgggacatttaacgatcagaaacgtggcatctgtcg  
 accctggacaaacatcagagtggtgacgaatggaatcatgattcacaagaaaagtattG  
 Aactattttctcggacttagctgaattctgtctttggaaagtggcttttttaaaaagtgt  
 tctttggatggaaagtctgtgcttgtgaatgggacgaaggagaggagcgtgggtctgtgga  
 ccatctccagccgacctctctccgggagcatcctctgtgaccccgctgcccctgcgaga  
 gagccaggacactctccgcagatcatctccttctttcttgcgctgacgtcgactgcgttg  
 ctcttcctgctgttcttctcacgctccgtttctctgttggttaaacggggcagaaagaaa  
 ctctgtatatattcaaacaacgtaagattaacataatcatattacagctctggca

Fig. 13a

**TNFR9 T4 (SEQ ID NO: 17)**

MGNSCYNIVATLLLVLNFERTRSLQDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGGQR  
 TCDICRQCKGVFRTRKECSSTSNAECDCTPGFHC LGAGCSMCEQDCKQGQELTKKGCKDC  
 CFGTFNDQKRGICRPWTNIRVADEWNHDSQEKY

Fig. 13b



17/39

hsu03397\_p4 (T4).pfs

Sequence name: /dir/tp/CGC/DATA/analysis\_db/sw.fasta:TNR9\_HUMAN

Sequence documentation:

Tumor necrosis factor receptor superfamily member 9 precursor (4-1BB ligand receptor) (T-cell antigen 4-1BB homolog) (T-cell antigen ILA) (CD137 antigen). Homo sapiens (Human). Q07011;

Alignment of: HSU03397\_P4 x TNR9\_HUMAN ..

```

      1 MGNSCYNIVATLLLVLNFERTRSLODPCSNCPAGTFCDNNRNQICSPCPP 50
      ||||||||||||||||||||||||||||||||||||||||||||||||
      1 MGNSCYNIVATLLLVLNFERTRSLODPCSNCPAGTFCDNNRNQICSPCPP 50

     51 NSFSSAGGQRTCDICRQCKGVFTRTRKECSSTSNAECDCTPGFHCLGAGCS 100
      ||||||||||||||||||||||||||||||||||||||||||||||||
     51 NSFSSAGGQRTCDICRQCKGVFTRTRKECSSTSNAECDCTPGFHCLGAGCS 100

    101 MCEQDCKQGQELTKKGCKDCCFGTFNDQKRGICRPWTNIRVADEWNHDSQ 150
      ||||||||||||||||||||||||||||||||||||||||||||
    101 MCEQDCKQGQELTKKGCKDCCFGTFNDQKRGICRPWTN..... 138

    151 EKY                                                    153

    138 ...                                                    138

```

Fig. 15

## TNFR 9- structure




Fig. 16

18/39

IL-4R T4 (SEQ ID NO: 23)

tgcagtgcggcagacagattgtactagttactgattgaagggtgttttactatccaaatgtggctggagtaggagttgggt  
aaacattttattgaagaatgtgcaaccactctcacttggaaagcgggtgttaggaagggaggaggttccagtcgccc  
gcccctccccaccaaagcgaactgccccggcgcaaaagaggccggcaggcaggagcaggtcctggaggcctgggt  
cgcggtgggcgttttattccgagaccaaggggatccactgcagagttctccgctgggcgtgacctcgggctacggcgtgg  
gaggaagcgcggcgcaagacacccagcgaggtgtcggggctcgccccaggagaggacggcgggtcggactgtccggcggc  
ggcggcggggacagcgacagggggcgcgaggtggccgggacccgggcccggcgccggggcgccggcgccgcatgcaaact  
gcccgggcggggggcggggagcaggaagccggggcggggtgggtctccgcgcccaggaagcccgcggcgccggggc  
gggaagggccacccaggggtcccccacttcccgttgggcgcccggacggcggaatggagcagggggcgcgagataa  
agatttacacacagctggaagaaatcatagagaagccggcggtgggtcctatgcctataatcccagcacttttggaggc  
tgaggcgggcagatcacttgagatcaggagttcgagaccagcctgggtccttggcatctcccaATGgggtgggttggctc  
tgggtccttccagcccagcgagcagtgctcctccaccttggaaagcgagctgggtcgcagTAGaccaccaagccccctcagcc  
cctgcgtctccgactacatgagcatctctacttgcgagtggaagatgaatgggtcccaccaattgcagcaccgagctccgc  
ctgttgtaccagctgggttttctgctctccgaagcccacagtgatccctgagaaacacggaggcgccgggtgcgtgtg  
ccacctgctcatggatgacgtggtcagtcgggataactatacactggacacctgtgggtcgggcagcagctgcttgaagg  
gtcctctcaagcccagcgagcagtgctcctccaccttggaaagcgagctgggtcgcagTAGaccaccaagccccctcagcc  
cagctgtttccacccctgaacttaagtggccaggaagggcgtattgagatgaggtgtgcttgcctggaaggcatgctgctg  
ctgattgaaacccgaactgggaacagtccttccattctgtgtccactggtcagctgctgcggcttggatggcttggacc  
gtggaaggctgaccttcttctggtaccggagtcctcgcaggaatcccccttgagcttggctgggtgtggaagaggt  
ttaaaacatgctgttattccagtgatgatgatgatgatgatgatgatgatgatgatgatgatgatgatgatgatgatgat  
ttgcttcaaaaggagaccaagttttaaaacagatgaatcaaaataaagaaaaatactcagtaaatcatataaagtacaga  
gatgtggccaaaggtgtgaaggatgcagctgtaaaagctgaagtttagggccgggtgtgggtgttcatgcctataatccc  
agcactttgggaggccgagccagcggtatcccgagggtcaggagttcgagaccagcctggacaacatgtgaaacccagg  
gccccaggaaacccagctgacagttcacaccaatgtctccgacactctgctgctgacctggagcaacccgtatccccctgaca  
ttacctgtataatcatctcacctatgcagtcaacatttggagtgaaaacgaccggcgagatttcagaatctataacgtga  
cctacctagaacccctccctccgcatcgacggcagcaccctgaagctctgggtatttccctacagggcacgggtgagggtcgg  
gctcagtgctataaacacacactggagtgagtgaggcccgacccaagtggaacaactcctacagggaacccctcggagca  
gcacctcctgctgggcgtcagcgttctctgcatctcctggcgtctgctgttgtgctatgtcagcatcaccaaga  
ttaagaaagaatgggtgggatacagattcccaacccagcccgacggcctcgtggctataataatccaggatgtcagggg  
tcacagtgaggagaagcgggtcccaggccaggaaccagccaaagtggccacactggaagaattgtcttaccagctcttggc  
ctgttttctggagcaacacatgaaaagggtgaagatcctcacaggctgccaaagagatgccttccagggtcctggaa  
aatcagcatgggtgcccagtgagatcagcaagacagtcctcctggccagagagcatcagcgtggtgcgagtgtgtggagt  
tttagggcccggtggagtgtagggaggaggaggaggttagaggaagaaaaaggagcttctgtgcatcgccctgagagcag  
caggatgacttccaggaggaagggagggcatttggcccggtcaaacagagagcctgttccctggacctgctcggagag  
agaatgggggcttttccagcaggacatgggggagtcagccttcttccaccttcgggaagtacgagtgctcacatgcc  
tgggatgagtcccaagtgccagggcccaaggaggcaccctccctggggcaggagcagccttccacctggagccaaagtcc  
tcttccagcccgacccagagtcagacaaacctgacttgcacagagacgccccctgctcatcgaggcaacccctgcttacc  
gcagcttcaagcaactccctgagccagtcacccgtgtccagagagcctgggtccagacccactgctggcagacacctggag  
gaagtagaacccgagatgcctgtgtccccagctctctgagccaacctgtgccccaaacctgagccagaacctggga  
gcagatcctccgccaagatgtcctccagcatggggcagctgcagccccctgctcggccccaccagtggtatcaggagt  
ttgtacatgcgggtggagcaggggtggcaccaggccagtcgggtgggtgggtgggtgggtgggtgggtgggtgggtgggt  
gccttctcaagcctgtgttccagcagtgctgttccccagagaaatgtgggtttggggctagcagtggggaagaggggta  
taagccttccaaagacctcatttctggctgcccctggggacccctgcccagtcctctgctcccttgttcccttggactgg  
acagggagccacctcgcagtcgcagagctcacatctcccaagcagctccccagagcacctgggtctggagccgggggaa  
aaggtagaggacatgcccaggccccacttccccaggagcaggccacagaccccttgggacagcctgggcagtggtgat  
tgtctactcagcccttacctgccacctgtcgggccacctgaaacagtgctatggccaggaggtatgggtggccagaccct  
gtcatggccagtccttctgtgtgctgtgtgtggagacaggtcctcgccccctacaaacccccctgaggggccccagacc  
ctctccaggtgggttccactggaggccagtcgtgttccggcctccctggcaccctcgggcatctcagagaagagtaaat  
cctcatccttccatctcctcctggcaatgtctcagagctcaagccagaccccccaaatcgtgaacttgtctccgtg  
ggaccacatatacatgaggtctcttaggtgcatgtcctcttgttgcctgagtcagatgaggactagggttatccatg  
cctgggaatgccacccctcctggaaagcagccaggctggcagatttccaaaagactgaagaacctggtatgaaggtgat  
tggccccactgacgttggcctaactcctgggtgcagagactggaccccccgccagcattgggtcgggtcgcacacatccca  
tgagagtagagggcactgggtcgcgtgccccagcgagccctgcaggaaaactgaggcccttggggacccctcagcttg  
tgaacgagttgttgggtgctccctccacagcttctgcagcagactgtccctgttgaactgcccaaggcatgttttgccc  
accagatcatggccacatggaggccacccctgcttctcactgaactagaagccgagcctagaaactaacacagcca  
tcaagggaatgacttggcgcccttgggaaatcgatggagaattgaacttcagggaagggtgtgctattgctcaggtgtct  
cattcatttaacagagcttcccttaggttgatgtgtggaggcagaatcccggtgtcaaggggtgttcagttaaggggagca  
acagaggacatgaaaaattgtgtgactaaagcagggacaatttgcgtgcaaacacccatgccagctgtatggctgggg  
gtcctcgtatgcatggaacccccagaataaataatgtctcagccacccctgtgggcccgggcaatccagacagcaggcataag  
gcaccagttaccctgcatgttggcccagacccaggtgctgaggaaggcggaaccccttgggttagtaaatgtctgtgt  
gtgttttagtttoatcacctgttatctgtgttggctgaggagagtggaacagaaggggtggagtttgtataaataaagt  
ttcttgtctctttaaaaaattatgtatttaacaaacatacctccagac

Fig. 17a

19/39

IL-4R T4 (SEQ ID NO: 21)

MGWLCSGLLFPVSLVLLQVASSGNMKVLQEPCTCVSDYMSISTCEWKMNPTNCSTELR  
 LLYQLVFLLEAHTCIPENNGGAGCVCHLLMDDVVSADNYTLDLWAGQQLLWKGSFKPS  
 EHVLPPLKRSWSQ

Fig. 17b

IL-4R T11 (SEQ ID NO: 27)

tgcagtccccgacagattgtactagttactgattgaagggtgttttactatccaaatgtggctggagtaggagttgggt  
 aaacattttattgaagaatgtgcaaccactctcacttggaaagccgggtgttaggaaggggaggaggattccagtcgcca  
 gccctccccaccacaaacgcaactgccccggcgcaaaagaggccgagggccagggcaggtcctggaggcctgggt  
 cggcgtggggtgttttattccgagaccaaggggatccactgcagagttctccgctgggctgacctcgggctacggcgtgg  
 gaggaagcgcgcggcaagacacccagcgaggtgctggggtcgccccaggagagggacggcggtcggactgtccggcggc  
 ggcgcggggacagcgacaggggacgggtggcgggacccgggacggcgccggcgccggcgccggcgccatgcaaatct  
 gccggcgccggggcgggggagcaggaaagccgggctgggtctccgcgccaggaaagccccgcgcggcgccggcca  
 gggaagggccacccagggtccccacttcccgcttggcgcccgacggcgcaatggagcagggcgccgagataattaa  
 agatttacacacagctggaagaaatcatagagaagccggcggtgtggctcatgcctataatcccagcacttttgaggc  
 tgaggcgggcagatcacttgagatcaggagttcgagaccagcctgtgccttggcatctccca<sup>100</sup>gggtggcttggctc  
 tgggtcctgttccctgtgagctgctgtgctgcaggtggcaagctctggaacatgaaggtcttgcaggagccca  
 cctgcgtotccgactacatgagcatctctacttgcgagtggaaagatgaatggctccaccaattgcagcaccgagctccgc  
 ctgtgtaccagctgggttttctgtctctccgaagcccacacgtgtatccctgagaacaacggaggcgccgggtgctgtg  
 ccacctgctcatggatgacgtgggtcagtgcggaataactatacactggacctgtgggtgggcagcagctgctgtggaagg  
 gctccttcaagcccagcgagcatgtgaaacccaggggccccaggaaacctgacagttcacaccaatgtctccgacactctg  
 ctgctgacctggagcaaccggtatccccctgacaattacctgtataatcatctcacctatgcagtcacacatttggagtgga  
 aaacgacccggcagatttcagaatctataacgtgacctacctagaacctccctccgcatcgagccagcaccctgaagt  
 ctgggatttccctacagggcacgggtgagggcctgggctcagtgctataacaccacctggagtgagtgagcccgagcacc  
 aagtggcacaactgtgagatcaagaggcc<sup>150</sup>gcaatggtaattccactctccattcttccccctgtggccagacactt  
 cccctggctgagttctgtggc

Fig. 17c

IL-4R T11 (SEQ ID NO: 25)

MGWLCSGLLFPVSLVLLQVASSGNMKVLQEPCTCVSDYMSISTCEWKMNPTNCSTELR  
 LLYQLVFLLEAHTCIPENNGGAGCVCHLLMDDVVSADNYTLDLWAGQQLLWKGSFKPS  
 EHVKPRAPGNLTVHTNVSdTLLLTWSNPYPNDNYLNLTYAVNIWSENDPADFRIYNV  
 TYLEPSLRIAASTLKSGISYRVRVRAWAQCYNTTWSEWSPSTKWHNCEYQEA

Fig. 18

20/39

cds-2\_hsil4r\_t4.pfs

Sequence name: /dir/tp/CGC/DATA/analysis\_db/sw.fasta:IL4R\_HUMAN

Sequence documentation:

Interleukin-4 receptor alpha chain precursor (IL-4R-alpha) (CD124 antigen). Homo sapiens (Human). P24394; Q96P01;

Alignment of: CDS-2\_HSIL4R\_T4 x IL4R\_HUMAN ..

```

      1 MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNNG 50
      |||||||||||||||||||||||||||||||||||||||||||||||||||
      1 MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNNG 50

     51 PTNCSTELRLLYQLVFLLEAHTCIPENNGGAGCVCHLLMDDVVSADNYT 100
      |||||||||||||||||||||||||||||||||||||||||||||||||||
     51 PTNCSTELRLLYQLVFLLEAHTCIPENNGGAGCVCHLLMDDVVSADNYT 100

    101 LDLWAGQQLLWKGSFKPSEHVLPPPKRSWSQ 131
      |||||||||||||||||||
    101 LDLWAGQQLLWKGSFKPSEHV..... 121

```

Fig. 19a

cds-2\_hsil4r\_t11.pfs

Sequence name: /dir/tp/CGC/DATA/analysis\_db/sw.fasta:IL4R\_HUMAN

Sequence documentation:

Interleukin-4 receptor alpha chain precursor (IL-4R-alpha) (CD124 antigen). Homo sapiens (Human). P24394; Q96P01;

Alignment of: CDS-2\_HSIL4R\_T11 x IL4R\_HUMAN ..

```

      1 MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNNG 50
      |||||||||||||||||||||||||||||||||||||||||||||||||||
      1 MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNNG 50

     51 PTNCSTELRLLYQLVFLLEAHTCIPENNGGAGCVCHLLMDDVVSADNYT 100
      |||||||||||||||||||||||||||||||||||||||||||||||||||
     51 PTNCSTELRLLYQLVFLLEAHTCIPENNGGAGCVCHLLMDDVVSADNYT 100

    101 LDLWAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTLTLLTWSNPYPDP 150
      |||||||||||||||||||||||||||||||||||||||||||||||||||
    101 LDLWAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTLTLLTWSNPYPDP 150

    151 NYLYNHLTYAVNIWSENDPADFRIYNVTYLEPSLRIAASTLKSGISYRAR 200
      |||||||||||||||||||||||||||||||||||||||||||||||||||
    151 NYLYNHLTYAVNIWSENDPADFRIYNVTYLEPSLRIAASTLKSGISYRAR 200

    201 VRAWAQCYNTTWSEWSPSTKWHNCEYQEA 229
      |||||||||||||||||||
    201 VRAWAQCYNTTWSEWSPSTKWHN..... 223

```

Fig. 19b



IL4R structure






Fig. 20

22/39

**TGR2 T7 (SEQ ID NO: 31)**

acctaaagaaaaacattttacaacttgacagtgtatgcacatacatatgcatatagac  
acaactgaagcacaaatttaataagtagaatttaccgttactattttatttgggaaaga  
aatgtgctcgcgactcaatagattggagatttcactcctggatctcaacttgcaatttga  
aaacgcatctctaaagcacctaggagcaatctgaagaaagctgaggggagggcggcagatg  
ttctgatctactagggaaaacgtggacgttttctgtttgttactttgtgaactgtgtgcac  
ttagtcattcttgagtaaatacttggagcgaggaactcctgagtggtgtgggagggcgggt  
gaggggagctgaaagtcggccaaagctctcggaggggctgggtctaggaaacatgattgg  
cagctacgagagagctaggggctggacgtcagagagagggagaaggctctcgggaggaga  
gaggtcctgccagctgttggcgaggagtttctgtttcccccgagcgtgagttgaag  
ttgagtgagtcactcgcgcgcacggagcgacgacacccccgcgcgtgcacccgctcggga  
caggagccggactcctgtgcagcttccctcggccgcgggggctccccgcgcctcggcg  
gcctccaggccccctcctggctggcgagcgggcccacatctggcccgcacatctgcgct  
gccggccccggcgggggtccggagagggcgcgggcgaggagggcgagccaggggtcggga  
aggcgccgtccgctgcgctgggggctcgggtctatgacgagcagcggggtctgccctgggt  
cgggggctgctcaggggctgtggccgctgcacatcgctcctgtggacgcgtatcgccagc  
acgatccacccgcacgttcagaagtcggttaataacgacatgatagtcactgacaacaac  
ggtgcagtcaagtttccacaactgtgtaaattttgtgatgtgagattttccacctgtgac  
aaccagaaatcctgcatgagcaactgcagcatcacctccatctgtgagaagccacaggaa  
gtctgtgtggctgtatggagaaagaatgacgagaacataacactagagacagtttgccat  
gacccaagctcccctaccatgactttattctggaagatgctgcttctccaaagtgcatt  
atgaaggaaaaaaaagcctgggtgagactttcttcatgtgttctctgtagctctgatgag  
tgcaatgacaacatcatcttctcagaaggtgagttttcttctcttaaggggtgtgggacct  
gagatctgtgccaatttttgtatccttgggtctgcagtggtcaatagacacattcctcctg  
tggtggattgcatacagtggattaggagctcattcagctgggtggaaagaggggcttgggg  
agtagcaggggttgttctggttctcatcaaatatggttgactggggcaaacattattatt  
tgtctttgacaaatagtttctttcacctagagcagtggttctcaaagtgcggcccccttga  
gcagccagcatcagtatcacctgggaacctgttataaatgcagattctcaggccccacta  
aatgagaaacatagaggggtgaaccccagctatctgtatttttaacaagccctccagtaat  
tctgtgcagctaaaatttggttaactattgttctaaagatttggtggggttgtttaatct  
tggaggaggactttctttataactgatgttgttcttgtacatagtccaggtttgtct  
ttaggggtacttgtcatcgatcccatttgagagacactttgcaatacagag

Fig. 21a

**TGR2 T7 (SEQ ID NO: 29)**

MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFST  
CDNQKSCMSNCSITSICEKPQEVCAVVRKNDENITLETVCHDPKLPYHDFILEDAAAPK  
CIMKEKKKPGETFFMCSRSSDECNDNIIFSEGEFSSLKGVGPEICANFLYPWSAVS

Fig. 21b



24/39

z21887\_p6(t7).pfs

Sequence name: /dir/tp/CGC/DATA/analysis\_db/sw.fasta:TGR2\_HUMAN

Sequence documentation:

TGF-beta receptor type II precursor (EC 2.7.1.37) (TGFR-2) (TGF-beta type II receptor). Homo sapiens (Human). P37173; Q99474;

Alignment of: Z21887\_P6 x TGR2\_HUMAN ..

```

      1 MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQL 50
      ||||||||||||||||||||||||||||||||||||||||||||||||
      1 MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQL 50

      51 CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCAVWRKNDENITLETV 100
      ||||||||||||||||||||||||||||||||||||||||||||||||
      51 CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCAVWRKNDENITLETV 100

      101 CHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS 150
      ||||||||||||||||||||||||||||||||||||||||||||||||
      101 CHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS 150

      151 EGEFSSLKGVGPEICANFLYPWSAVS 176
      |
      151 E..... 151

```

Fig. 23

TGR2 structure




Fig. 24



27/39

ITAV T3 (SEQ ID NO: 33)

MAFPFRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDS PAEYSGPEGSYFGFAVDFFVPSA  
SSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKS  
HQWFGASVRSKQDKILACAPLYHWRTMKQEREPVGTCTFLQDGTKTVEYAPCRSQDIDAD  
GQGFCQGGFSIDFTKADRVLLGGPGSFYWQQLISDQVAEIVSKYDPNVYSIKYNNQLAT  
RTAQAIFFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGE  
QMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGS DGKLQEVGQVSVSLQRASGDFQTTK  
LNGFEVFARFGSAIAPLGLDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQI  
LEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVY  
PSILNQDNKTCSLPGTALKVSCFNVRFLKADGKGVLPKLNQVELLLDKLKQKGAIRR  
ALFLYSRSPSHSKNMTISRGGMLQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAAD  
TTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVSDSQKKIYIGDDNPLTLIVK  
AQNQGE GAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAG  
TQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSP  
DHIFLPIPNWEHKENPETEEDVGPVVQHIYEVCSC

Fig. 25b





humvtnr\_p3(t3).pfs

29/39

Sequence name: /dir/tp/CGC/DATA/analysis\_db/sw.fasta:ITAV\_HUMAN

## Sequence documentation:

Integrin alpha-V precursor (Vitronectin receptor alpha subunit) (CD51 antigen). Homo sapiens (Human). P06756;

Alignment of: HUMVTNR\_P3 x ITAV\_HUMAN ..

```

      1 MAFFPRLRLGPRGLPLLLSGLLLPLCRAFNLVDVSPA EYSGPEGSYFG 50
      |||
      1 MAFFPRLRLGPRGLPLLLSGLLLPLCRAFNLVDVSPA EYSGPEGSYFG 50

    51 FAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPI 100
      |||
    51 FAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPI 100

   101 EFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQ 150
      |||
   101 EFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQ 150

   151 EREFVGTCTFLQDGTCTVEYAPCRSQDIDADGQGFCCGGFSIDFTKADRVL 200
      |||
   151 EREFVGTCTFLQDGTCTVEYAPCRSQDIDADGQGFCCGGFSIDFTKADRVL 200

   201 LGGPGSFYWQQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFFDDS 250
      |||
   201 LGGPGSFYWQQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFFDDS 250

   251 YLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGE 300
      |||
   251 YLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGE 300

   301 QMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGS DGKLEVGQVSVSLQ 350
      |||
   301 QMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGS DGKLEVGQVSVSLQ 350

   351 RASGDFQTTKLNGFEVVFARFGSAIAPLGDLDDQDGFNDIAIAAPYGGEDKK 400
      |||
   351 RASGDFQTTKLNGFEVVFARFGSAIAPLGDLDDQDGFNDIAIAAPYGGEDKK 400

   401 GIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYP 450
      |||
   401 GIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYP 450

   451 DLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKV 500
      |||
   451 DLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKV 500

   501 SCFNVRFCCLKADGKGVLPRLNLFQVELLLDKLKQKGAI RRALFLYSRSPS 550
      |||
   501 SCFNVRFCCLKADGKGVLPRLNLFQVELLLDKLKQKGAI RRALFLYSRSPS 550

   551 HSKNMTISRGGMLQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAAD 600
      |||
   551 HSKNMTISRGGMLQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAAD 600

```

Fig. 27

30/39

```
601 TTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDS DQKKIYIG 650
   |||||||||||||||||||||||||||||||||||||||||||
601 TTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDS DQKKIYIG 650
   .
651 DDNPLTLIVKAQNQGEGAYEAE LIVSIPLQADFIGVVRNNEALARLSCAF 700
   |||||||||||||||||||||||||||||||||||||||||||
651 DDNPLTLIVKAQNQGEGAYEAE LIVSIPLQADFIGVVRNNEALARLSCAF 700
   .
701 K TENQTRQVVCDLGNPMKAGTQLLAGLRFSVHQQSEMDTSVKFDLQIQSS 750
   |||||||||||||||||||||||||||||||||||||||||||
701 K TENQTRQVVCDLGNPMKAGTQLLAGLRFSVHQQSEMDTSVKFDLQIQSS 750
   .
751 NLFDKVSPVVSHKVDLAVLA AVEIRGVSSPDHIFLPIPNWEHKENPETEE 800
   |||||||||||||||||||||||||||||||||||||||||||
751 NLFDKVSPVVSHKVDLAVLA AVEIRGVSSPDHIFLPIPNWEHKENPETEE 800
   .
801 DVGPVVQHIYEVCSC 815
   |||||||||||
801 DVGPVVQHIYE.... 811
```

Fig. 27 (Cont.)




Fig. 28

32/39

IL-10-R- $\beta$  T1 (SEQ ID NO: 39)

cccgcccatctccgctggttcccgggaagccgcccgggacaagctctcccgggcgcgggcg  
ggggtcgtgtgcttggaggaagccgcggaacccccagcgtccgtccATGgcggtggagcct  
tgggagctggctgggtggctgctgctggtgtcagcattgggaatggtaccacctcccga  
aatgtcagaatgaattctgttaatttcaagaacattctacagtgggagtcacctgcttt  
tgccaaaggggaacctgactttcacagctcagtacctaagttataggatattccaagataa  
atgcatgaatactaccttgacggaatgtgatttctcaagtctttccaagtatggtgacca  
caccttgagagtcagggctgaatttgcagatgagcattcagactgggtaaacatcacctt  
ctgtcctgtggatgacaccattattggacccccctggaatgcaagtagaagtacttgctga  
ttctttacatatgcgtttcttagccccctaaaattgagaatgaatacgaaccttgactat  
gaagaatgtgtataactcatggacttataatgtgcaatactggaaaaacggtagtgatga  
aaagtttcaaattactccccagtatgacttttgaggctcctcagaaacctggagccatggac  
aacttattgtgttcaagttcaggggttcttccctgatcggaaacaaagctggggaatggag  
tgagcctgtctgtgagcaaacaccatgaCGtttttgggccatcctcatcaTAAcacac  
ttctgtttttctcctttccattgtcggatgagaatgatgtttttgacaagctaagtgatca  
ttgcagaagactctgagagcggcaagcagaatcctgggtgacagctgcagcctcgggaccc  
cgcttgggcaggggccccaaagctaggctctgagaaggaaacacactcggctgggcacag  
tgacgtactccatctcacatctgcctcagtgagggatcagggcagcaaacaaagggccaag  
accatctgagccagccccacatctagaactcccagacctggacttagccaccagagagc  
tacattttaaggctgtcttggcaaaaaatactccatttgggaactcactgccttataaag  
gctttcatgatgttttcagaagttggccactgagagtgtaattttcagccttttatatca  
ctaaaataagatcatgttttaattgtgagaaacagggccgagcacagtggtcacgcctg  
taataaccagcaccttagaggctcagggcagggcggtcacttgagggtcaggagttcaagacc  
agcctggccaatatggtgaaacccagtccttactaaaaatacaaaaaattagctaggcatg  
atggcgcatgcctataatcccagctactcgagtgcttgaggcaggagaattgcatgaacc  
cgggaggaggaggaggaggttgagtgagccgagatagcggcactgcactccagcctggg  
tgacaaagtgagactccatctcaaaaaaaaaaaaaaaaaaattgtgagaaacagaaatact  
taaaatgaggaataagaatggagatgttacatctggtagatgtaacattctaccagatta  
tggtatggactgatctgaaaatcaacctcaactcaaggggtggtcagctcaatgctacacag  
agcacggacttttggattctttgcagtactttgaattttatttttctacctatatatgttt  
tatatgctgctggtgctccattaaagtttactctgtgttgactatatgtgttcatgat  
aaaaaa

Fig. 29a

IL-10-R- $\beta$  T1 (SEQ ID NO: 37)

MAWSLGSWLGGCLLVSALGMVPPPENVRMNSVNFKNILQWESPAFAKGNLTFTAQYLSYR  
IFQDKCMNTTLTECDFSSLSKYGDHTLRVRAEFADEHSDWVNITFCPVDDTIIGPPGMQV  
EVLADSLHMRFLAPKIENEYETWTMKNVYNSWTYNVQYWKNGTDEKFQITPQYDFEVLRN  
LEPWTTCVQVRGFLPDRNKAGEWSEPVCEQTTTHDVFGPSSS

Fig. 29b

33/39

Interleukin-10 receptor  $\beta$  chain




Fig. 30

t48767\_p2(t1).pfs

34/39

Sequence name: /dir/tp/CGC/DATA/analysis\_db/sw.fasta:I10S\_HUMAN

Sequence documentation:

Interleukin-10 receptor beta chain precursor (IL-10R-B) (IL-10R2)  
(Cytokine receptor class-II CRF2-4). Homo sapiens (Human). Q08334;

Alignment of: T48767\_P2 x I10S\_HUMAN ..

```
      1 MAWSLGSWLGGCLLVSA LGMVPPPENVRMNSVNFKNILQWESPAFAKGNL 50
      |||
      1 MAWSLGSWLGGCLLVSA LGMVPPPENVRMNSVNFKNILQWESPAFAKGNL 50

    51 TFTAQYLSYRIFQDKCMNTTLTECDFSSLSKYGDHTLRVRAEFADEHSDW 100
      |||
    51 TFTAQYLSYRIFQDKCMNTTLTECDFSSLSKYGDHTLRVRAEFADEHSDW 100

   101 VNITFCPVDDTIIGPPGMQVEVLADSLHMRFLAPKIENEYETWTMKNVYN 150
      |||
   101 VNITFCPVDDTIIGPPGMQVEVLADSLHMRFLAPKIENEYETWTMKNVYN 150

   151 SWTYNVQYWKNGTDEKFQITPQYDFEVLRLNLEPWTTYCVQVRGFLPDRNK 200
      |||
   151 SWTYNVQYWKNGTDEKFQITPQYDFEVLRLNLEPWTTYCVQVRGFLPDRNK 200

   201 AGEWSEPVC EQTTHDVF GPSSS 222
      |||
   201 AGEWSEPVC EQTTHD..... 215
```

Fig. 31

35/39

# IL10-R-β-chain structure

W.T	SP	Fibronectin type III	Fibronectin type III	TM	Cytoplasmic
	1-19	21-98	112-202	221-242	243-325

Fig. 32

SV	SP	Fibronectin type III	Fibronectin type III	7 a.a	
	1-19	21-98	112-202		

36/39

**INR1 T11 (SEQ ID NO: 43)**

agaagaggcggcgcgtagagggggcggtgagagctaagaggggcagcgcggtgtgcag  
 agggggcggtgtgacttaggacggggcgatggcggtgagaggagctgcgcgtgcgcgaac  
 atgtaactggtgggatctgcggcggtctccagatgATGgtcgtcctcctgggcgcgacga  
 ccctagtgtcgtcgccgtggcgccatgggtgtgtccgcagccgcaggtggaaaaaatc  
 taaaatctcctcaaaaagtagaggtcgacatcatagatgacaactttatcctgaggtgga  
 acaggagcgatgagtctgtcgggaatgtgactttttcattcgattatcaaaaaactggga  
 tggataattggataaaaattgtctgggtgtcagaatattactagtaccaaagtgaactttt  
 cttcactcaagctgaatgtttatgaagaaattaaattgcggtataagagcagaaaaagaaa  
 acactttctcatggtatgaggttgactcatttacaccatttcgcaaagctcagattgggtc  
 ctccagaagtacatttagaagctgaagataaggcaatagtgtatacacatctctcctggaa  
 caaaagatagtgttatgtgggctttggatgggtttaagctttacatatagcttagttatct  
 ggaaaaactcttcaggtgtagaagaaaggattgaaaatatatttccagacataaaaattt  
 ataaactctcaccagagactacttattgtctaaaagttaaagcagcactacttacgtcat  
 ggaaaaattgggtgtctatagtccagtagattgtataaagaccacagttgaaaaatgaactac  
 ctccaccagaaaaatatagaagtcagtggtccaaaatcagaactatgttcttaaatgggatt  
 atacatatgcaaacatgacctttcaagttcagtggtccacgcctttttaaaaaggaatc  
 ctggaaaccatttgtataaatggaaacaaatacctgactgtgaaaatgtcaaaactacc  
 agtgtgtctttcctcaaaacgttttccaaaaaggaatttaccttctccgcgtacaagcat  
 ctgatggaaataacacatctttttgggtctgaagagataaagtttgatactgaaatacaag  
 ctttctacttctccagtccttaacatttagatcccttagtgattcattccatatctata  
 tcgggtgtccaaaacagtcctggaaacacgcctgtgatccaggattatccactgatttatg  
 aaattattttttgggaaaaacacttcaaattgctgagagaaaaattatcgagaaaaaaactg  
 atgttacagttcctaatttgaaccactgactgtatatattgtgtgaaagccagagcacaca  
 ccatggatgaaaagctgaataaaaagcagtggttttttagtgacgctgtatgtgagaaaaaca  
 aaccaggtcagaatcttttattgtcttttttaaaaatgTAGctagacataataaaagtaa  
 ttctatactgta


**Fig. 33a****INR1 T11 (SEQ ID NO: 41)**

MVLLGATTLVLVAVAPWVLSAAAGGKNLKPQKVEVDIIDDNFILRWNRSDSVGNVTF  
 SFDYQKTGMNDWIKLSGCQNITSTKCNFSSLKLNVEEIKLRIRAEKENTSSWYEVDST  
 PFRKAQIGPPEVHLEADKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERIE  
 NIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQN  
 QNYVLKWDYTYANMTFQVQWLHAFKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQKG  
 IYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTPV  
 IQDYPLIYEIIFWENTSNAERKIIIEKKTDTVPNLKPLTVYCVKARAHTMDEKLNKSSVF  
 SDAVCEKTKPGQNLLLSFLKM

**Fig. 33b**



37/39



**Fig. 34**

38/39

t07758\_p5(t11).pfs

Sequence name: /dir/tp/CGC/DATA/analysis\_db/sw.fasta:INR1\_HUMAN

Sequence documentation:

Interferon-alpha/beta receptor alpha chain precursor (IFN-alpha-REC).  
Homo sapiens (Human). P17181;

Alignment of: T07758\_P5 x INR1\_HUMAN ..

```

      1 MVVLLGATTTLVLVAVAPWVLSAAAGGKNLKSPOKVEVDIIDDNFILRW 48
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
      2 MVVLLGATTTLVLVAVGPWVLSAAAGGKNLKSPOKVEVDIIDDNFILRW 49

      49 NRSDES VGNTFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVEE 98
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
      50 NRSDES VGNTFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVEE 99

      99 IKLRIRAEKENTSSWYEVDSTPFRKAQIGPPEVHLEAEDKAIVIHISPG 148
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
     100 IKLRIRAEKENTSSWYEVDSTPFRKAQIGPPEVHLEAEDKAIVIHISPG 149

     149 TKDSVMWALDGLSFTYSLVIWKNSSGVEERIENIYSRHKIYKLSPETTY 197
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
     150 TKDSVMWALDGLSFTYSLLIWKNSSGVEERIENIYSRHKIYKLSPETTY 198

     198 CLKVKAALLTSWKIGVYSPVHCKITTVENELPPPENIEVSVQNQNYVLKW 247
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
     199 CLKVKAALLTSWKIGVYSPVHCKITTVENELPPPENIEVSVQNQNYVLKW 248

     248 DYTANMTFQVQWLHAFKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVF 297
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
     249 DYTANMTFQVQWLHAFKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVF 298

     298 QKGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHI 347
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
     299 QKGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHI 348

     348 YIGAPKQSGNTPVIQDYPLIYEIIFWENTSNAERKIIKKTDVTVPNLKP 397
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
     349 YIGAPKQSGNTPVIQDYPLIYEIIFWENTSNAERKIIKKTDVTVPNLKP 398

     398 LTVYCVKARAHTMDEKLNKSSVFS DAVCEKTKPGQNLLLSFLKM 441
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
     399 LTVYCVKARAHTMDEKLNKSSVFS DAVCEKTKPG..... 432

```

Fig. 35

INR1 structure

W.T	SP		FN III-like	FN III-like	FN III-like	FN III-like	FN III-like	TM	Cytoplasmic
	1-27	30-127	129-230	230-330	334-427	437-457	458-557		
T11	SP		FN III-like	FN III-like	FN III-like	FN III-like	FN III-like	10 a.a	
	1-27	30-127	129-230	230-330	334-427				

Fig. 36

1  
SEQUENCE LISTING

<110> Ayalon, Michal  
 Pollock, Sarah  
 Diber, Alex  
 Levine, Zurit  
 Nemzer, Sergey  
 Dahary, Dvir  
 Sorek, Rotem  
 Levanon, Erez  
 Rotman, Galit  
 Savitsky, Kineret  
 Chermesh, Chen  
 Mintz, Liat  
 Freilich, Shiri  
 Beck, Nili  
 Zhu, Wei-Yong  
 Wasserman, Alon  
 Azar, Idit  
 Bernstein, Jeanne

<120> NOVEL POLYNUCLEOTIDES ENCODING SOLUBLE POLYPEPTIDES AND METHODS USING  
 SAME

<130> 27253

<160> 43

<170> PatentIn version 3.2

<210> 1

<211> 934

<212> PRT

<213> Homo sapiens

<400> 1

Met Lys Ala Pro Ala Val Leu Ala Pro Gly Ile Leu Val Leu Leu Phe  
 1 5 10 15

Thr Leu Val Gln Arg Ser Asn Gly Glu Cys Lys Glu Ala Leu Ala Lys  
 20 25 30

Ser Glu Met Asn Val Asn Met Lys Tyr Gln Leu Pro Asn Phe Thr Ala  
 35 40 45

Glu Thr Pro Ile Gln Asn Val Ile Leu His Glu His His Ile Phe Leu  
 50 55 60

Gly Ala Thr Asn Tyr Ile Tyr Val Leu Asn Glu Glu Asp Leu Gln Lys  
 65 70 75 80

Val Ala Glu Tyr Lys Thr Gly Pro Val Leu Glu His Pro Asp Cys Phe  
 85 90 95

Pro Cys Gln Asp Cys Ser Ser Lys Ala Asn Leu Ser Gly Gly Val Trp  
 100 105 110

Lys Asp Asn Ile Asn Met Ala Leu Val Val Asp Thr Tyr Tyr Asp Asp  
 115 120 125

Gln Leu Ile Ser Cys Gly Ser Val Asn Arg Gly Thr Cys Gln Arg His  
 130 135 140

Val Phe Pro His Asn His Thr Ala Asp Ile Gln Ser Glu Val His Cys  
 145 150 155 160

Ile Phe Ser Pro Gln Ile Glu Glu Pro Ser Gln Cys Pro Asp Cys Val  
 165 170 175

Val Ser Ala Leu Gly Ala Lys Val Leu Ser Ser Val Lys Asp Arg Phe  
 180 185 190

Ile Asn Phe Phe Val Gly Asn Thr Ile Asn Ser Ser Tyr Phe Pro Asp  
 195 200 205

His Pro Leu His Ser Ile Ser Val Arg Arg Leu Lys Glu Thr Lys Asp  
 210 215 220

Gly Phe Met Phe Leu Thr Asp Gln Ser Tyr Ile Asp Val Leu Pro Glu  
 225 230 235 240

Phe Arg Asp Ser Tyr Pro Ile Lys Tyr Val His Ala Phe Glu Ser Asn  
 245 250 255

Asn Phe Ile Tyr Phe Leu Thr Val Gln Arg Glu Thr Leu Asp Ala Gln  
 260 265 270

Thr Phe His Thr Arg Ile Ile Arg Phe Cys Ser Ile Asn Ser Gly Leu  
 275 280 285

His Ser Tyr Met Glu Met Pro Leu Glu Cys Ile Leu Thr Glu Lys Arg  
 290 295 300

Lys Lys Arg Ser Thr Lys Lys Glu Val Phe Asn Ile Leu Gln Ala Ala  
 305 310 315 320

Tyr Val Ser Lys Pro Gly Ala Gln Leu Ala Arg Gln Ile Gly Ala Ser  
 325 330 335

Leu Asn Asp Asp Ile Leu Phe Gly Val Phe Ala Gln Ser Lys Pro Asp  
 340 345 350

Ser Ala Glu Pro Met Asp Arg Ser Ala Met Cys Ala Phe Pro Ile Lys  
 355 360 365

Tyr Val Asn Asp Phe Phe Asn Lys Ile Val Asn Lys Asn Asn Val Arg  
 370 375 380

Cys Leu Gln His Phe Tyr Gly Pro Asn His Glu His Cys Phe Asn Arg

	385				390					395						400
Thr	Leu	Leu	Arg	Asn 405	Ser	Ser	Gly	Cys	Glu 410	Ala	Arg	Arg	Asp	Glu 415	Tyr	
Arg	Thr	Glu	Phe 420	Thr	Thr	Ala	Leu	Gln 425	Arg	Val	Asp	Leu	Phe 430	Met	Gly	
Gln	Phe	Ser 435	Glu	Val	Leu	Leu	Thr 440	Ser	Ile	Ser	Thr	Phe 445	Ile	Lys	Gly	
Asp	Leu 450	Thr	Ile	Ala	Asn 455	Leu	Gly	Thr	Ser	Glu	Gly 460	Arg	Phe	Met	Gln	
Val	Val	Val	Ser	Arg	Ser 470	Gly	Pro	Ser	Thr	Pro 475	His	Val	Asn	Phe	Leu 480	
Leu	Asp	Ser	His 485	Pro	Val	Ser	Pro	Glu	Val 490	Ile	Val	Glu	His	Thr 495	Leu	
Asn	Gln	Asn	Gly 500	Tyr	Thr	Leu	Val	Ile 505	Thr	Gly	Lys	Lys	Ile 510	Thr	Lys	
Ile	Pro	Leu 515	Asn	Gly	Leu	Gly	Cys 520	Arg	His	Phe	Gln	Ser 525	Cys	Ser	Gln	
Cys	Leu 530	Ser	Ala	Pro	Pro	Phe 535	Val	Gln	Cys	Gly	Trp 540	Cys	His	Asp	Lys	
Cys	Val	Arg	Ser	Glu 550	Glu	Cys	Leu	Ser	Gly	Thr 555	Trp	Thr	Gln	Gln	Ile 560	
Cys	Leu	Pro	Ala 565	Ile	Tyr	Lys	Val	Phe 570	Pro	Asn	Ser	Ala	Pro	Leu 575	Glu	
Gly	Gly	Thr 580	Arg	Leu	Thr	Ile	Cys	Gly 585	Trp	Asp	Phe	Gly	Phe 590	Arg	Arg	
Asn	Asn	Lys 595	Phe	Asp	Leu	Lys	Lys 600	Thr	Arg	Val	Leu	Leu 605	Gly	Asn	Glu	
Ser	Cys 610	Thr	Leu	Thr	Leu	Ser 615	Glu	Ser	Thr	Met	Asn 620	Thr	Leu	Lys	Cys	
Thr	Val	Gly 625	Pro	Ala 630	Met	Asn	Lys	His	Phe 635	Asn	Met	Ser	Ile	Ile	Ile 640	
Ser	Asn	Gly 645	His	Gly	Thr	Thr	Gln	Tyr	Ser 650	Thr	Phe	Ser	Tyr 655	Val	Asp	

4

Pro Val Ile Thr Ser Ile Ser Pro Lys Tyr Gly Pro Met Ala Gly Gly  
660 665 670

Thr Leu Leu Thr Leu Thr Gly Asn Tyr Leu Asn Ser Gly Asn Ser Arg  
675 680 685

His Ile Ser Ile Gly Gly Lys Thr Cys Thr Leu Lys Ser Val Ser Asn  
690 695 700

Ser Ile Leu Glu Cys Tyr Thr Pro Ala Gln Thr Ile Ser Thr Glu Phe  
705 710 715 720

Ala Val Lys Leu Lys Ile Asp Leu Ala Asn Arg Glu Thr Ser Ile Phe  
725 730 735

Ser Tyr Arg Glu Asp Pro Ile Val Tyr Glu Ile His Pro Thr Lys Ser  
740 745 750

Phe Ile Ser Gly Gly Ser Thr Ile Thr Gly Val Gly Lys Asn Leu Asn  
755 760 765

Ser Val Ser Val Pro Arg Met Val Ile Asn Val His Glu Ala Gly Arg  
770 775 780

Asn Phe Thr Val Ala Cys Gln His Arg Ser Asn Ser Glu Ile Ile Cys  
785 790 795 800

Cys Thr Thr Pro Ser Leu Gln Gln Leu Asn Leu Gln Leu Pro Leu Lys  
805 810 815

Thr Lys Ala Phe Phe Met Leu Asp Gly Ile Leu Ser Lys Tyr Phe Asp  
820 825 830

Leu Ile Tyr Val His Asn Pro Val Phe Lys Pro Phe Glu Lys Pro Val  
835 840 845

Met Ile Ser Met Gly Asn Glu Asn Val Leu Glu Ile Lys Gly Asn Asp  
850 855 860

Ile Asp Pro Glu Ala Val Lys Gly Glu Val Leu Lys Val Gly Asn Lys  
865 870 875 880

Ser Cys Glu Asn Ile His Leu His Ser Glu Ala Val Leu Cys Thr Val  
885 890 895

Pro Asn Asp Leu Leu Lys Leu Asn Ser Glu Leu Asn Ile Glu Val Gly  
900 905 910

Phe Leu His Ser Ser His Asp Val Asn Lys Glu Ala Ser Val Ile Met  
915 920 925

Leu Phe Ser Gly Leu Lys  
930

<210> 2  
<211> 24  
<212> PRT  
<213> Homo sapiens

<400> 2

Val Gly Phe Leu His Ser Ser His Asp Val Asn Lys Glu Ala Ser Val  
1 5 10 15

Ile Met Leu Phe Ser Gly Leu Lys  
20

<210> 3  
<211> 3042  
<212> DNA  
<213> Homo sapiens

<400> 3  
gaattccgcc ctcgccgccc gcggcgcccc gagcgctttg tgagcagatg cggagccgag 60  
tggagggcgc gagccagatg cggggcgaca gctgacttgc tgagaggagg cggggaggcg 120  
cggagcgcgc gtgtggtcct tgcgcgctg acttctccac tggttcctgg gcaccgaaag 180  
ataaacctct cataatgaag gccccgctg tgcttgacc tggcatctc gtgctcctgt 240  
ttaccttggg gcagaggagc aatggggagt gtaaaggagg actagcaaag tccgagatga 300  
atgtgaatat gaagtatcag cttcccaact tcaccgcgga aacacccatc cagaatgtca 360  
ttctacatga gcatcacatt ttccttgggt ccactaacta catttatgtt ttaaagagg 420  
aagaccttca gaaggttgc gagtacaaga ctgggcctgt gctggaacac ccagattgtt 480  
tcccatgtca ggactgcagc agcaaagcca atttatcagg aggtgtttgg aaagataaca 540  
tcaacatggc totagtgtgc gacacctact atgatgatca actcattagc tgtggcagcg 600  
tcaacagagg gacctgccag cgacatgtct tccccacaa tcatactgct gacatacagt 660  
cggagggttca ctgcatattc tccccacaga tagaagagcc cagccagtgt cctgactgtg 720  
tggtgagcgc cctgggagcc aaagtccttt catctgtaa ggaccggttc atcaacttct 780  
ttgtaggcaa taccataaat ttttcttatt tcccagatca tccattgcat tcgatatcag 840  
tgagaaggct aaaggaaacg aaagatggtt ttatgttttt gacggaccag tctacattg 900  
atgttttacc tgagttcaga gattcttacc ccattaagta tgtccatgcc tttgaaagca 960  
acaattttat ttacttcttg acggtccaaa gggaaactct agatgctcag acttttcaca 1020  
caagaataat caggttctgt tccataaact ctggattgca ttcctacatg gaaatgcctc 1080  
tggagtgtat tctcacagaa aagagaaaaa agagatccac aaagaaggaa gtgtttaata 1140  
tacttcaggc tgcgtatgtc agcaagcctg gggcccagct tgctagacaa ataggagcca 1200  
gcctgaatga tgacattctt ttcggggtgt tcgcacaaag caagccagat tctgccgaac 1260



caatggatcg atctgccatg tgtgcattcc ctatcaaata tgtcaacgac ttcttcaaca 1320  
 agatcgtaa caaaaacaat gtgagatgtc tccagcattt ttacggaccc aatcatgagc 1380  
 actgctttaa taggacactt ctgagaaatt catcaggctg tgaagcgcg cgtgatgaat 1440  
 atcgaacaga gtttaccaca gctttgcagc gcgttgactt attcatgggt caattcagcg 1500  
 aagtctctt aacatctata tccaccttca ttaaaggaga cctcaccata gctaactttg 1560  
 ggacatcaga gggtcgcttc atgcagggtt tggtttctcg atcaggacca tcaaccctc 1620  
 atgtgaattt tctcctggac tcccatccag tgtctccaga agtgattgtg gagcatacat 1680  
 taaacaaaaa tggctacaca ctggttatca ctgggaagaa gatcacgaag atcccatgga 1740  
 atggcttggg ctgcagacat ttccagtcct gcagtcaatg cctctctgcc ccaccctttg 1800  
 ttcagtgtgg ctggtgccac gacaaatgtg tgcgatcgga ggaatgcctg agcgggacat 1860  
 ggactcaaca gatctgtctg cctgcaatct acaaggtttt cccaaatagt gcaccctttg 1920  
 aaggagggac aaggctgacc atatgtggct gggactttgg atttcggagg aataataaat 1980  
 ttgatttaaa gaaaactaga gttctccttg gaaatgagag ctgcaccttg actttaagt 2040  
 agagcacgat gaatacattg aaatgcacag ttggtcctgc catgaataag catttcaata 2100  
 tgtccataat tatttcaaat ggccacggga caacacaata cagtacattc tcctatgtgg 2160  
 atcctgtaat aacaagtatt tcgccgaaat acggtcctat ggctggtggc actttactta 2220  
 ctttaactgg aaattaccta aacagtggga attctagaca catttcaatt ggtggaaaaa 2280  
 catgtacttt aaaaagtgtg tcaaacagta ttcttgaatg ttatacccca gcccaaacca 2340  
 tttcaactga gtttgcgtgt aaattgaaaa ttgacttagc caaccgagag acaagcatct 2400  
 tcagttaccg tgaagatccc attgtctatg aaattcatcc aaccaaactt tttattagt 2460  
 gtgggagcac aataacaggt gttgggaaaa acctgaattc agttagtgtc ccgagaatgg 2520  
 tcataaatgt gcatgaagca ggaaggaaact ttacagtggc atgtcaacat cgctctaatt 2580  
 cagagataat ctggtgtacc actccttccc tgcaacagct gaatctgcaa ctccccctga 2640  
 aaaccaaagc ctttttcatg ttagatggga tcctttccaa atactttgat ctcatttatg 2700  
 tacataatcc tgtgtttaag ccttttgaaa agccagtgat gatctcaatg ggcaatgaaa 2760  
 atgtactgga aattaaggga aatgatattg acctgaagc agttaaagggt gaagtgttaa 2820  
 aagttgaaa taagagctgt gagaatatac acttacattc tgaagccgtt ttatgcacgg 2880  
 tccccaatga cctgctgaaa ttgaacagcg agctaaatat agaggtggga ttcctgcatt 2940  
 cctctcatga tgtaataaag gaagccagtg taattatgtt attctcaggc ttaaaataaa 3000  
 tcattaaagc tcatttatgt gtgggttttg gctcatcaac tc 3042

<210> 4  
 <211> 118  
 <212> DNA  
 <213> Homo sapiens

7

<400> 4  
 gtgggattcc tgcattcctc tcatgatgta aataaggaag ccagtgtaat tatgttattc 60  
 tcaggcttaa aataaatcat taaagctcat ttatgtgtgg gttttggctc atcaactc 118

<210> 5  
 <211> 198  
 <212> PRT  
 <213> Homo sapiens

<400> 5

Met Asn Ser Phe Ser Thr Ser Ala Phe Gly Pro Val Ala Phe Ser Leu  
 1 5 10 15

Gly Leu Leu Leu Val Leu Pro Ala Ala Phe Pro Ala Pro Val Pro Pro  
 20 25 30

Gly Glu Asp Ser Lys Asp Val Ala Ala Pro His Arg Gln Pro Leu Thr  
 35 40 45

Ser Ser Glu Arg Ile Asp Lys Gln Ile Arg Tyr Ile Leu Asp Gly Ile  
 50 55 60

Ser Ala Leu Arg Lys Glu Thr Cys Asn Lys Ser Asn Met Cys Glu Ser  
 65 70 75 80

Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu Asn Leu Pro Lys Met Ala  
 85 90 95

Glu Lys Asp Gly Cys Phe Gln Ser Gly Phe Asn Glu Glu Thr Cys Leu  
 100 105 110

Val Lys Ile Ile Thr Gly Leu Leu Glu Phe Glu Val Tyr Leu Glu Tyr  
 115 120 125

Leu Gln Asn Arg Phe Glu Ser Ser Glu Glu Gln Ala Arg Ala Val Gln  
 130 135 140

Met Ser Thr Lys Val Leu Ile Gln Phe Leu Gln Lys Lys Val Gly Val  
 145 150 155 160

Ser Ser Phe Pro Gln Leu Gly Val Gly Glu Asp Arg Leu Lys Asp Ser  
 165 170 175

Val Leu Asp Asn Ser Gly Met Gln Cys His Phe Gln Lys Arg Arg Leu  
 180 185 190

His Val Asn Lys Arg Val  
 195

<210> 6  
 <211> 41

8

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

Val Gly Val Ser Ser Phe Pro Gln Leu Gly Val Gly Glu Asp Arg Leu  
 1 5 10 15

Lys Asp Ser Val Leu Asp Asn Ser Gly Met Gln Cys His Phe Gln Lys  
 20 25 30

Arg Arg Leu His Val Asn Lys Arg Val  
 35 40

&lt;210&gt; 7

&lt;211&gt; 1126

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

ccatgtttgg taaataagtg ttttgggtgt gtgcaagggt ctggtttcag cctgaagcca 60  
 tctcagagct gtctgggtct ctggagactg gagggacaac ctagtctaga gccatttgc 120  
 atgagaccaa ggatcctcct gcaagagaca ccatcctgag ggaagagggc ttctgaacca 180  
 gcttgaccca ataagaaatt cttgggtgcc gacgcggaag cagattcaga gcctagagcc 240  
 gtgcctgcgt ccgtagtttc cttctagctt cttttgattt caaatcaaga cttacaggga 300  
 gagggagcga taaacacaaa ctctgcaaga tgccacaagg tctcctttg acatccccaa 360  
 caaagaggac tggagatgtc tgaggctcat tctgccctcg agcccaccgg gaacgaaaga 420  
 gaagctctat cttccctcca ggagcccagc tatgaactcc ttctccacaa gcgccttcgg 480  
 tccagttgcc ttctccctgg ggctgctcct ggtgttgctt gctgccttcc ctgccccagt 540  
 acccccagga gaagattcca aagatgtagc cgccccacac agacagccac tcacctcttc 600  
 agaacgaatt gacaaacaaa ttcggtacat cctcgacggc atctcagccc tgagaaagga 660  
 gacatgtaac aagagtaaca tgtgtgaaag cagcaaagag gcaactggcag aaaacaacct 720  
 gaaccttcca aagatggctg aaaaagatgg atgcttccaa tctggattca atgaggagac 780  
 ttgcctggtg aaaatcatca ctggtctttt ggagtttgag gtatacctag agtacctcca 840  
 gaacagattt gagagtagtg aggaacaagc cagagctgtg cagatgagta caaaagtcct 900  
 gatccagttc ctgcagaaaa aggtgggtgt gtcctcattc cctcaacttg gtgtggggga 960  
 agacaggctc aaagacagtg tcctggacaa ctcagggatg caatgccact tccaaaagag 1020  
 aaggctacac gtaaacaata gagtctgaga aatagtttct gattgttatt gttaaatctt 1080  
 tttttgtttg tttggttggg tggtctctct ctgcaaagga catcaa 1126

&lt;210&gt; 8

&lt;211&gt; 185

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

9

<400> 8  
 tgggtgtgtc ctcattccct caacttggtg tgggggaaga caggctcaaa gacagtgtcc 60  
 tggacaactc agggatgcaa tgccacttcc aaaagagaag gctacacgta aacaaaagag 120  
 tctgagaaat agtttctgat tgttattggt aaatcttttt ttgtttgttt ggttggttgg 180  
 ctctc 185

<210> 9  
 <211> 167  
 <212> PRT  
 <213> Homo sapiens

<400> 9

Met Phe His Val Ser Phe Arg Tyr Ile Phe Gly Leu Pro Pro Leu Ile  
 1 5 10 15

Leu Val Leu Leu Pro Val Ala Ser Ser Asp Cys Asp Ile Glu Gly Lys  
 20 25 30

Asp Gly Lys Gln Tyr Glu Ser Val Leu Met Val Ser Ile Asp Gln Leu  
 35 40 45

Leu Asp Ser Met Lys Glu Ile Gly Ser Asn Cys Leu Asn Asn Glu Phe  
 50 55 60

Asn Phe Phe Lys Arg His Ile Cys Asp Ala Asn Lys Glu Gly Met Phe  
 65 70 75 80

Leu Phe Arg Ala Ala Arg Lys Leu Arg Gln Phe Leu Lys Met Asn Ser  
 85 90 95

Thr Gly Asp Phe Asp Leu His Leu Leu Lys Val Ser Glu Gly Thr Thr  
 100 105 110

Ile Leu Leu Asn Cys Thr Gly Gln Val Lys Gly Arg Lys Pro Ala Ala  
 115 120 125

Leu Gly Glu Ala Gln Pro Thr Lys Ser Leu Ser Ser Gly Leu Gln Lys  
 130 135 140

Gln Phe Thr Phe Tyr Arg Ser Asn Gly Arg His Thr His Ser Phe His  
 145 150 155 160

Cys Lys Leu Ser Phe Leu His  
 165

<210> 10  
 <211> 29  
 <212> PRT  
 <213> Homo sapiens

<400> 10

10

Ser Ser Gly Leu Gln Lys Gln Phe Thr Phe Tyr Arg Ser Asn Gly Arg  
 1 5 10 15

His Thr His Ser Phe His Cys Lys Leu Ser Phe Leu His  
 20 25

<210> 11  
 <211> 1789  
 <212> DNA  
 <213> Homo sapiens

<400> 11  
 aagacgaata gtttgattta ttagccaatt cagataaatg tgcacgtgga agtcatagtt 60  
 aaatattatc gtcagtttcc acgtcctgcg ttttaatttg ggtttgattt tccaaataca 120  
 acacttacca gattaggtgg acccacagga ttatTTTTcc ttgaggctc acctgagcag 180  
 gtgcatgtac agcagacgga gcagaaagag actgattaga gaggttgag tggtagagg 240  
 cgtgaccctc ttaatcatc ttcacttct tttttaaaag acgacttggc atcgtccacc 300  
 acatccgcgg caacgcctcc ttggtgtcgt ccgcttccaa taaccagct tgcgtcctgc 360  
 acacttggtg cttccgtgca cacattaaca actcatggtt ctagctcca gtcgccaagc 420  
 gtgccaagg cgttgagaga tcatctggga agtcttttac ccagaattgc ttgattcag 480  
 gccagctggt ttttctgcg gtgattcgga aattcgcgaa ttcctctggt cctcatccag 540  
 gtgcgcggga agcaggtgcc caggagagag gggataatga agattccatg ctgatgatcc 600  
 caaagattga acctgcagac caagcgcaaa gtagaaactg aaagtacact gctggcggat 660  
 cctacggaag ttatggaaaa ggcaaagcgc agagccacgc cgtagtgtgt gccgcccccc 720  
 ttgggatgga tgaaactgca gtcgcggcgt gggtagagg aaccagctgc agagatcacc 780  
 ctgccaaca cagactcggc aactccgagg aagaccaggg tcctgggagt gactatgggc 840  
 ggtgagagct tgctcctgct ccagttgagg tcatcatgac tacgcccgcc tcccgcagac 900  
 catgttccat gtttctttta ggtatatctt tggacttct cccctgatcc ttgttctgtt 960  
 gccagtagca tcatctgatt gtgatattga aggtaaagat ggcaaacaat atgagagtgt 1020  
 tctaattggtc agcatcgatc aattattgga cagcatgaaa gaaattggtg gcaattgcct 1080  
 gaataatgaa ttttaactttt ttaaaagaca tatctgtgat gctaataagg aaggatgtt 1140  
 tttattccgt gctgctcgca agttgaggca atttcttaaa atgaatagca ctggtgattt 1200  
 tgatctccac ttattaaaag tttcagaagg cacaacaata ctgttgaaact gcaactggcca 1260  
 ggtaaagga agaaaaccag ctgccctggg tgaagcccaa ccaacaaaga gtttgcctc 1320  
 aggactacag aagcagttca catTTTtacag atcaaacgga cgacacacac attctttcca 1380  
 ctgcaaattg tcctttctcc actagaaggt atcagtttct ccaataaat tgtatcaact 1440  
 tgagggcaga cacttaatta catcttatta tctcgatccc catcattgca tatccagaaa 1500  
 gagcacataa agcgTTTTc aatgcttatt ttagttgatg gactatttgt ttctttgttt 1560

11

tgaccaataa gactgaataa agataactga ggggaaaaaa attaacaact aatcaggaaa 1620  
 taaacttttt tcggatttat gaaataattt gttgacatgc tctacaggag tgaccttaac 1680  
 atacctaag gtaactaaaa ctgttctctt taattacaaa attcccagca tctatcctac 1740  
 tatgatacta tctgaagata ggcaccaata atacaaatgt ttatccaaa 1789

<210> 12  
 <211> 474  
 <212> DNA  
 <213> Homo sapiens

<400> 12  
 tcctcaggac tacagaagca gttcacattt tacagatcaa acggacgaca cacacattct 60  
 ttccactgca aattgtcctt tctccactag aaggatcag tttctccaaa taaattgtat 120  
 caacttgagg gcagacactt aattacatct tattatctcg atcccatca ttgcatatcc 180  
 agaaagagca cataaagcgt ttttcaatgc ttattttagt tgatggacta tttgtttctt 240  
 tgttttgacc aataagactg aataaagata actgagggga aaaaaattaa caactaatca 300  
 ggaaataaac ttttttcgga tttatgaaat aatttgttga catgctctac aggagtgcac 360  
 ttaacatacc taatggtaac taaaactggt ctctttaatt acaaaattcc cagcatctat 420  
 cctactatga tactatctga agataggcac caataatata aatgtttatc caaa 474

<210> 13  
 <211> 157  
 <212> PRT  
 <213> Homo sapiens

<400> 13

Met Phe His Val Ser Phe Arg Tyr Ile Phe Gly Leu Pro Pro Leu Ile  
 1 5 10 15

Leu Val Leu Leu Pro Val Ala Ser Ser Asp Cys Asp Ile Glu Gly Lys  
 20 25 30

Asp Gly Lys Gln Tyr Glu Ser Val Leu Met Val Ser Ile Asp Gln Leu  
 35 40 45

Leu Asp Ser Met Lys Glu Ile Gly Ser Asn Cys Leu Asn Asn Glu Phe  
 50 55 60

Asn Phe Phe Lys Arg His Ile Cys Asp Ala Asn Lys Glu Gly Met Phe  
 65 70 75 80

Leu Phe Arg Ala Ala Arg Lys Leu Arg Gln Phe Leu Lys Met Asn Ser  
 85 90 95

Thr Gly Asp Phe Asp Leu His Leu Leu Lys Val Ser Glu Gly Thr Thr  
 100 105 110

12

Ile Leu Leu Asn Cys Thr Gly Gln Val Lys Gly Arg Lys Pro Ala Ala  
 115 120 125

Leu Gly Glu Ala Gln Pro Thr Lys Ser Leu Val Glu Leu Ile Ile Pro  
 130 135 140

Ser Cys Met Pro Pro Leu Leu Ser Ser Thr Ser Asn Ser  
 145 150 155

<210> 14  
 <211> 19  
 <212> PRT  
 <213> Homo sapiens

<400> 14

Val Glu Leu Ile Ile Pro Ser Cys Met Pro Pro Leu Leu Ser Ser Thr  
 1 5 10 15

Ser Asn Ser

<210> 15  
 <211> 1541  
 <212> DNA  
 <213> Homo sapiens

<400> 15  
 aagacgaata gtttgattta ttagccaatt cagataaatg tgcacgtgga agtcatagtt 60  
 aaatattatc gtcagtttcc acgtcctgcg ttaattttgg ggtttgattt tccaaataca 120  
 acacttacca gattaggtgg acccacagga ttatttttcc ttgaggtctc acctgagcag 180  
 gtgcatgtac agcagacgga gcagaaagag actgattaga gaggttgag tggtagaggg 240  
 cgtgaccctc ttaatcattc ttcacttctt tttttaaaag acgacttggc atcgctccacc 300  
 acatccgcgg caacgcctcc ttggtgtcgt ccgcttccaa taaccagct tgcgtcctgc 360  
 acacttggtg cttccgtgca cacattaaca actcatgggt ctagctccca gtcgccaagc 420  
 gttgccaagg cgttgagaga tcatctggga agtcttttac ccagaattgc tttgattcag 480  
 gccagctggt ttttctgcg gtgattcgga aattcgcgaa ttcctctggt cctcatccag 540  
 gtgcgcggga agcaggtgcc caggagagag gggataatga agattccatg ctgatgatcc 600  
 caaagattga acctgcagac caagcgcaa gtagaaactg aaagtacact gctggcggat 660  
 cctacggaag ttatggaaaa ggcaaagcgc agagccacgc cgtagtgtgt gccgcccccc 720  
 ttgggatgga tgaaactgca gtcgcggcgt gggtaagagg aaccagctgc agagatcacc 780  
 ctgccaaca cagactcggc aactccgcgg aagaccaggg tcctgggagt gactatgggc 840  
 ggtgagagct tgctcctgct ccagttgcgg tcatcatgac tacgcccgcc tcccgagac 900  
 catgttccat gtttctttta ggtatatctt tggacttctt cccctgatcc ttgttctgtt 960  
 gccagtagca tcatctgatt gtgatattga aggtaaagat ggcaaacaat atgagagtgt 1020

13

tctaattgggc agcatcgatc aattattgga cagcatgaaa gaaattggta gcaattgcct 1080  
gaataatgaa tttaactttt ttaaaagaca tatctgtgat gctaataagg aaggtatgtt 1140  
tttattccgt gctgctcgca agttgaggca atttcttaaa atgaatagca ctggtgattt 1200  
tgatctccac ttattaaaag tttcagaagg cacaacaata ctggtgaact gcactggcca 1260  
ggttaaagga agaaaaccag ctgccctggg tgaagcccaa ccaacaaaga gtttggtgga 1320  
actgatcatt ccttcatgta tgcctccact gtcagctca acagtaact cttataaacc 1380  
taccacctgt tatctctggg agagggacat atgtttgccca atttctatct tcaatgctta 1440  
tcacaaattt tottatattt gaaataatct gattcaaagc agaactttaa cctaaaaactt 1500  
taattggaaa gacaatctta taaaaatctt ataacatatt c 1541

<210> 16  
<211> 225  
<212> DNA  
<213> Homo sapiens

<400> 16  
tggaactgat cattccttca tgtatgcctc cactgctcag ctcaacaagt aactcttaat 60  
aacctaccac ctgttatctc tgggagaggg acatatgttt gccaatctct atcttcaatg 120  
cttatcacia attttcttat atttgaaata atctgattca aatgagaact ttaacctaaa 180  
actttaattg gaaagacaat cttataaaaa tcttataaca tattu 225

<210> 17  
<211> 153  
<212> PRT  
<213> Homo sapiens

<400> 17

Met Gly Asn Ser Cys Tyr Asn Ile Val Ala Thr Leu Leu Leu Val Leu  
1 5 10 15

Asn Phe Glu Arg Thr Arg Ser Leu Gln Asp Pro Cys Ser Asn Cys Pro  
20 25 30

Ala Gly Thr Phe Cys Asp Asn Asn Arg Asn Gln Ile Cys Ser Pro Cys  
35 40 45

Pro Pro Asn Ser Phe Ser Ser Ala Gly Gly Gln Arg Thr Cys Asp Ile  
50 55 60

Cys Arg Gln Cys Lys Gly Val Phe Arg Thr Arg Lys Glu Cys Ser Ser  
65 70 75 80

Thr Ser Asn Ala Glu Cys Asp Cys Thr Pro Gly Phe His Cys Leu Gly  
85 90 95

Ala Gly Cys Ser Met Cys Glu Gln Asp Cys Lys Gln Gly Gln Glu Leu  
100 105 110



14

Thr Lys Lys Gly Cys Lys Asp Cys Cys Phe Gly Thr Phe Asn Asp Gln  
 115 120 125

Lys Arg Gly Ile Cys Arg Pro Trp Thr Asn Ile Arg Val Ala Asp Glu  
 130 135 140

Trp Asn His Asp Ser Gln Glu Lys Tyr  
 145 150

<210> 18  
 <211> 15  
 <212> PRT  
 <213> Homo sapiens

<400> 18

Ile Arg Val Ala Asp Glu Trp Asn His Asp Ser Gln Glu Lys Tyr  
 1 5 10 15

<210> 19  
 <211> 946  
 <212> DNA  
 <213> Homo sapiens

<400> 19  
 gagaccaagg agtggaaagt tctccggcag ccctgagatc tcaagagtga catttgtgag 60  
 accagctaatt ttgattaaaa ttctcttggg atcagctttg ctagtatcat acctgtgcc 120  
 gatttcattca tgggaaacag ctgttacaac atagtagcca ctctgttgct ggtcctcaac 180  
 tttgagagga caagatcatt gcaggatcct tgtagtaact gccagctgg tacattctgt 240  
 gataataaca ggaatcagat ttgcagtcct tgctctccaa atagtttctc cagcgcagg 300  
 ggacaaaagga cctgtgacat atgcaggcag tgtaaaagg 360  
 tgctctccca ccagcaatgc agagtgtgac tgcaactccag gggttccactg cctgggggca 420  
 ggatgcagca tgtgtgaaca ggattgtaaa caaggtcaag aactgacaaa aaaagggtgt 480  
 aaagactggt gctttgggac atttaacgat cagaaacgtg gcactctgtc accctggaca 540  
 aacatcagag tggctgacga atggaatcat gattcacaag aaaagtattg actattttct 600  
 cggacttagc tgaattctgt ctttggaag tggctttttt aaaaagctgt tctttggatg 660  
 gaaagtctgt gcttgtgaat gggacgaag agagggacgt ggtctgtgga ccatctccag 720  
 ccgacctctc tccgggagca tcctctgtga cccgcctgc ccctgcgaga gagccaggac 780  
 actctccgca gatcatctcc ttctttcttg cgctgacgtc gactgcgttg ctcttctgtc 840  
 tgttcttctc cacgctcgt ttctctgttg ttaaacyggg cagaaagaaa ctctgtata 900  
 tattcaaca acgtaagatt aacataatca tattacagct ctggca 946

<210> 20  
 <211> 104  
 <212> DNA

15

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

catcagagtg gctgacgaat ggaatcatga ttcacaagaa aagtattgac tattttctcg 60

gacttagctg aattctgtct ttggaaagtg gcttttttaa aaag 104

&lt;210&gt; 21

&lt;211&gt; 131

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

Met Gly Trp Leu Cys Ser Gly Leu Leu Phe Pro Val Ser Cys Leu Val  
1 5 10 15Leu Leu Gln Val Ala Ser Ser Gly Asn Met Lys Val Leu Gln Glu Pro  
20 25 30Thr Cys Val Ser Asp Tyr Met Ser Ile Ser Thr Cys Glu Trp Lys Met  
35 40 45Asn Gly Pro Thr Asn Cys Ser Thr Glu Leu Arg Leu Leu Tyr Gln Leu  
50 55 60Val Phe Leu Leu Ser Glu Ala His Thr Cys Ile Pro Glu Asn Asn Gly  
65 70 75 80Gly Ala Gly Cys Val Cys His Leu Leu Met Asp Asp Val Val Ser Ala  
85 90 95Asp Asn Tyr Thr Leu Asp Leu Trp Ala Gly Gln Gln Leu Leu Trp Lys  
100 105 110Gly Ser Phe Lys Pro Ser Glu His Val Leu Pro Pro Leu Lys Arg Ser  
115 120 125Trp Ser Gln  
130

&lt;210&gt; 22

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

Leu Pro Pro Leu Lys Arg Ser Trp Ser Gln  
1 5 10

&lt;210&gt; 23

&lt;211&gt; 4848

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

16

<400> 23  
 tgcagtgcc gacagattgt actagttact gattgaagg ctgttttact atccaaatgt 60  
 ggctggagta ggagttgggt aaacatttat tgaagaatgt gcaaccactc tcaacttgga 120  
 gccgggctgt taggaagggg aggaggatc cagtcgcca gccctcccc accaaacgca 180  
 actgccccgg cgcaaaagag gccgcggagg ccaggcagga gcaggtcctg gaggcctggt 240  
 cggcgtgggc gttttattcc gagaccaagg ggatccactg cagagttctc cgctgggcgt 300  
 gacctcgggc tacggcgtgg gaggaagcgc gcggcaagac acccagcgag gtgctgggg 360  
 cgccccagg agaggacggc ggctcggact gtccggcggc ggcgggggg acagcgacag 420  
 gggcgcgagg tggccgggac ccgggcccgg cgcgccgggc gggcgggcg atgcaaactc 480  
 gccgggcgcg gggcgggga gcaggaagcc gggcggggt ggtctccgc gccaggaaa 540  
 gccccgcgcg gcgcgggcca gggaagggcc acccaggggt ccccaacttc ccgcttgggc 600  
 gccgggacgg cgaatggagc aggggcgcgc agataattaa agatttacac acagctggaa 660  
 gaaatcatag agaagccggg cgtggtggct catgcctata atcccagcac ttttgaggc 720  
 tgaggcgggc agatcacttg agatcaggag ttcgagacca gcctggtgcc ttggcatctc 780  
 ccaatggggg ggctttgctc tgggctcctg ttccctgtga gctgcctggt cctgctgcag 840  
 gtggcaagct ctgggaacat gaaggtcttg caggagccca cctgcgtctc cgactacatg 900  
 agcatctcta cttgcgagtg gaagatgaat ggtccacca attgcagcac cgagctccgc 960  
 ctgtgttacc agctggtttt tctgctctcc gaagcccaca cgtgtatccc tgagaacaac 1020  
 ggaggcgcgg ggtgcgtgtg ccacctgctc atggatgacg tggtcagtgc ggataactat 1080  
 aactggacc tgtgggctgg gcagcagctg ctgtggaagg gtccttcaa gccagcgag 1140  
 catgtcctcc caccttgaa acggagctgg tcgcagtaga ccaccaagcc cccttcagcc 1200  
 cagctgtttc caccctgaa cttaagtgc caggaaggcg tattgagatg aggtgtgctt 1260  
 gctggaaggc atgcctgctg ctgattgaaa accgaactgg gaacagtcct tccattctgt 1320  
 gtccactggt cagctgctgc ggctttggat ggtcttgacc gtggaaggct gacctcttc 1380  
 tggatcccg agtccctgca ggaatcccc ttgagcttgc tgggctgtgg tgacaggagt 1440  
 ttaaaacatg cgttgtattc cagtgatgca tgatatgaca tgcacacag gaataaaaac 1500  
 ctgaggtctc atggatatga ttgcttcaa ggagaccaag ttttaaaaca gatgaatcaa 1560  
 aataaagaaa aatactcagt aaatcatcat aaagtacaga gatgtggcca aaggtgtgaa 1620  
 ggatgcagct gtaaaagctg aagtttgagg ccgggtgtgg tggttcatgc ctataatccc 1680  
 agcactttgg gaggcggagc ccagcggatc accggaggtc aggagttcga gaccagcctg 1740  
 gacaacatgt gaaaccagg gccccaggaa acctgacagt tcacaccaat gtctccgaca 1800  
 ctctgctgct gacctggagc aaccgtatc cccctgacaa ttacctgtat aatcatctca 1860  
 cctatgcagt caacatttgg agtgaaaacg acccggcaga tttcagaatc tataacgtga 1920  
 cctacctaga accctccctc cgcacgcag ccagcacct gaagtctggg atttcctaca 1980

17

gggcacgggt gagggcctgg gctcagtgtg ataacaccac ctggagtgtg tggagcccca	2040
gcaccaagtg gcacaactcc tacagggagc ccttcgagca gcacctcctg ctgggcgtca	2100
gcgtttcctg cattgtcctc ctggccgtct gcctgttgtg ctatgtcagc atcaccaaga	2160
ttaagaaaga atggtgggat cagattccca acccagcccg cagccgcctc gtggctataa	2220
taatccagga tgctcagggg tcacagtggg agaagcggtc ccgaggccag gaaccagcca	2280
agtgccaca ctggaagaat tgtcttacca agctcttgcc ctgttttctg gagcacaaca	2340
tgaagggga tgaagatcct cacaaggctg ccaaagagat gcctttccag ggctctggaa	2400
aatcagcatg gtgcccagtg gagatcagca agacagtcct ctggccagag agcatcagcg	2460
tggtgcgatg tgtggagttg tttgaggccc cgggtggagt tgaggaggag gaggaggtag	2520
aggaagaaaa agggagcttc tgtgcatcgc ctgagagcag cagggatgac ttccaggagg	2580
gaagggaggg cattgtggcc cggctaacag agagcctgtt cctggacctg ctcgagagg	2640
agaatggggg cttttgccag caggacatgg gggagtcag ccttcttcca ccttcgggaa	2700
gtacgagtgc tcacatgccc tgggatgagt tccaagtgc agggcccaag gaggcacctc	2760
cctggggcaa ggagcagcct ctccacctgg agccaagtcc tcctgccagc ccgaccaga	2820
gtccagacaa cctgaactgc acagagacgc ccctcgtcat cgcaggcaac cctgcttacc	2880
gcagcttcag caactccctg agccagtcac cgtgtcccag agagctgggt ccagaccac	2940
tgctggccag acacctggag gaagtagaac ccgagatgcc ctgtgtcccc cagctctctg	3000
agccaaccac tgtgccccaa cctgagccag aaacctggga gcagatcctc cgcggaaatg	3060
tcctccagca tggggcagct gcagccccgc tctcgcccc caccagtggc tatcaggagt	3120
ttgtacatgc ggtggagcag ggtggcacc aggccagtgc ggtggtgggc ttgggtcccc	3180
caggagaggc tggttacaag gccttctcaa gcctgcttgc cagcagtgtg gtgtccccag	3240
agaaatgtgg gtttggggct agcagtgggg aagaggggta taagccttcc caagacctca	3300
ttcctggctg ccctggggac cctgccccag tcctgttccc cttgttcacc tttggaactg	3360
acaggagacc acctcgagct ccgagagct cacatctccc aagcagctcc ccagagcacc	3420
tgggtctgga gccgggggaa aaggtagagg acatgccaaa gccccactt cccagaggc	3480
aggccacaga ccccttgtg gacagcctgg gcagtggcat tgtctactca gccccttacc	3540
tgccacctgt gcggccacct gaaacagtgt catggccagg aggatggtgg ccagaccct	3600
gtcatggcca gtccttgctg tggtgtgtgc tgtggagaca ggtcctcgcc ccctacaacc	3660
cccctgaggg cccagacccc ctctccaggt ggggttccac tggaggccag tctgtgtccg	3720
gcctccctgg caccctcggg catctcagag aagagtaaat cctcatcatc cttccatcct	3780
gcccctggca atgtcagag ctcaagccag acccccaaaa tcgtgaactt tgtctccgtg	3840
ggaccacat acatgagggg ctcttaggtg catgtcctct tggtgctgag tctgcagatg	3900
aggactaggg cttatccatg cctgggaaat gccacctcct ggaaggcagc caggctggca	3960
gatttccaaa agacttgaag aaccatggta tgaagggtgat tggccccact gacgttggcc	4020

18

```

taacactggg ctgcagagac tggaccccgcc ccagcattgg gctgggctcg ccacatccca 4080
tgagagtaga gggcactggg tcgccgtgcc ccacggcagg cccctgcagg aaaactgagg 4140
cccttgggca cctcgacttg tgaacgagtt gttggctgct ccctccacag cttctgcage 4200
agactgtccc tgttgttaact gcccaaggca tgttttggcc accagatcat ggcccacatg 4260
gaggccccacc tgcctctgtc tcactgaact agaagccgag cctagaaact aacacagcca 4320
tcaagggaat gacttgggcg gccttgggaa atcgatgaga aattgaactt caggaggagg 4380
ggtcattgcc tagagggtgt cattcattta acagagcttc cttagggtga tgctggaggc 4440
agaatcccggt ctgtcaagggt gtgttcagtt aaggggagca acagaggaca tgaaaaattg 4500
ctgtgactaa agcaggggaca atttgctgcc aaacacccat gccagctgt atggctgggg 4560
gctcctcgta tgcattggaac cccagaata aatatgctca gccaccctgt gggccgggca 4620
atccagacag caggcataag gcaccagtta ccctgcatgt tggcccagac ctcagggtgt 4680
aggggaaggcg ggaaccttgg gttgagtaat gctcgtctgt gtgttttagt ttcattcacct 4740
gttatctgtg tttgctgagg agagtgaac agaaggggtg gagttttgta taaataaagt 4800
ttctttgtct ctttaaaaat tatgtattaa ccaaacatac ctccagac 4848

```

<210> 24  
 <211> 605  
 <212> DNA  
 <213> Homo sapiens

```

<400> 24
catgtcctcc cacctttgaa acggagctgg tcgcagtaga ccaccaagcc cccttcagcc 60
cagctgtttc caccctgaa ctttaagtgc caggaaggcg tattgagatg aggtgtgctt 120
gctggaaggc atgcctgctg ctgattgaaa accgaactgg gaacagtcct tccattctgt 180
gtccactggg cagctgctgc ggctttggat ggtcttgacc gtggaaggct gaccttcttc 240
tggatcccggt agtccctgca ggaatcccc ttgagcttgc tgggctgtgg tgacaggagt 300
ttaaacaatg cgttgtattc cagtgatgca tgatatgaca tgcatcacag gaataaaaac 360
ctgagggtctc atggatatga ttgcttcaaa ggagaccaag ttttaaaaca gatgaatcaa 420
aataaagaaa aatactcagt aaatcatcat aaagtacaga gatgtggcca aaggtgtgaa 480
ggatgcagct gtaaaagctg aagtttgagg ccgggtgtgg tggttcatgc ctataatccc 540
agcactttgg gaggccgagc ccagcggatc accggaggtc aggagttcga gaccagcctg 600
gacaa 605

```

<210> 25  
 <211> 229  
 <212> PRT  
 <213> Homo sapiens

<400> 25

Met Gly Trp Leu Cys Ser Gly Leu Leu Phe Pro Val Ser Cys Leu Val

19  
 1                      5                      10                      15  
 Leu Leu Gln Val Ala Ser Ser Gly Asn Met Lys Val Leu Gln Glu Pro  
                     20                      25                      30  
 Thr Cys Val Ser Asp Tyr Met Ser Ile Ser Thr Cys Glu Trp Lys Met  
                     35                      40                      45  
 Asn Gly Pro Thr Asn Cys Ser Thr Glu Leu Arg Leu Leu Tyr Gln Leu  
                     50                      55                      60  
 Val Phe Leu Leu Ser Glu Ala His Thr Cys Ile Pro Glu Asn Asn Gly  
                     65                      70                      75                      80  
 Gly Ala Gly Cys Val Cys His Leu Leu Met Asp Asp Val Val Ser Ala  
                     85                      90                      95  
 Asp Asn Tyr Thr Leu Asp Leu Trp Ala Gly Gln Gln Leu Leu Trp Lys  
                     100                      105                      110  
 Gly Ser Phe Lys Pro Ser Glu His Val Lys Pro Arg Ala Pro Gly Asn  
                     115                      120                      125  
 Leu Thr Val His Thr Asn Val Ser Asp Thr Leu Leu Leu Thr Trp Ser  
                     130                      135                      140  
 Asn Pro Tyr Pro Pro Asp Asn Tyr Leu Tyr Asn His Leu Thr Tyr Ala  
                     145                      150                      155                      160  
 Val Asn Ile Trp Ser Glu Asn Asp Pro Ala Asp Phe Arg Ile Tyr Asn  
                     165                      170                      175  
 Val Thr Tyr Leu Glu Pro Ser Leu Arg Ile Ala Ala Ser Thr Leu Lys  
                     180                      185                      190  
 Ser Gly Ile Ser Tyr Arg Ala Arg Val Arg Ala Trp Ala Gln Cys Tyr  
                     195                      200                      205  
 Asn Thr Thr Trp Ser Glu Trp Ser Pro Ser Thr Lys Trp His Asn Cys  
                     210                      215                      220  
 Glu Tyr Gln Glu Ala  
 225  
 <210> 26  
 <211> 6  
 <212> PRT  
 <213> Homo sapiens  
 <400> 26  
 Cys Glu Tyr Gln Glu Ala

<210> 27  
 <211> 1541  
 <212> DNA  
 <213> Homo sapiens

<400> 27  
 tgcagtgccc gacagattgt actagttact gattgaaggg ctgttttact atccaaatgt 60  
 ggctggagta ggagttgggt aaacatttat tgaagaatgt gcaaccactc tcaattggaa 120  
 gccgggctgt taggaagggg aggaggattc cagtcgcca gccctcccc accaaacgca 180  
 actgccccgg cgcaaaagag gccgcggagg ccaggcagga gcaggctctg gaggcctggt 240  
 cggcgtgggc gttttattcc gagaccaagg ggatccactg cagagttctc cgctgggcgt 300  
 gacctcgggc tacggcgtgg gaggaagcgc gcggcaagac acccagcgag gtgctgggggt 360  
 cgccccagg agaggacggc ggctcggact gtccggcggc ggcgcgggg acagcgacag 420  
 gggcgcgagg tggccgggac ccgggcccgg cgcgccgggc ggggcggcgc atgcaaactc 480  
 gccgggcgcc ggggcgggga gcaggaagcc ggggcgggct gggctctcgc gccagga 540  
 gccccgcgcg gcgcgggcca gggaagggcc acccagggt cccccacttc ccgcttgggc 600  
 gcccgacgg cgaatggagc aggggcgcgc agataattaa agatttacac acagctggaa 660  
 gaaatcatag agaagccggg cgtggtggct catgcctata atcccagcac ttttgagggc 720  
 tgaggcgggc agatcacttg agatcaggag ttcgagacca gcctggtgcc ttggcatctc 780  
 ccaatggggt ggctttgctc tgggctcctg ttccctgtga gctgcctggt cctgctgcag 840  
 gtggcaagct ctgggaacat gaaggctctg caggagccca cctgcgtctc cgactacatg 900  
 agcatctcta cttgcgagtg gaagatgaat ggtcccacca attgcagcac cgagctccgc 960  
 ctgttgtacc agctggtttt tctgctctcc gaagcccaca cgtgtatccc tgagaacaac 1020  
 ggaggcgcgg ggtgcgtgtg ccacctgctc atggatgacg tggtcagtgc ggataactat 1080  
 aactggacc tgtgggctgg gcagcagctg ctgtggaagg gctccttcaa gccagcgag 1140  
 catgtgaaac ccaggggccc aggaacctg acagttcaca ccaatgtctc cgacactctg 1200  
 ctgctgacct ggagcaacct gtatccccct gacaattacc tgtataatca tctcacctat 1260  
 gcagtcaaca tttggagtga aaacgacctg gcagatttca gaatctataa cgtgacctac 1320  
 ctagaacct ccctccgcat cgcagccagc accctgaagt ctgggatttc ctacagggca 1380  
 cgggtgaggg cctgggctca gtgctataac accacctgga gtgagtggag cccagcacc 1440  
 aagtggcaca actgtgagta tcaagaggcc taagcaatgg taatctccac tctccattct 1500  
 tccctgtgg ccagacactt cccctggctg agtctctggg c 1541

<210> 28  
 <211> 88  
 <212> DNA  
 <213> Homo sapiens

21

<400> 28  
 gtgagtatca agaggcctaa gcaatggtaa tctccactct ccattcttcc cctgtggcca 60  
 gacacttccc ctggctgagt ctctgggc 88

<210> 29  
 <211> 176  
 <212> PRT  
 <213> Homo sapiens

<400> 29

Met Gly Arg Gly Leu Leu Arg Gly Leu Trp Pro Leu His Ile Val Leu  
 1 5 10 15

Trp Thr Arg Ile Ala Ser Thr Ile Pro Pro His Val Gln Lys Ser Val  
 20 25 30

Asn Asn Asp Met Ile Val Thr Asp Asn Asn Gly Ala Val Lys Phe Pro  
 35 40 45

Gln Leu Cys Lys Phe Cys Asp Val Arg Phe Ser Thr Cys Asp Asn Gln  
 50 55 60

Lys Ser Cys Met Ser Asn Cys Ser Ile Thr Ser Ile Cys Glu Lys Pro  
 65 70 75 80

Gln Glu Val Cys Val Ala Val Trp Arg Lys Asn Asp Glu Asn Ile Thr  
 85 90 95

Leu Glu Thr Val Cys His Asp Pro Lys Leu Pro Tyr His Asp Phe Ile  
 100 105 110

Leu Glu Asp Ala Ala Ser Pro Lys Cys Ile Met Lys Glu Lys Lys Lys  
 115 120 125

Pro Gly Glu Thr Phe Phe Met Cys Ser Cys Ser Ser Asp Glu Cys Asn  
 130 135 140

Asp Asn Ile Ile Phe Ser Glu Gly Glu Phe Ser Ser Leu Lys Gly Val  
 145 150 155 160

Gly Pro Glu Ile Cys Ala Asn Phe Leu Tyr Pro Trp Ser Ala Val Ser  
 165 170 175

<210> 30  
 <211> 25  
 <212> PRT  
 <213> Homo sapiens

<400> 30

Gly Glu Phe Ser Ser Leu Lys Gly Val Gly Pro Glu Ile Cys Ala Asn  
 1 5 10 15



Phe Leu Tyr Pro Trp Ser Ala Val Ser  
20 25

<210> 31  
<211> 1850  
<212> DNA  
<213> Homo sapiens

<400> 31  
acctaaagaa aaacatttta caacttgaca gtgtatgcac atacatacat gcatatagac 60  
acaactgaag cacaaattta atgaagtaga atttaccgtt actatittat ttgggaaaga 120  
aatgtgctcg cgactcaata gattggagta ttactctctg gatctcaact tgcaatttga 180  
aaacgcacat ctaaagcacc taggagcaat ctgaagaaag ctgaggggag gcggcagatg 240  
ttctgatcta ctagggaaaa cgtggacggt ttctgttgtt actttgtgaa ctgtgtgcac 300  
ttagtcattc ttgagtaaat acttgagcgc aggaactcct gagtgggtgtg ggagggcggt 360  
gaggggcagc tgaaagtcgg ccaaagctct cgagggggt ggtctaggaa acatgattgg 420  
cagctacgag agagctaggg gctggacgtc gaggagagg agaaggctct cggcgaggaga 480  
gaggtcctgc ccagctgttg gcgaggagtt tctgtttcc cccgcagcgc tgagttgaag 540  
ttgagtgagt cactcgcgcg cacggagcga cgacaccccc gcgcgtgcac ccgctcggga 600  
caggagcccg actcctgtgc agcttccttc gccgcgcgg ggccctcccc cgccctcgccg 660  
gcctccaggc cccctcctgg ctggcgagcg gccgccacat ctggcccga catctgcgct 720  
gccggcccgg cgcgggggtcc ggagagggcg gcgcgcggag gcgcagccag gggctccggga 780  
aggcgccgtc cgctgcgctg ggggctcgggt ctatgacgag cagcggggtc tgccatgggt 840  
cgggggctgc tcaggggctt gtggccgctg cacatcgctc tgtggacgcg tatcgccagc 900  
acgatcccac cgcacgttca gaagtcgggt aataacgaca tgatagtcac tgacaacaac 960  
ggtgcagtca agtttcaca actgtgtaaa ttttgtgatg tgagattttc cacctgtgac 1020  
aaccagaaat cctgcatgag caactgcagc atcacctcca tctgtgagaa gccacaggaa 1080  
gtctgtgtgg ctgtatggag aaagaatgac gagaacataa cactagagac agtttgccat 1140  
gaccccaagc tcccctacca tgactttatt ctggaagatg ctgcttctcc aaagtgcatt 1200  
atgaaggaaa aaaaaaagcc tggtagagact ttcttcatgt gttcctgtag ctctgatgag 1260  
tgcaatgaca acatcatctt ctgagaaggt gagttttctt ctcttaaggg tgtgggacct 1320  
gagatctgtg ccaatttttt gtatccttgg tctgcagtgt catagagcac attcctcctg 1380  
tggtaggattg catagcagtg attaggagct cattcagctg gtggaaagag gggcttgagg 1440  
agtagcaggg tttgttctgg ttctcatcaa atatgggtga ctggggcaaa cattattatt 1500  
tgtctttgac aaatagtttc ttacacctag agcagtgttt ctcaaagtgc ggccccttga 1560  
gcagccagca tcagtatcac ctgggaacct gttataaatg cagattctca ggcccacta 1620  
aatgagaaac atagaggggtg aacccagct atctgtatgt taacaagccc tcccagtaat 1680

23

tctgtgcagc taaaatttgg taactattgt tctaaagatt tggatgggggt tgtttaatct 1740  
 tggaggagga ctttctttat aactgatgtt gtttcttgta catagtccca ggatttgtct 1800  
 ttaggggtact tgtcatcgat cccatttgag agacactttg caatacagag 1850

<210> 32  
 <211> 564  
 <212> DNA  
 <213> Homo sapiens

<400> 32  
 aggtgagttt tcttctctta aggggtgtggg acctgagatc tgtgccaatt ttttgatatcc 60  
 ttggctctgca gtgtcataga gcacattcct cctgtggtgg attgcataca gtggattagg 120  
 agctcattca gctggtggaa agaggggctt ggggagtagc agggtttggt ctggttctca 180  
 tcaaatatgg ttgactgggg caaacattat tatttgcctt tgacaaatag tttctttcac 240  
 ctagagcagt gtttctcaaa gtgcggcccc ttgagcagcc agcatcagta tcacctggga 300  
 acctgttata aatgcagatt ctcaggcccc actaaatgag aaacatagag ggtgaacccc 360  
 agctatctgt attttaacaa gccctcccag taattctgtg cagctaaaat ttggtaacta 420  
 ttgttctaaa gatttggtg ggttggttta atcttggagg aggactttct ttataactga 480  
 tgttgtttct tgtacatagt cccaggattt gtctttaggg tacttgtcat cgatccatt 540  
 tgagagacac ttgcaatac agag 564

<210> 33  
 <211> 815  
 <212> PRT  
 <213> Homo sapiens

<400> 33

Met Ala Phe Pro Pro Arg Arg Arg Leu Arg Leu Gly Pro Arg Gly Leu  
 1 5 10 15

Pro Leu Leu Leu Ser Gly Leu Leu Leu Pro Leu Cys Arg Ala Phe Asn  
 20 25 30

Leu Asp Val Asp Ser Pro Ala Glu Tyr Ser Gly Pro Glu Gly Ser Tyr  
 35 40 45

Phe Gly Phe Ala Val Asp Phe Phe Val Pro Ser Ala Ser Ser Arg Met  
 50 55 60

Phe Leu Leu Val Gly Ala Pro Lys Ala Asn Thr Thr Gln Pro Gly Ile  
 65 70 75 80

Val Glu Gly Gly Gln Val Leu Lys Cys Asp Trp Ser Ser Thr Arg Arg  
 85 90 95

Cys Gln Pro Ile Glu Phe Asp Ala Thr Gly Asn Arg Asp Tyr Ala Lys  
 100 105 110

Asp Asp Pro Leu Glu Phe Lys Ser His Gln Trp Phe Gly Ala Ser Val  
 115 120 125

Arg Ser Lys Gln Asp Lys Ile Leu Ala Cys Ala Pro Leu Tyr His Trp  
 130 135 140

Arg Thr Glu Met Lys Gln Glu Arg Glu Pro Val Gly Thr Cys Phe Leu  
 145 150 155 160

Gln Asp Gly Thr Lys Thr Val Glu Tyr Ala Pro Cys Arg Ser Gln Asp  
 165 170 175

Ile Asp Ala Asp Gly Gln Gly Phe Cys Gln Gly Gly Phe Ser Ile Asp  
 180 185 190

Phe Thr Lys Ala Asp Arg Val Leu Leu Gly Gly Pro Gly Ser Phe Tyr  
 195 200 205

Trp Gln Gly Gln Leu Ile Ser Asp Gln Val Ala Glu Ile Val Ser Lys  
 210 215 220

Tyr Asp Pro Asn Val Tyr Ser Ile Lys Tyr Asn Asn Gln Leu Ala Thr  
 225 230 235 240

Arg Thr Ala Gln Ala Ile Phe Asp Asp Ser Tyr Leu Gly Tyr Ser Val  
 245 250 255

Ala Val Gly Asp Phe Asn Gly Asp Gly Ile Asp Asp Phe Val Ser Gly  
 260 265 270

Val Pro Arg Ala Ala Arg Thr Leu Gly Met Val Tyr Ile Tyr Asp Gly  
 275 280 285

Lys Asn Met Ser Ser Leu Tyr Asn Phe Thr Gly Glu Gln Met Ala Ala  
 290 295 300

Tyr Phe Gly Phe Ser Val Ala Ala Thr Asp Ile Asn Gly Asp Asp Tyr  
 305 310 315 320

Ala Asp Val Phe Ile Gly Ala Pro Leu Phe Met Asp Arg Gly Ser Asp  
 325 330 335

Gly Lys Leu Gln Glu Val Gly Gln Val Ser Val Ser Leu Gln Arg Ala  
 340 345 350

Ser Gly Asp Phe Gln Thr Thr Lys Leu Asn Gly Phe Glu Val Phe Ala  
 355 360 365

Arg Phe Gly Ser Ala Ile Ala Pro Leu Gly Asp Leu Asp Gln Asp Gly

25

370 375 380  
 Phe Asn Asp Ile Ala Ile Ala Ala Pro Tyr Gly Gly Glu Asp Lys Lys  
 385 390 395 400  
 Gly Ile Val Tyr Ile Phe Asn Gly Arg Ser Thr Gly Leu Asn Ala Val  
 405 410 415  
 Pro Ser Gln Ile Leu Glu Gly Gln Trp Ala Ala Arg Ser Met Pro Pro  
 420 425 430  
 Ser Phe Gly Tyr Ser Met Lys Gly Ala Thr Asp Ile Asp Lys Asn Gly  
 435 440 445  
 Tyr Pro Asp Leu Ile Val Gly Ala Phe Gly Val Asp Arg Ala Ile Leu  
 450 455 460  
 Tyr Arg Ala Arg Pro Val Ile Thr Val Asn Ala Gly Leu Glu Val Tyr  
 465 470 475 480  
 Pro Ser Ile Leu Asn Gln Asp Asn Lys Thr Cys Ser Leu Pro Gly Thr  
 485 490 495  
 Ala Leu Lys Val Ser Cys Phe Asn Val Arg Phe Cys Leu Lys Ala Asp  
 500 505 510  
 Gly Lys Gly Val Leu Pro Arg Lys Leu Asn Phe Gln Val Glu Leu Leu  
 515 520 525  
 Leu Asp Lys Leu Lys Gln Lys Gly Ala Ile Arg Arg Ala Leu Phe Leu  
 530 535 540  
 Tyr Ser Arg Ser Pro Ser His Ser Lys Asn Met Thr Ile Ser Arg Gly  
 545 550 555 560  
 Gly Leu Met Gln Cys Glu Glu Leu Ile Ala Tyr Leu Arg Asp Glu Ser  
 565 570 575  
 Glu Phe Arg Asp Lys Leu Thr Pro Ile Thr Ile Phe Met Glu Tyr Arg  
 580 585 590  
 Leu Asp Tyr Arg Thr Ala Ala Asp Thr Thr Gly Leu Gln Pro Ile Leu  
 595 600 605  
 Asn Gln Phe Thr Pro Ala Asn Ile Ser Arg Gln Ala His Ile Leu Leu  
 610 615 620  
 Asp Cys Gly Glu Asp Asn Val Cys Lys Pro Lys Leu Glu Val Ser Val  
 625 630 635 640

26

Asp Ser Asp Gln Lys Lys Ile Tyr Ile Gly Asp Asp Asn Pro Leu Thr  
645 650 655

Leu Ile Val Lys Ala Gln Asn Gln Gly Glu Gly Ala Tyr Glu Ala Glu  
660 665 670

Leu Ile Val Ser Ile Pro Leu Gln Ala Asp Phe Ile Gly Val Val Arg  
675 680 685

Asn Asn Glu Ala Leu Ala Arg Leu Ser Cys Ala Phe Lys Thr Glu Asn  
690 695 700

Gln Thr Arg Gln Val Val Cys Asp Leu Gly Asn Pro Met Lys Ala Gly  
705 710 715 720

Thr Gln Leu Leu Ala Gly Leu Arg Phe Ser Val His Gln Gln Ser Glu  
725 730 735

Met Asp Thr Ser Val Lys Phe Asp Leu Gln Ile Gln Ser Ser Asn Leu  
740 745 750

Phe Asp Lys Val Ser Pro Val Val Ser His Lys Val Asp Leu Ala Val  
755 760 765

Leu Ala Ala Val Glu Ile Arg Gly Val Ser Ser Pro Asp His Ile Phe  
770 775 780

Leu Pro Ile Pro Asn Trp Glu His Lys Glu Asn Pro Glu Thr Glu Glu  
785 790 795 800

Asp Val Gly Pro Val Val Gln His Ile Tyr Glu Val Cys Ser Cys  
805 810 815

&lt;210&gt; 34

&lt;211&gt; 4

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 34

Val Cys Ser Cys

1

&lt;210&gt; 35

&lt;211&gt; 3379

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

gataaaaagc tttcctcatt tttaaacaac agtcgcacgg aagttcccgg cgggacaagg 60

gaacgtgggt gcccttgcta ctcccgtgga cgcgggtaga ttgggacgct ggaccgtatc 120

tccccgcccc cgccccacg cctcctcagg tgctcagcct gaggccttcg tccaggagcg 180

27

ctgccgctga cccaggetca ggagctgggg gcccctgcac agacgcccag gtctcgggac	240
aggcggcgac tgcactcacg gaagtacgt gagctctccc ctgtagaagg gcgcctctcc	300
tccccactt cctcctccag ctccacagca gcctcccggg ccggtcctc ctcttccag	360
gtctcctccc agtgcgcgcg cggtctcag gcctgaggtg cggcgtcac ccgcgcagtc	420
cccagcctca gacgtgcgt ggagcggcgg agccggaggg aagcaaagga ccgtctgcgc	480
tgctgtcccc gcccgcgcg ctctgcgcc ctgcctctg gcggtcgtc cgaagctcag	540
ccctcttgcc tgcccggag ctgtcccggg ctagccgaga agagagcggc cggcaagttt	600
gggcgcgcgc aggcggcggg ccgcgggcac tgggcgcctc gctggggcgg ggggaggtg	660
ctaccgctcc cggcttgggg tcccgcgcgc acttcggcga tggcttttcc gccgcggcga	720
cggtgcgcc tcggtccccg cggcctcccg cttcttctc cgggactcct gctacctctg	780
tgccgcgcct tcaacctaga cgtggacagt cctgccagt actctggccc cgagggaagt	840
tacttcggct tcgccgtgga tttcttcgtg cccagcgcgt cttcccggat gttcttctc	900
gtgggagctc ccaaagcaaa caccaccag cctgggattg tggaaggagg gcaggtcctc	960
aaatgtgact ggtcttctac ccgcgggtgc cagccaattg aatttgatgc aacaggcaat	1020
agagattatg ccaaggatga tccattgaa ttaagtccc atcagtgggt tggagcatct	1080
gtgaggtcga aacaggataa aattttggcc tgtgccccat tgtaccattg gagaactgag	1140
atgaaacagg agcgagagcc tgttggaaca tgctttcttc aagatggaac aaagactgtt	1200
gagtatgctc catgtagatc acaagatatt gatgctgatg gacagggatt ttgtcaagga	1260
ggattcagca ttgattttac taaagctgac agagtacttc ttgggtggcc tggtagcttt	1320
tattggcaag gtcagcttat ttcggatcaa gtggcagaaa tcgtatctaa atacgacccc	1380
aatgtttaca gcatcaagta taataaccaa ttagcaactc ggactgcaca agctattttt	1440
gatgacagct atttgggtta ttctgtggct gtcggagatt tcaatgggtga tggcatagat	1500
gactttgttt caggagttcc aagagcagca aggactttgg gaatgggtta tatttatgat	1560
gggaagaaca tgcctcctt atacaatttt actggcgagc agatggctgc atatttcgga	1620
ttttctgtag ctgccactga cattaatgga gatgattatg cagatgtgtt tattggagca	1680
cctctcttca tggatcgtgg ctctgatggc aaactccaag aggtggggca ggtctcagt	1740
tctctacaga gagcttcagg agacttcag acgacaaagc tgaatggatt tgaggctttt	1800
gcacggtttg gcagtgccat agctccttg ggagatctgg accaggatgg tttcaatgat	1860
attgcaattg ctgctccata tgggggtgaa gataaaaaag gaattgttta tatcttcaat	1920
ggaagatcaa caggcttgaa cgcagtcca tctcaaatcc ttgaaggga gtgggctgct	1980
cgaagcatgc caccaagctt tggtattca atgaaaggag ccacagatat agacaaaaat	2040
ggatatccag acttaattgt aggagctttt ggtgtagatc gagctatctt atacagggcc	2100
agaccagtta tactgtaaa tgctggtctt gaagtgtacc ctgacatttt aaatcaagac	2160
aataaaacct gtcactgcc tggaacagct ctcaaagttt cctgttttaa tgtaggttc	2220

28

tgcttaaagg cagatggcaa aggagtactt cccaggaaac ttaatttcca ggtggaactt 2280  
 cttttggata aactcaagca aaagggagca attcgacgag cactgtttct ctacagcagg 2340  
 tccccaagtc actccaagaa catgactatt tcaagggggg gactgatgca gtgtgaggaa 2400  
 ttgatagcgt atctgcggga tgaatctgaa tttagagaca aactcactcc aattactatt 2460  
 tttatggaat atcggttgga ttatagaaca gctgctgata caacaggctt gcaaccatt 2520  
 ctttaaccagt tcacgcctgc taacattagt cgacaggctc acattctact tgactgtggt 2580  
 gaagacaatg tctgtaaacc caagctggaa gtttctgtag atagtgatca aaagaagatc 2640  
 tatattgggg atgacaaccc tctgacattg attgttaagg ctgagaatca aggagaaggt 2700  
 gcctacgaag ctgagctcat cgtttccatt ccaactgcagg ctgatttcat cggggttgtc 2760  
 cgaaacaatg aagccttagc aagactttcc tgtgcattta agacagaaaa ccaaactcgc 2820  
 caggtggtat gtgaccttg aaaccaatg aaggctggaa ctcaactctt agctggtctt 2880  
 cgtttcagtg tgcaccagca gtcagagatg gatacttctg tgaaatttga cttacaaatc 2940  
 caaagctcaa atctatttga caaagtaagc ccagttgtat ctcaaaagt tgatcttgct 3000  
 gttttagctg cagttgagat aagaggagtc tgcagtcctg atcatatctt tcttccgatt 3060  
 ccaaactggg agcacaagga gaacctgag actgaagaag atgttgggcc agttgttcag 3120  
 cacatctatg aggtttgcag ttgtagatt ttactcaaac ctctgagca agccaacgaa 3180  
 gagaggaaca actaagctac tttaaaaaaa aaattctatg taatttttat gtaaactcta 3240  
 cattgggtta gtatgtgtca gagatttctt tgaatatatt ccctatacat aaattcattt 3300  
 ttatttgaca aatagacttg tttaaataaa gcagtttata taatttggtt tttaaaataa 3360  
 attagtctta cttgaataa 3379

<210> 36  
 <211> 247  
 <212> DNA  
 <213> Homo sapiens

<400> 36  
 gtttgcagtt gtagatttt actcaaacct cgtgagcaag ccaacgaaga gaggaacaac 60  
 taagctactt taaaaaaaaa attctatgta atttttatgt aaactctaca ttgggttaagt 120  
 atgtgtcaga gatttctttg aatattttcc ctatacataa attcattttt atttgacaaa 180  
 tagacttggt taaataaagc agtttatata atttgttggt taaaataaat tagttctact 240  
 tgaataa 247

<210> 37  
 <211> 222  
 <212> PRT  
 <213> Homo sapiens

<400> 37

Met Ala Trp Ser Leu Gly Ser Trp Leu Gly Gly Cys Leu Leu Val Ser

29

1 5 10 15

Ala Leu Gly Met Val Pro Pro Pro Glu Asn Val Arg Met Asn Ser Val  
20 25 30

Asn Phe Lys Asn Ile Leu Gln Trp Glu Ser Pro Ala Phe Ala Lys Gly  
35 40 45

Asn Leu Thr Phe Thr Ala Gln Tyr Leu Ser Tyr Arg Ile Phe Gln Asp  
50 55 60

Lys Cys Met Asn Thr Thr Leu Thr Glu Cys Asp Phe Ser Ser Leu Ser  
65 70 75 80

Lys Tyr Gly Asp His Thr Leu Arg Val Arg Ala Glu Phe Ala Asp Glu  
85 90 95

His Ser Asp Trp Val Asn Ile Thr Phe Cys Pro Val Asp Asp Thr Ile  
100 105 110

Ile Gly Pro Pro Gly Met Gln Val Glu Val Leu Ala Asp Ser Leu His  
115 120 125

Met Arg Phe Leu Ala Pro Lys Ile Glu Asn Glu Tyr Glu Thr Trp Thr  
130 135 140

Met Lys Asn Val Tyr Asn Ser Trp Thr Tyr Asn Val Gln Tyr Trp Lys  
145 150 155 160

Asn Gly Thr Asp Glu Lys Phe Gln Ile Thr Pro Gln Tyr Asp Phe Glu  
165 170 175

Val Leu Arg Asn Leu Glu Pro Trp Thr Thr Tyr Cys Val Gln Val Arg  
180 185 190

Gly Phe Leu Pro Asp Arg Asn Lys Ala Gly Glu Trp Ser Glu Pro Val  
195 200 205

Cys Glu Gln Thr Thr His Asp Val Phe Gly Pro Ser Ser Ser  
210 215 220

<210> 38  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 38

Val Phe Gly Pro Ser Ser Ser  
1 5

<210> 39



30

&lt;211&gt; 1806

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 39

```

cccgcccatc tccgctgggt cccggaagcc gccgcggaca agctctcccg ggcgcgggcg      60
ggggtcgtgt gcttggagga agccgcggaa cccccagcgt ccgtccatgg cgtggagcct      120
tgggagctgg ctgggtggct gcctgctggt gtcagcattg ggaatggtac cacctcccga      180
aatgtcaga atgaattctg ttaatttcaa gaacattcta cagtgggagt cacctgcttt      240
tgccaaaggg aacctgactt tcacagctca gtacctaatg tataggatat tccaagataa      300
atgcatgaat actaccttga cggaatgtga tttctcaagt ctttccaagt atggtgacca      360
caccttgaga gtcagggctg aatttgaga tgagcattca gactgggtaa acatcacctt      420
ctgtcctgtg gatgacacca ttattggacc ccctggaatg caagtagaag tacttgctga      480
ttctttacat atgcgtttct tagcccctaa aattgagaat gaatacgaac cttggactat      540
gaagaatgtg tataactcat ggacttataa tgtgcaatac tggaaaaacg gtactgatga      600
aaagtttcaa attactcccc agtatgactt tgaggctctc agaaacctgg agccatggac      660
aacttattgt gttcaagttc gagggtttct tcctgatcgg aacaaagctg gggaatggag      720
tgagcctgtc tgtgagcaaa caacccatga cgtttttggg ccctcctcat cataacacac      780
ttctgttttt ctcttttcca ttgtcggatg agaatgatgt ttttgacaag ctaagtgtca      840
ttgcagaaga ctctgagagc ggcaagcaga atcctggtga cagctgcagc ctcgggaccc      900
cgctgggca ggggccccaa agctaggctc tgagaaggaa acacactcgg ctgggcacag      960
tgacgtactc catctcacat ctgcctcagt gagggatcag ggcagcaaac aagggccaaag     1020
accatctgag ccagccccac atctagaact ccagaccct ggacttagcc accagagagc     1080
tacattttaa aggctgtctt ggcaaaaata ctccatttgg gaactcactg cttataaaag     1140
gctttcatga tgttttcaga agttggccac tgagagtgtg attttcagcc ttttatatca     1200
ctaaaataag atcatgtttt aattgtgaga aacagggccg agcacagtgg ctcacgcctg     1260
taataccagc accttagagg tcgaggcagg cggatcactt gaggtcagga gttcaagacc     1320
agcctggcca atatggtgaa acccagtctc tactaaaaat acaaaaatta gctaggcatg     1380
atggcgcgatg cctataatcc cagctactcg agtgcctgag gcaggagaat tgcataaacc     1440
cgggaggagg aggaggagg tgcagtgagc cgagatagcg gcactgcact ccagcctggg     1500
tgacaaagtg agactccatc tcaaaaaaaaa aaaaaaaaaa ttgtgagaaa cagaaatact     1560
taaaatgagg aataagaatg gagatgttac atctggtaga tgtaacattc taccagatta     1620
tgatgggact gatctgaaaa tcaacctcaa ctcaaggggtg gtcagctcaa tgctacacag     1680
agcacggact tttggattct ttgcagtact ttgaatttat tttctacct atatatgttt     1740
tatatgctgc tgggtgtcca ttaaagtttt actctgtgtt gcactatatg tgttcagat     1800
aaaaaa                                           1806

```

31

<210> 40  
 <211> 65  
 <212> DNA  
 <213> Homo sapiens

<400> 40  
 tcagaatctt ttattgtctt ttttaaaaat gtagctagac ataataaaag taattctata 60  
 ctgta 65

<210> 41  
 <211> 441  
 <212> PRT  
 <213> Homo sapiens

<400> 41

Met Val Val Leu Leu Gly Ala Thr Thr Leu Val Leu Val Ala Val Ala  
 1 5 10 15

Pro Trp Val Leu Ser Ala Ala Ala Gly Gly Lys Asn Leu Lys Ser Pro  
 20 25 30

Gln Lys Val Glu Val Asp Ile Ile Asp Asp Asn Phe Ile Leu Arg Trp  
 35 40 45

Asn Arg Ser Asp Glu Ser Val Gly Asn Val Thr Phe Ser Phe Asp Tyr  
 50 55 60

Gln Lys Thr Gly Met Asp Asn Trp Ile Lys Leu Ser Gly Cys Gln Asn  
 65 70 75 80

Ile Thr Ser Thr Lys Cys Asn Phe Ser Ser Leu Lys Leu Asn Val Tyr  
 85 90 95

Glu Glu Ile Lys Leu Arg Ile Arg Ala Glu Lys Glu Asn Thr Ser Ser  
 100 105 110

Trp Tyr Glu Val Asp Ser Phe Thr Pro Phe Arg Lys Ala Gln Ile Gly  
 115 120 125

Pro Pro Glu Val His Leu Glu Ala Glu Asp Lys Ala Ile Val Ile His  
 130 135 140

Ile Ser Pro Gly Thr Lys Asp Ser Val Met Trp Ala Leu Asp Gly Leu  
 145 150 155 160

Ser Phe Thr Tyr Ser Leu Val Ile Trp Lys Asn Ser Ser Gly Val Glu  
 165 170 175

Glu Arg Ile Glu Asn Ile Tyr Ser Arg His Lys Ile Tyr Lys Leu Ser  
 180 185 190

32

Pro Glu Thr Thr Tyr Cys Leu Lys Val Lys Ala Ala Leu Leu Thr Ser  
 195 200 205

Trp Lys Ile Gly Val Tyr Ser Pro Val His Cys Ile Lys Thr Thr Val  
 210 215 220

Glu Asn Glu Leu Pro Pro Pro Glu Asn Ile Glu Val Ser Val Gln Asn  
 225 230 235 240

Gln Asn Tyr Val Leu Lys Trp Asp Tyr Thr Tyr Ala Asn Met Thr Phe  
 245 250 255

Gln Val Gln Trp Leu His Ala Phe Leu Lys Arg Asn Pro Gly Asn His  
 260 265 270

Leu Tyr Lys Trp Lys Gln Ile Pro Asp Cys Glu Asn Val Lys Thr Thr  
 275 280 285

Gln Cys Val Phe Pro Gln Asn Val Phe Gln Lys Gly Ile Tyr Leu Leu  
 290 295 300

Arg Val Gln Ala Ser Asp Gly Asn Asn Thr Ser Phe Trp Ser Glu Glu  
 305 310 315 320

Ile Lys Phe Asp Thr Glu Ile Gln Ala Phe Leu Leu Pro Pro Val Phe  
 325 330 335

Asn Ile Arg Ser Leu Ser Asp Ser Phe His Ile Tyr Ile Gly Ala Pro  
 340 345 350

Lys Gln Ser Gly Asn Thr Pro Val Ile Gln Asp Tyr Pro Leu Ile Tyr  
 355 360 365

Glu Ile Ile Phe Trp Glu Asn Thr Ser Asn Ala Glu Arg Lys Ile Ile  
 370 375 380

Glu Lys Lys Thr Asp Val Thr Val Pro Asn Leu Lys Pro Leu Thr Val  
 385 390 395 400

Tyr Cys Val Lys Ala Arg Ala His Thr Met Asp Glu Lys Leu Asn Lys  
 405 410 415

Ser Ser Val Phe Ser Asp Ala Val Cys Glu Lys Thr Lys Pro Gly Gln  
 420 425 430

Asn Leu Leu Leu Ser Phe Leu Lys Met  
 435 440

<210> 42  
 <211> 10  
 <212> PRT

33

&lt;213&gt; Homo sapiens

&lt;400&gt; 42

Gln Asn Leu Leu Leu Ser Phe Leu Lys Met  
 1 5 10

&lt;210&gt; 43

&lt;211&gt; 1512

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 43

agaagaggcg ggcggtgcgt agaggggagg tgagagctaa gaggggcagc gcgtgtgcag 60  
 agggggcgggtg tgacttagga cggggcgatg gcggctgaga ggagctgcgc gtgcgcgaac 120  
 atgtaactgg tgggatctgc ggcggctccc agatgatggg cgtcctcctg ggcgcgacga 180  
 ccctagtgtc cgtcgccgtg gcgccatggg tgttgtccgc agccgcagggt ggaaaaaatc 240  
 taaaatctcc tcaaaaagta gaggtcgaca tcatagatga caactttatc ctgaggtgga 300  
 acaggagcga tgagtctgtc gggaatgtga ctttttcatt cgattatcaa aaaactggga 360  
 tggataattg gataaaattg tctgggtgtc agaattattac tagtaccaaa tgcaactttt 420  
 cttcactcaa gctgaatgtt tatgaagaaa ttaaattgcg tataagagca gaaaaagaaa 480  
 acacttcttc atggtatgag gttgactcat ttacaccatt tcgcaaagct cagattgggc 540  
 ctccagaagt acatttagaa gctgaagata aggcaatagt gatacacatc tctcctggaa 600  
 caaaagatag tggtatgtgg gctttggatg gtttaagctt tacatatagc ttagttatct 660  
 ggaaaaactc ttcagggtga gaagaaagga ttgaaaatat ttattccaga cataaaattt 720  
 ataaaactctc accagagact acttattgtc taaaagttaa agcagcacta cttacgtcat 780  
 ggaaaaattg tgtotatagt ccagtacatt gtataaagac cacagttgaa aatgaactac 840  
 ctccaccaga aaatatagaa gtcagtgtcc aaaatcagaa ctatgttctt aaatgggatt 900  
 atacatatgc aaacatgacc tttcaagttc agtggctcca cgccttttta aaaaggaatc 960  
 ctggaaacca tttgtataaa tggaacaaa tacctgactg tgaaaatgtc aaaactaccc 1020  
 agtgtgtctt tctcaaaaac gttttccaaa aaggaattta cttctccgc gtacaagcat 1080  
 ctgatggaaa taacacatct ttttggctg aagagataaa gtttgatact gaaatacaag 1140  
 ctttctact tctccagtc ttttaacatta gatcccttag tgattcattc catatctata 1200  
 tcgggtgtcc aaaacagtct ggaaacacgc ctgtgatcca ggattatcca ctgatttatg 1260  
 aaattatttt ttgggaaaac acttcaaatg ctgagagaaa aattatcgag aaaaaaactg 1320  
 atgttacagt tcctaatttg aaaccactga ctgtatattg tgtgaaagcc agagcacaca 1380  
 ccatggatga aaagctgaat aaaagcagtg tttttagtga cgctgtatgt gagaaaacaa 1440  
 aaccagggtca gaatctttta ttgtcttttt taaaaatgta gctagacata ataaaagtaa 1500  
 ttctatactg ta 1512

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**